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Diabetes is a global health problem. The consumption of dietary polyphenols may help
to decrease the risk of type 2 diabetes and slow the progression of diabetic complications.
Aronia (Aronia melanocarpa) and elderberry (Sambucus nigra L. ssp. canadensis) fruits are rich
in polyphenols and exhibit health-promoting properties, but they are underutilized. Aronia and
elderberries are rarely consumed raw due to the astringent mouth feel. New food products are
needed to increase their consumption. Kefir, a fermented dairy beverage, was chosen to be the
matrix for incorporating berries due to: 1) the protein matrix can help mask the astringency; 2)
an acidic environment is beneficial for the stability of phenolic compounds; 3) fermentative
microorganisms may be able to increase the bioavailability of polyphenols.
The first objective of this research was to develop new palatable products using
underutilized berries and different sweeteners (sucrose, stevia and monk fruit extracts).
Sensory evaluations were conducted to assess consumer acceptability of berry-containing

kefirs. The results showed that aronia and elderberry kefirs sweetened with stevia or sucrose
were all accepted by consumers where sucrose was the best-accepted sweetener. The second
objective was to assess the health-promoting characteristics of the berry-containing kefirs.
Aronia kefirs contained high levels of total phenolics and anthocyanins. Elderberry kefirs were
moderate in total phenolics. All kefirs exhibited antioxidant capacity. The third objective was to
evaluate the diabetes-beneficial properties of aronia kefir using an in-vitro digestion model. The
impacts of fermentation on aronia polyphenols were also assessed. The results showed that the
levels of bioaccessible polyphenols were elevated during digestion and the antioxidant capacity
increased. Fermentation enhanced the inhibitory activity of aronia kefir on α-glucosidase but
did not alter its weak inhibition on pancreatic α-amylase. Specific inhibition of α-glucosidase
may decrease the absorption of carbohydrates and contribute to blood glucose control without
side effects compared to pharmaceutical agents, such as acarbose.
In conclusion, new berry-containing kefirs were well-accepted by the consumers and the
consumption of berry-containing kefirs may help to reduce oxidative stress and aid in blood
glucose control. In addition, fermentation may be a good strategy to increase the bioavailability
of dietary polyphenols.
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CHAPTER 1
LITERATURE REVIEW
The prevalence of diabetes has grown rapidly. In 2015, 9.4% of the United States
population had diabetes [1]. Epidemiological studies demonstrate that the consumption of
bioactive compounds from various fruits and vegetables may help to decrease the risk of
chronic diseases, including diabetes [2, 3]. In addition, bioactive compounds obtained from the
diet have been shown to be beneficial to prevent and delay secondary diabetic complications
[4]. Aronia berries and elderberries are rich in bioactive compounds, but they lack palatability
and are rarely consumed raw. New food products using aronia and elderberries were
developed in this research. The hypotheses of this research were: 1) sucrose-sweetened berry
kefirs will be better accepted by consumers compared to products sweetened with nonnutritive sweeteners; and 2) fermentation will improve the bioavailability of dietary
polyphenols. In this literature review, the mechanism of diabetes, the health-promoting
properties and the bioavailability of polyphenols will be introduced. In addition, current studies
focusing on the health-beneficial properties of aronia berries, elderberry and kefir will be
discussed in detail.
1.1 Oxidative Stress and Type 2 Diabetes
Oxidative stress is an underlying mechanism for the development and progression of
type 2 Diabetes Mellitus (T2DM). In individuals with T2DM, hyperglycemia can increase the
production of reactive oxygen/nitrogen species, which elevates cellular oxidative stress [4].
Strategies that decrease oxidative stress may help to decrease the risk of T2DM and its
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secondary complications. The occurrence of oxidative stress and its relationship with T2DM will
be explained in this section.
1.1.1 Oxidative Stress
Under aerobic conditions, oxygen participates in the energy production process in living
organisms [5]. In eukaryotes, more than 90% of consumed oxygen is converted to water by
cytochrome oxidase located in electron-transport chain (ETC) in mitochondria. Less than 10% of
consumed oxygen is reduced to reactive oxygen species (ROS) [6]. ROS include hydrogen
peroxide (H2O2), hydroxyl radicals (·OH), and superoxide radical (O2·-). ROS are important
molecules involved in the normal metabolism of cells. They can directly interact with signaling
molecules and participate in pathways that are critical to cell survival and proliferation [7, 8]. In
addition to mitochondria, plasma membranes, endoplasmic reticulum and lysosomes also
generate ROS [9]. Cells have an antioxidant defense system to scavenge ROS and maintain
redox homeostasis. Antioxidant enzymes, such as superoxide dismutase (SOD), glutathione
peroxidase (GPx) and catalase (CAT), are vital players in the free radical detoxifying process
[10]. SOD can neutralize superoxide to less toxic hydrogen peroxide. Hydrogen peroxide can be
converted to water and hydrogen by CAT and/or GPx [11]. Under normal conditions, the
capacity of the antioxidant defense system is adequate to neutralize the ROS and no oxidative
damage occurs to cells and tissues.
Oxidative stress is defined as an imbalance between the production of ROS and the
elimination capacity of the antioxidant defense system where oxidative damages may occur to
cellular proteins, lipids and DNA [12, 13]. Oxidative stress is associated with the overproduction
of ROS and/or a decline in the antioxidant defense system. Oxidative stress can be triggered by
2

an unhealthy diet, such as high-fat and high-sugar diets. In addition, sedentary lifestyle and
abnormal metabolic conditions including hyperglycemia and hyperlipidemia can aggravate
oxidative stress [14]. Under oxidative stress conditions, excessive ROS can react with nitric
oxide (NO) and form reactive nitrogen species (RNS), including peroxynitrite (ONOO-) and
nitrogen dioxide (NO2) [15]. RNS is another group of free radicals that can result in oxidative
damages to cells. Excessive ROS/RNS can modify the structure of proteins and lipids, and impair
their function [15]. Elevated ROS/RNS may lead to damages to the mitochondrial membrane
and DNA, which can result in apoptosis [16]. Oxidative stress can intensify metabolic disorders
and increase the risk of several diseases, such as cardiovascular disease, neurodegenerative
diseases and diabetes mellitus. Additionally, oxidative stress can accelerate the development
and progression of secondary complications of chronic diseases.
1.1.2 Oxidative Stress and Chronic Inflammation
Inflammation is part of the body’s defense system against threats, such as infection and
injury [17]. There are two stages of inflammation: acute and chronic [18]. Acute inflammation
only persists for a short duration and benefits the host. If acute inflammation cannot eliminate
these threats, the inflammatory response will continue and chronic inflammation will be
developed [19]. Chronic inflammation is closely interrelated with oxidative stress [20]. ROS can
activate pro-inflammatory pathways, such as NF-ƙB and elevate the production of proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) [19].
Under chronic inflammatory conditions, the phagocytic cells can generate ROS/RNS and induce
oxidative damage to tissues. In addition, the pro-inflammatory cytokines can also trigger the
generation of ROS/RNS in non-phagocytic cells [21]. Thus, a vicious cycle between chronic
3

inflammation and oxidative stress is formed. In addition to oxidative stress, chronic
inflammation is one of the underlying mechanism of the initiation and progression of chronic
diseases [22].
1.1.3 Diabetes Mellitus
1.1.3.1 Introduction to Diabetes Mellitus
Diabetes Mellitus (DM) is a chronic metabolic disease that is characterized by high blood
glucose levels (fasting blood glucose level ≥7 mmol/L) [23], which is associated with insulin
deficiency and/or insulin resistance [24]. There are two major types of diabetes: type 1 diabetes
mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM is also known as insulin-dependent
diabetes and accounts for about 10% of diabetic cases [24]. T1DM is caused by the autoimmune
destruction of β cells in the pancreatic islets. T1DM can be genetically linked and/or influenced
by environmental factors [25]. T1DM typically develops in children and teenagers younger than
19 years old [26]. The destruction of β cells leads to diminished insulin production and
eventually no production at all.

For type 1 diabetic patients, lifelong exogenous insulin

administration is necessary to control blood glucose [27]. T2DM is the more predominant type
which accounts for approximately 90% of all diabetic cases [24]. T2DM is characterized by an
impairment of insulin secretion and/or a decline in insulin sensitivity [28]. The onset of T2DM is
strongly influenced by environmental factors, such as unhealthy eating habits, a sedentary
lifestyle and obesity [29]. Healthy eating habits, regular exercise and pharmaceutical
medication such as acarbose are used to assist blood glucose control in T2DM patients.
Exogenous insulin administration may not be involved at the early stage but may be necessary
when T2DM progresses over time [30].
4

From a global perspective in 2016, 422 million people were reported to have diabetes
[31]. The United States Centers for Disease Control and Prevention (CDC) reported that 30.3
million (9.4%) of the United States population had diabetes in 2015 including 1.5 million newly
diagnosed patients [1]. Diabetic patients need strict control of their blood glucose levels,
otherwise complications may occur and deteriorate the individual's quality of life [32]. In the
United States, the expense of diabetic health care is the highest among 155 disease conditions
and health-related problems, including ischemic heart disease and cancer [33]. The annual
expense of diabetic health care in 2013 was $101.4 billion where 57.6% was spent on
medication and 23.5% was spent on ambulatory care. From 1996 to 2013, the prevalence of
diabetes in the United States increased from 3.0% to 6.5% and the diabetic health care cost
increased $64.4 billion in this time period [31, 33].
1.1.3.2 Diabetic Complications
Individuals with diabetes may suffer chronic or acute complications. Acute diabetic
complications include ketoacidosis in individuals with T1DM and coma due to hypoglycemia
[11]. Chronic diabetic complications are associated with damage to vascular endothelial cells
caused by hyperglycemia. Vascular endothelial cells are susceptible to hyperglycemia due to
lack of ability to down-regulate glucose uptake while extracellular glucose levels are elevated.
[34]. Chronic diabetic complications are grouped into either microvascular (retinopathy,
neuropathy and nephropathy) or macrovascular complications (diabetic cardiovascular
diseases).
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Diabetic retinopathy (DR) is diagnosed by the lesions in the retinal vascular system. The
development of DR is associated with increased vascular permeability. This is caused by
hyperglycemia via damage to the blood-retinal barrier, inducing edema and loss of pericytes
[35, 36]. DR is the leading cause of vision loss worldwide among middle-aged and elderly people
[37] and the vision loss is irreversible. The prevalence of diabetic retinopathy is estimated to
reach 247.3 million by 2030 [38]. Almost all T1DM patients will develop retinopathy after
twenty years of being diagnosed with diabetes [37]. More than 80% of insulin-treated and 50%
of non-insulin-treated T2DM patients will develop some degree of retinopathy after having
diabetes for two decades. Early detection and tight blood glucose control are beneficial to delay
the progression of diabetic retinopathy [39].
Diabetic neuropathy is associated with progressive degeneration of the nerve fibers or
whole nerve cells. Glucose toxicity is the primary cause of the nerve damage [40]. Patients with
neuropathy have impaired sensation in the limbs, suffer extreme pain or may be asymptomatic
[40]. The risk of peripheral neuropathy of diabetes increases along with the duration of
diabetes and it is estimated that more than half of diabetic patients develop neuropathy to
some extent [41]. For most cases, diabetic peripheral neuropathy is not reversible [40, 42].
Patients with nephropathy are characterized with morphological and ultrastructural
changes in the kidney, such as the accumulation of extracellular matrix proteins, glomerular
basement membrane thickening, podocyte injury, mesangial matrix expansion and
tubulointerstitial damage [43-45]. Genetic predisposition and environmental factors, such as
smoking and a sedentary lifestyle, contribute to the development of nephropathy [46, 47].
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More than one-third of diabetic patients have hyperglycemia-induced renal changes [48].
Kidney transplant or dialysis may be necessary when nephropathy progresses to maintain the
patient’s life [43].
Cardiovascular disease (CVD) is a common macrovascular complication of diabetes
mellitus, including accelerated atherosclerosis, cardiomyopathy, and stroke [49]. CVD is the
leading cause of mortality in diabetes where 80% of deaths are caused by myocardial infarction
and stroke [24, 50]. Diabetic patients have an estimated three to ten-fold higher risk of
developing cardiovascular diseases compared to the non-diabetic population [51]. Even with
adequate glycemic control, diabetic patients can still develop diabetic cardiovascular diseases
[52]. This phenomenon indicates that hyperglycemia is not the only factor in the development
of diabetic cardiovascular diseases. Other factors, such as excessive ROS, may be more relevant
[49]. A healthy lifestyle, such as healthy eating habits, frequent exercise and smoking cessation,
is a necessary component to delay the development and progression of diabetic cardiovascular
diseases [53, 54].
1.1.4 Vicious Cycle between Type 2 Diabetes and Oxidative Stress
Elevated oxidative stress is common in T2DM. High serum glucose levels can enhance
ROS/RNS production in the mitochondrial ETC [55]. High glucose level can partially block the
electron transportation in complex III, which is a multisubunit transmembrane protein that
plays a critical role in ETC, via increasing the hyperpolarization of the inner mitochondrial
membrane potential. The inhibited electron transportation leads to excessive electrons which
are accumulated to coenzyme Q and eventually result in the incomplete reduction of O 2 and
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form superoxide [5]. Increased superoxide production contributes to glucose-induced damages
to cells by inhibiting glyceraldehyde-3 phosphate dehydrogenase (GAPDH). Hyperglycemia
activates the following pathways: the polyol pathway, the protein kinase C (PKC) pathway, the
hexosamine pathway and the advanced glycation end product (AGE) pathway [56]. The
activation of these pathways will contribute to oxidative stress. In the polyol pathway, an
increased amount of glucose triggers aldose reductase to convert glucose to poly-alcohol.
Nicotinamide adenine dinucleotide phosphate (NADPH) is consumed in this process. The
decreased NADPH leads to a reduced regeneration of glutathione (GSH), which is a ROS
scavenger, and eventually increases the ROS level [5]. Endothelial hyperglycemia activates the
PKC pathway by increasing diacylglycerol synthesis. The activated PKC pathway results in the
activation of NADPH oxidase and generates more ROS [5]. In the hexosamine pathway,
fructose-6-phosphate is converted to uridine di-phosphate by glutamine fructose-6 phosphate
amidotransferase (GFAT). Hyperglycemia can increase hexosamine pathway flux and lead to
elevated GFAT activity. Increased GFAT activity causes more modification of proteins, including
the modified transcription factor SP1, transforming growth factor β1 and plasminogen activator
inhibitor-1, which are harmful to blood vessels [5, 56]. AGEs are formed by non-enzymatic
reactions between extracellular proteins and glucose. In a hyperglycemic condition, the
inhibition of GAPDH leads to an increased production of the AGE precursor – methylglyoxal that
is formed from glyceraldehyde-3 phosphate [56]. The increased AGE levels can bind their
receptors and activate NADPH oxidase. The activation of NADPH oxidase favors the production
of ROS [5]. In summary, hyperglycemia can contribute to oxidative stress in diabetic patients.
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Oxidative stress can aggravate the dysfunction of β-cells and insulin resistance which can then
accelerate the progression of type 2 diabetes.
1.1.5 Oxidative Stress and Diabetic Complications
1.1.5.1 Oxidative Stress and Diabetic Microvascular Complications
Under oxidative stress conditions, the excessive activation of PKC pathways can cause
and accelerate diabetic complications by inducing blood-flow abnormalities & capillary
occlusions and increasing vascular permeability [57]. In addition, oxidative stress can increase
the production of AGE [58]. The intracellular accumulated AGE levels may alter cytoplasmic and
nuclear factors, such as the alteration of gene transcription [58, 59]. In addition, the AGE can
cross-link with structural proteins, such as collagen, and result in microvascular structural and
functional changes. These changes include membrane thickening with reduced elasticity and
sensitivity to protein clearance [36, 58]. Another mechanism behind increased AGE levels the
diabetic microvascular complications is the interaction between AGE and their receptors which
are located on the plasma membrane. This interaction can alter intracellular signaling, gene
expression, release pro-inflammatory cytokines and free radicals, which can, in turn, increase
the production of AGEs and result in a vicious cycle [58].
1.1.5.2 Oxidative Stress and Diabetic Macrovascular Complications
The development and progression of diabetic cardiovascular disease is associated with
chronic inflammation which is linked to oxidative stress. Excessive free radicals in the system
can increase the oxidation of low-density lipoprotein (LDL). The oxidized LDL will increase
vascular inflammation via augmentation of the intimal macrophage infiltration and the
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formation of foam-cells [60]. The reaction between AGE and AGE receptors also contributes to
vascular inflammation by activating nuclear factor (NF)-κB signaling [58]. Chronic vascular
inflammation contributes to the atherogenesis and the formation of arterial thrombus [61]. In
addition, ROS can damage contractile function[60] and induce cardiomyocyte apoptosis [62,
63]. Thus, the development and progression of diabetic macrovascular complications can be
accelerated by low-grade inflammation and the action of ROS.
1.1.6 Dietary Strategies to Decrease Oxidative Stress
Nutrition plays an important role in the status of redox homeostasis. It is reported that
diets containing high-sugar and high-fat content can cause oxidative stress [64]. Thus, these
unhealthy diets can increase the risk of metabolic syndrome and chronic diseases. A decreased
consumption of fat and sugar may reduce the production of ROS. The consumption of dietary
antioxidants has been suggested as an effective strategy to decrease oxidative stress due to
their capacity to eliminate ROS and/or boost the antioxidant defense system. Dietary
antioxidants, include but are not limited to polyphenols, antioxidant vitamins (such as vitamin C
and E), carotenoids and oil lecithin [65]. Some minerals, such as selenium and zinc, are also
considered dietary antioxidants due to their essential roles as cofactors of endogenous
antioxidant enzymes. The next section will focus on polyphenols and their impacts on T2DM.
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1.2 Polyphenols
1.2.1 Introduction
Polyphenols are secondary, plant-based metabolites that are directly involved in the
defense system of the plant to overcome abiotic stress [66, 67]. They are the largest group of
phytochemicals [68]. Polyphenols are categorized by the number of aromatic rings and the
basic structural elements that bind to the rings. Polyphenols are generally classified into two
groups: non-flavonoids and flavonoids. Non-flavonoids are sub-classified as phenolic acids,
lignans and stilbenes [68, 69]. Phenolic acids include hydroxyderivatives of benzoic acid and
cinnamic acid and their esters. Stilbenes, such as resveratrol, have a double bond between the
phenolic rings. Lignans are characterized by 2-phenylpropane units [70]. Flavonoids consist of
more than 6000 phenolic compounds and account for 60% of total dietary polyphenols [70, 71].
Flavonoids are further sub-categorized as flavones, flavonols, isoflavones, anthocyanins,
flavanols, tannins and flavanones [72]. The chemical structures of some polyphenols are shown
in Figure 1.1.
Polyphenols are found in fruits, vegetables and cereal grains [72]. Berries, citrus fruits
and broccoli are naturally rich in polyphenols. The amount of polyphenols in plants is affected
by environmental factors, such as sun exposure and rainfall [68]. Polyphenol levels in plants
may increase due to a response to stressful environmental conditions [66]. In addition, the
degree of ripeness influences the amount of polyphenols in a fruit. During ripening, the
phenolic acid content in the fruit decreases while the anthocyanin content usually increases
[66]. The phenolic compound levels of fruits and vegetables may decrease during processing or
storage [73]. The stability of individual phenolic compounds is related to structure. For instance,
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catechin and ellagic acid are susceptible to heat due to its highly hydroxylated structure [73].
Cyanidins and delphinidins are less stable than pelargonidins during storage due to catechol
groups [74].
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Polyphenols, especially flavanol polymers, are associated with bitter flavors and an
astringent sensation [75, 76]. Astringency is defined as a puckering, rough and/or dry-mouth
feel [75]. Bitter and astringency are generally considered as unappealing sensory properties to
consumers. The plant-based foods that are rich in polyphenols, especially those that are rich in
flavanols, may lack palatability due to astringency [76]. Sweeteners, like sucrose, are used to
minimize bitterness and astringency in polyphenol-rich beverages, but beverages with added
sugar may be less attractive to health-conscious consumers [77]. In order to better capitalize
on the potential health benefits offered by polyphenols, effective strategies are needed to
mask the less pleasant flavor and sensation.
1.2.1.1 Anthocyanins
Anthocyanins are a subclass of flavonoids that belong to the polyphenol group. They act
as pollinator attractants and phytoprotective agents. Anthocyanins occur in all parts of plant:
the leaves, stems, roots, flowers and fruits

[78]. Anthocyanins are odorless and almost

flavorless, but as other phenolic compounds, they contribute to the astringent. Structurally,
anthocyanins have two benzene rings (A and B rings) and a heterocyclic ring (C ring). Most
anthocyanins are derived from six common aglycones (anthocyanidins): malvidin, petunidin,
delphinidin, peonidin, pelargonidin and cyanidin [79]. The structure of these aglycones is shown
in Figure 1.2. In plants, anthocyanins are commonly found in the form of glycosides. A sugar
moiety normally bonds to form the aglycone at position 3 of the C ring [79]. Sugar moieties that
are frequently linked to anthocyanidins are glucose, galactose, arabinose and rutinose [79].
Anthocyanins are strong antioxidants. The antioxidant capacity of anthocyanins depends on
their structure [80]. The ability of anthocyanins to neutralize free radicals depends on the
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delocalization of the π-electron system of aromatic rings. The free radical scavenging capacity
of anthocyanins is also related to the position of the hydroxyl groups [70].
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Figure 1.2 Structures of most common anthocyanidins [79]
Anthocyanins are also natural pigments that are responsible for the blue, red and purple
color in plants [78]. In the food industry, they are used as natural dyes [78]. The color of
anthocyanins is depended on the pH of the environment. When the environmental pH level
shifts from a strong acid to a mild alkaline, the structure of anthocyanins shifts from a flavylium
cation to a quinonoid (Figure 1.3) and the color changes from red to blue [81]. Anthocyanins are
colorless at a pH level of 4.5 [82]. Anthocyanins are labile to pH of the environment and an
acidic environment (pH 1-4) is beneficial to their stability, as they can easily degrade in alkaline
environments [83]. Many factors can accelerate the degradation of anthocyanins, such as
strong light and heat exposure [81]. The instability of anthocyanins restricts their utilization in
the food industry and negatively affects their bioavailability.
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Figure 1.3 Molecular structure of anthocyanins in different environmental pH levels [84]
1.2.1.2 Proanthocyanins
Proanthocyanins are oligomers or polymers of polyhydroxyflavans linked by the C-C
bonds, the polymerization of proanthocyanins can be up to 200 monomeric flavonol units [85].
Proanthocyanins are a subcategory of tannins which are also referred to as condensed tannins.
Proanthocyanins can break down to anthocyanidins when they are heated under acidic
conditions [86]. Proanthocyanins are widely present in plant-based food, such as tea, wine and
cereals [87]. They are strong antioxidants but relatively labile to thermal treatment and UV
exposure. Proanthocyanins are soluble in water, short-chain alcohols and acetone. At high
concentrations (40-45%), proanthocyanins may yield to viscous colloids in water at room
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temperature [88]. Proanthocyanins have a strong ability to bind to proteins and metal ions due
to their multiple phenolic hydroxyl groups [89]. The interaction between proanthocyanins and
salivary proteins causes an astringent sensation in the mouth. The intensity of this
astringency/bitterness is associated with the structure of proanthocyanins, especially the
degree of polymerization [90]. The levels of proanthocyanins decrease during the ripening
process of berries due to oxidation/degradation [90]. Food products using berries at their full
ripeness can help to reduce the unpalatable astringent sensation to some extent.
1.2.1.3 Phenolic Acids
Phenolic acids exist naturally in plants and are subcategorized as benzoic and cinnamic
acids depending on the number of carbon atoms (Figure 1.1). Benzoic acids contain seven
carbon atoms, such as gallic acid, salicylic acid, protocatechuic acid and ellagic acid. Cinnamic
acids contain nine carbon atoms, which include caffeic acid, ferulic acid, chlorogenic acid, pcoumaric acid, etc. [91]. Compared to hydroxybenzoic acids, hydroxycinnamic acids are more
commonly found in plant-based foods [92]. Phenolic acids are antioxidants and their
antioxidant capacity is related to its structure. Based on their antioxidant activity, phenolic
acids are utilized in the food industry as food preservatives and/or are used to prevent
enzymatic browning [93].
1.2.2 Potential Health-Promoting Characteristics of Polyphenols
1.2.2.1 Polyphenols and Oxidative Stress
The consumption of polyphenol-rich foods can increase the antioxidant capacity of the
human serum. Plaza et al. observed an enhanced serum antioxidant capacity in healthy
volunteers after consumption of jaboticaba peel (containing 1.25 g total phenolics with
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anthocyanins as the predominant phenolic compound) [94]. The ability of polyphenols to
increase serum antioxidant capacity may be achieved by improving the activity of endogenous
antioxidant enzymes, such as GPx, SOD and CAT. Noratto et al. demonstrated that the GPx
activity in obese diabetic mice fed with raspberry powder (containing 963 mg of extracted gallic
acid equivalent phenolics) was higher than the control group (no consumption of raspberry)
[95]. Wu et al. reported that the consumption of anthocyanin-rich mulberry extract and cherry
extract (200 mg/kg body weight) increased the activity of SOD and GPx in obese mice [96]. Shen
et al. conducted an experiment using mice fed with a high-fat diet and demonstrated that
supplementation with a polyphenol extract (containing flavonols and phenolic acids) from black
highland barley (600 mg/kg body weight) increased the levels of CAT, SOD and GPx in the liver
[97]. Increases in the gene expression of these antioxidant enzymes were also observed [97].
The improvement in the activity of antioxidant enzymes may enhance the antioxidant defense
system and be beneficial to reduce oxidative stress. In summary, polyphenol intake shows
promise to enhance the antioxidant capacity of the blood serum and decrease oxidative stress
by improving the activity and gene expression of endogenous antioxidant enzymes.
1.2.2.2 Polyphenols and Chronic Inflammation
Polyphenols can attenuate chronic inflammation by down-regulating the production of
pro-inflammatory cytokines and/or up-regulating the generation of anti-inflammatory
molecules. Lee et al. reported that after an eight-week supplementation with blueberries (10g
freeze-dried blueberry powder/100g diet), levels of pro-inflammatory cytokines (TNF-α and IL1β) in rats were lower compared to rats without blueberry supplementation [98]. Roth et al.
demonstrated that treatment of ingesting anthocyanin-rich bilberry extract reduced
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inflammation in patients with ulcerative colitis [99]. Compared to baseline levels (before
treatment), the levels of pro-inflammatory cytokines (TNF-α and interferon-γ) were decreased
and the levels of anti-inflammatory cytokines (IL-10) were increased [99]. The cytokine
regulatory activity of polyphenols may be related to their interaction with cellular proteins,
such as signaling molecules, receptors and transcription factors, and may influence the signaling
pathways [100, 101]. In addition, polyphenols may interact with nucleic acids and alter the
protein expression of inflammation-related molecules [100, 102].
1.2.2.3 Polyphenols and Type 2 Diabetes
Epidemiological studies reveal that higher consumption of polyphenols (mostly
flavonoids) is correlated with a lower risk of T2DM [2]. Wedick et al. investigated the
consumption of flavonoids and the risk of T2DM, the results showed that a higher intake of
anthocyanins was related to a lower risk of developing the disease. No relationship was found
between the consumption of other flavonoids and T2DM [3]. In addition to epidemiologic
studies, the beneficial properties of polyphenols are well documented in experimental studies.
Polyphenol intake can decrease cellular oxidative stress generated by metabolism and
potentially reduce the risk for the initiation and/or delay the progression of T2DM. In addition,
the consumption of polyphenols can increase insulin sensitivity and/or secretion, inhibit the
production of AGE and improve glucose homeostasis by decreasing glucose absorption and/or
increasing the cellular glucose uptake [103-106].
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1.2.2.3.1 Polyphenols and insulin sensitivity. Insulin is the key hormone for maintaining
glucose homeostasis. Insulin resistance commonly occurs in T2DM patients where the insulin
signaling and/or action on the target tissues is impaired [107]. Insulin resistance leads to a
lowered glucose uptake in non-hepatic peripheral tissues, a decreased suppression of hepatic
glucose production and an elevated level of plasma glucose. Polyphenol consumption can
attenuate insulin resistance. Oral administration of apple procyanidins ameliorated the hepatic
insulin resistance in diabetic mice by suppressing hepatic inflammation [108]. The
administration of anthocyanin-rich mulberry extracts improved insulin sensitivity in diabetic
mice via activation of AMP-activated protein kinase [109]. Insulin sensitivity was increased in
insulin-resistant-non-diabetic human subjects by consuming 333 mg/day of strawberry and
cranberry polyphenol mixtures for six weeks [110]. Increased insulin sensitivity may help to
decrease the hyperproduction of insulin and then restrain the β-cell failure [107, 111]. In
summary, polyphenol consumption may help to enhance insulin sensitivity and delay the
progression of T2DM.
1.2.2.3.2 Polyphenols and insulin-independent blood glucose control. Polyphenol intake
can aid in blood glucose control by delaying carbohydrate absorption. The inhibitory activity of
phenolic compounds on carbohydrate-hydrolyzing enzymes, such as pancreatic α-amylase and
α-glucosidase, has been well documented [112-114]. Pancreatic α –amylase is responsible for
hydrolyzing the α-bonds of large polysaccharides, such as starch and glycogen. Alphaglucosidase can catalyze the breaking down of 1, 4 - α bonds in oligosaccharides and
disaccharides. The inhibition of these digestive enzymes delays the digestion of complex
carbohydrates and reduces the proportion of absorbed glucose [103]. In addition, the
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consumption of polyphenols can increase the glucose uptake in skeletal muscle cells and help
to maintain blood glucose homeostasis. This effect may be related to the altered expression
and activity of GLUT4 through the activation of AMPK and/or PPAR gamma pathways [71, 115117].
1.2.2.1.3 Polyphenols and AGE production. The consumption of dietary polyphenols can
help to suppress the formation of AGEs under hyperglycemic conditions and delay the
progression of diabetic complications [118]. The anti-glycation activity has been investigated by
several in-vivo studies. Umadevi et al. stated that gallic acid had a protective effect on AGEinduced cardiac fibrosis in rats [119]. Chao et al. observed that the consumption of caffeic acid
and ellagic acid decreased the formation of glycation products in the kidney of diabetic mice
[120]. The anti-glycation property of polyphenols is related to their free radical scavenging
capacity, metal chelating activity and their capacity to trap reactive carbonyl species, such as
methylglyoxal [121].
In addition to the beneficial effects of phenolic compounds on diabetes, polyphenols are
reported to have beneficial activity toward other health-related problems, such as
cardiovascular disease [2], cancer [122], obesity [123], osteoporosis [124] and Alzheimer’s
disease [125, 126]. In order to better utilize the health-promoting potential of dietary
polyphenols, the bioavailability of dietary polyphenols from various sources needs to be
investigated.
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1.3 Bioavailability of Phenolic Compounds
Bioavailability is defined as the proportion of ingested food compounds that enter
metabolic circulation and reach specific sites in the body to exhibit biological function [127].
The bioavailability of different phenolic compounds varies, not only due to structural variations
in polyphenols, but also because of individual physiological and biochemical differences of
consumers. Generally, the bioavailability of phenolic compounds is relatively low due to low
absorption rates, instability of these compounds in the gastrointestinal tract (GIT) and quick
elimination [128]. Several steps are crucial for food constituents to be bioavailable: liberation,
absorption, distribution, metabolism and elimination [129]. Bioaccessibility is an important
factor to evaluate the potential of food compounds to be bioavailable and it is related to the
liberation process. Bioaccessibility is defined as the amount of food compounds that are
released in the GIT and have the potential to pass the intestinal barrier to be absorbed [127].
In-vitro digestion models are commonly used to evaluate the bioaccessibility of food
components. The metabolism and bioavailability of proanthocyanins, anthocyanins and
phenolic acid will be discussed in further detail in this section.
1.3.1 Bioavailability of Proanthocyanins
The bioavailability of proanthocyanins (condensed tannins) is generally low due to the
large molecular size of these compounds. Proanthocyanins are polymerized flavan-3-ols and/or
flavan-3,4-diols [85, 130]. Due to the large molecular size of proanthocyanins, it is unlikely for
them to be absorbed intact. In the stomach, in-vitro studies showed that some proanthocyanins
could be hydrolyzed into monomers due to the acidic environment [85], and then monomers

21

can be absorbed in the small intestine. However, in-vivo studies suggested that the
depolymerization of proanthocyanins in the upper GIT (stomach and small intestine) was
minimal [85, 131, 132]. The absorption characteristics of proanthocyanins in the small intestine
are largely affected by the degree of polymerization. Dimeric and trimeric proanthocyanins are
relatively easily absorbed because the permeability coefficients of proanthocyanins are similar
to a paracellular transport marker – mannitol [133]. The absorbed dimeric and trimeric
proanthocyanins reach the liver via the portal vein. The absorbed dimers/trimers conjugate in
the liver. The conjugated derivatives may be exported into the bile and go back to the intestinal
lumen or be released into the systemic circulation and then distributed to the organs. The
metabolites are excreted in the urine. Most large proanthocyanins pass the upper GIT without
alteration and reach the colon in their original form or as complexes with macronutrients.
Proanthocyanins that are not absorbed may be metabolized by the colonic microflora in the GIT
and excreted in the feces [134].
It has been suggested that proanthocyanins can exhibit bioactivity without being
absorbed by altering the gut microflora profile [135]. A study conducted with rats showed that
consuming proanthocyanins for three weeks caused a shift towards increasing gram-negative
bacteria in the GIT [136]. In addition, proanthocyanin-rich grape seed extract (38.5%, w/w)
increased the population of probiotics (Bifidobacterium) in healthy adults [137]. Gut microbiota
plays a vital role in human health, such as synthesizing vitamins and protecting the host from
potentially harmful invasive bacteria [128]. Thus, ingested proanthocyanins may affect human
health by modulating the composition and catabolic activity of the gut microbiota [138, 139].
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More studies are needed to better understand the impacts of proanthocyanins on gut
microflora and to better utilize the potential benefits of proanthocyanins.
1.3.2 Bioavailability of Anthocyanins
Anthocyanins are relatively easily absorbed compared to proanthocyanins. The stomach
is a major site for the liberation of anthocyanins from food matrices. The stomach pH and body
temperature helps to hydrolyze and/or release anthocyanins. The major absorption site of
anthocyanins is the small intestine [140]. Anthocyanin aglycones can pass the cellular
membrane of enterocytes via passive diffusion. The absorption of anthocyanin glycosides
involves enzymes or transporters [128, 141], such as lactate phlorizin hydrolase (LPH). LPH is
located in the enterocyte brush border and LPH can cleave the glycosidic moieties of
anthocyanin glycosides in the small intestinal lumen. The released aglycones can then enter the
enterocytes via passive diffusion [128]. In addition, anthocyanin glycosides can be transported
into the enterocytes in their glycoside form by using sodium-dependent glucose transporters
(SGLT) [141]. The anthocyanin glycosides are hydrolyzed within the epithelial cells by a cytosolic
β-glucosidase (CBG) and release the aglycones [140]. The absorption efficiency of anthocyanins
varies depending on their structure. Yi et al. demonstrated that the transport efficiency of
cyanidin glucoside was higher than cyanidin galactosides [142]. The authors also concluded that
fewer free hydroxy groups and more methoxy groups contributed to a higher absorption
efficiency [142]. The absorbed anthocyanin aglycones are transported via the portal vein to the
liver, where anthocyanins undergo phase II transformations including conjugations to methyl,
glucuronic acid and/or sulfate groups [141, 143]. After being metabolized in the liver,
anthocyanins can either re-enter the enteric system through bile or can be distributed to
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organs, such as the eyes, bladder, kidney, and brain [144-149] and then be excreted in urine
[141].
One restricting factor for the bioavailability of anthocyanins is their instability in an
alkaline environment. The small intestine is a mild alkaline environment and anthocyanins may
degrade in the small intestine before being absorbed [143]. The instability of anthocyanins in
the small intestine was observed by many studies using in-vitro models. Liu et al. reported that
42% of total anthocyanins from blueberries degraded during intestinal digestion [150].
Strategies that can increase the stability of anthocyanins in the small intestine may help to
enhance their bioavailability.
1.3.3 Bioavailability of Phenolic Acids
The absorption of phenolic acids can occur in the stomach, small intestine and colon
[151]. Absorption in the stomach provides the lowest phenolic absorption levels and may be
achieved by passive diffusion [152]. The small intestine, specifically the jejunum is the major
absorption site for phenolic acids [153]. The intestinal absorption of phenolic acids can occur
via monocarboxylic acids transporters (MCT) and the absorption rate is affected by the affinity
between phenolic acids and MCT [154]. Free phenolic acids are absorbed rapidly in the stomach
and in the small intestine [155, 156], but the majority of phenolic acids (approximately 80%) in
plant-based foods are bound to cell wall polymers by covalent cross-linkages [157] and are
inaccessible for absorption. Bound phenolic acids are insoluble and the human endogenous
enzymes cannot release them [155]. The microflora in the colon may produce enzymes that are
able to liberate the bound phenolic acids, such as xylanases and esterases [158]. The absorption
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of the released phenolic acids in the colon is low due to: 1) poor absorption capacity of the
colon and 2) break down of the aglycones by colon microflora [155]. Thus, the bound phenolic
acids can be released and absorbed in the colon to some extent. However, the bioavailability of
bound phenolic acids is lower than free phenolic acids.
After absorption, phenolic acids are distributed to organs and undergo several
biotransformations in the intestine, liver and kidney where the liver is the major site [151]. The
biotransformation

of

phenolic

acids

includes

dehydroxylation,

demethylation,

dehydrogenation, hydrogenation, O-methylation, sulphation, glucuronization, glycination
and/or GSH conjugation [151]. Phenolic acids and the conjugates may re-enter the intestinal
lumen via bile when the circulating levels are high. Phenolic acids are mainly excreted in the
urine in both the intact and biotransformed form [159].
1.3.4 Factors Affecting the Bioavailability of Phenolic Compounds
Many factors affect the bioaccessibility and bioavailability of phenolic compounds. First,
processing methods such as thermal treatments and storage may either increase the
bioavailability by enhancing the release of polyphenols from the food matrices [160] or
decrease the bioavailability by accelerating degradation [161]. Second, the interaction with
other ingested dietary ingredients such as proteins may alter the liberation process of phenolic
compounds and in most cases negatively affect the bioaccessibility of phenolic compounds
[162]. Third, the molecular structures of polyphenols have a vital impact on their bioavailability.
Larger phenolic compounds like proanthocyanins are difficult to absorb while the absorption
rates of smaller phenolics like phenolic acids are much higher. Fourth, digestion related factors,
such as the intestinal transit time of polyphenols and enzyme activity, may positively or
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negatively affect the release of phenolic compounds. Longer retention times in the small
intestine leads to more degradation of anthocyanins but longer retention times in the stomach
may cause more liberation [161]. Additionally, the microbiota in the lower GIT may break down
some larger phenolic compounds and increase their bioavailability [163, 164]. Fifth, the
frequency of polyphenol consumption may alter the expression of transport proteins and/or
metabolizing enzymes that associated with polyphenol metabolism in human [166, 167]. Thus,
consuming polyphenol-rich foods may affect their bioavailability by altering the individual’s
ability to absorb and metabolize phenolic compounds [165].
1.3.5 Potential Methods to Improve Bioavailability of Phenolic Compounds
1.3.5.1 Thermal Processing
Thermal processing methods are frequently used to heat treat food ingredients.
Thermal treatments can decrease the bioavailability of polyphenols in food by accelerating the
degradation process. Some phenolic compounds, such as anthocyanins, are labile to heat [168].
However, some thermal processing methods are found to be beneficial to enhance the
bioavailability of phenolic compounds in certain foods. For example, roasting nuts can increase
the amount of free phenolic acids which are more bioavailable compared to bound phenolic
acids [73, 169]. Rossi et al. reported that steam blanching blueberries inactivated the
polyphenol oxidase and resulted in an increase in extractable polyphenols [170]. ArkoubDjermoune et al. demonstrated that some thermal processing methods, such as grilling and
baking, enhanced the total phenolic compounds content and flavonol content in eggplant but
decreased the flavonoid and anthocyanin levels [171]. In summary, thermal processing may
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increase the bioavailability of some phenolic compounds in certain food matrices, but the
effects vary and need to be investigated on a case by case basis.
1.3.5.2 Fermentation
Fermentation has been widely utilized to process polyphenol-rich foods for centuries, as
in the making of wine. Fermentation not only adds flavor to the food but also modifies the food
components including phenolic compounds. Lactic acid bacteria are commonly utilized in
fermentation [172]. Some lactic acid bacteria, such as Lactobacillus plantarum, can metabolize
phenolic compounds and the metabolites may be more bioavailable [173]. Frediansyah et al.
demonstrated that black grape juice fermented with Lactobacillus plantarum exhibited higher
α-glucosidase inhibitory activity than non-fermented black grape juice [174]. Hole et al.
observed that fermentation with lactic acid bacteria increased the level of free phenolic acids in
whole barley grains and improved their bioavailability [175]. These increases may be caused by
the liberation of bound phenolic acids due to the esterase activity of lactic acid bacteria [175].
Similarly, Curiel et al. reported that due to the esterase activity, L. plantarum fermentation
increased the levels of gallic acid, ellagic acid, myricetin and quercetin in Myrtus communis
berries and increased radical scavenging capacity [176]. In addition to lactic acid bacteria, other
fermentative microorganisms may have the capacity to alter the bioavailability of phenolic
compounds. Wang et al. demonstrated that fermentation with yeast (Saccharomyces cerevisiae
bayanus EC 118) enhanced the anti-inflammatory activity of maqui berry juice by improving the
capacity to inhibit the expression of iNOS and COX-2 in a macrophage cell line (RAW264.7)
[177]. The authors concluded that this enhancement might be related to the increase of gallic
acid due to yeast fermentation [177]. In summary, fermentation may increase the
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bioavailability of dietary polyphenols by altering the structure, generating more bioavailable
metabolites and/or releasing the bound phenolic compounds. Studies in regard to the impacts
of fermentation on the bioavailability of phenolic compounds are limited. More research
involving various microorganisms and different food matrices is needed.
In addition to the above-listed processing methods (thermal processing and
fermentation), other methods, such as milling, high-pressure processing and encapsulation may
have positive impacts on the bioavailability of phenolic compounds [160, 178]. The effects of
processing on the bioavailability of phenolics depend on not only the processing methods, but
also the phenolic compounds structure and the food matrix. Currently, research studies are
investigating impacts of a variety of processing methods on the bioavailability of phenolic
compounds from different food matrices, but more processing studies are needed to efficiently
utilize the potential health benefits of certain phenolic compounds.
1.4 Aronia Berries
1.4.1 Botany and Current Commercial Utilization of Aronia Berries
Aronia shrubs are native to North America [179]. The genus Aronia (belongs to the
Rosaceae family and Maloideae subfamily) includes two species: Aronia melanocarpa and
Aronia arbutifolia. A. melanocarpa fruits are black, also known as the “black chokeberry”, “wild
gooseberry”, “chokepear” or “dogberry”. A. arbutifolia fruits are red and are known as the “red
chokeberry”. A third controversial species is called A. prunifolia (purple chokeberry), which is
considered a hybrid of A. melanocarpa and A. arbutifolia [180]. Most research has been
conducted on the black aronia – A. melanocarpa. In this thesis, the word “aronia” is used to
indicate the black aronia, specifically. Aronia are relatively easy to grow and they are not
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susceptible to severe diseases and pests [179]. Birds do not consume the fruit which may be
due to its astringent taste [179, 181, 182]. Mature aronia shrubs can be 2-3 meters in height
and yield up to 1.2 kg fruit/m2 in five years [183]. Aronia has been traditionally used as an
alternative medicine to treat colds among Native Americans [179]. Aronia gained popularity in
the Soviet Union and Eastern Europe in the 20th century, and it was used as a treatment for
hypertension, atherosclerosis, hemorrhoids and achlorhydria [179]. Currently, aronia extracts
are used as natural food colorants to provide dark purple or blue color [184]. Some food
products made with aronia, such as juice, jam, jelly and tea are commercially available in the
United States, but these products are limited. More products need to be developed with aronia
berries to increase their consumption [185].
1.4.2 Nutritional Value and Bioactive Compounds of Aronia Berries
The content of nutrients and bioactive compounds in aronia berries are affected by
several factors, such as the shrub cultivar, the maturation of the berries, the variety and
frequency of fertilizers used and the growth location/climate [186, 187]. Fresh aronia berries
contain 5.6% dietary fiber which includes pectin [188, 189]. The seedless fraction of aronia
pomace contains 70% dietary fiber on a dry weight basis [190]. Total sugar content in fresh
aronia is approximately 620 mmol/kg including 3.5% glucose, 2.8% fructose and 0.41% sucrose
[191]. Though the reported individual sugar content varies, glucose and fructose are the
dominant sugars in aronia berries [192, 193]. Aronia berries contain a relatively high amount of
sorbitol (46.2 g/kg), which is a sugar alcohol [192]. Malic acid is the predominant organic acid in
aronia berries, which is approximately 1.22 g/100 g in fresh berries, followed by citric acid (0.13
g/100 g). Tartaric acid, fumaric acid and shikimic acid are detected in aronia berries but these
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amounts are low [191]. Fresh aronia berries contain small amounts of fat (0.14 g/100g) and up
to 0.7 g/100g protein [183]. The predominant fatty acid is linoleic acid which is contained in its
seeds [194]. Aronia berries have a relatively high concentration of potassium (0.22 g/100g fresh
weight). Vitamins B1 (17-19 µg/100g), B2 (17-27 µg/100g), B6 (24-29 µg/100g), B9 (2-4 µg/100g),
C (4.0-19.3 mg/100g), niacin (27-34 µg/100g) and pantothenic acid (225-382 µg/100g) have also
been identified in aronia berries [183, 195].
Phenolic compounds are the most important bioactive compounds in aronia berries.
They are potentially responsible for the pharmaceutical effects of aronia, such as anti-influenza
activity [183]. Aronia berries are rich in phenolic compounds ranging from 1013 to 2010 mg
gallic acid equivalents/100 g fresh berries, which is higher than that in blueberries, bilberries,
blackberries, strawberries, blackcurrants and cranberries [191, 196 - 198]. The major type of
phenolic compounds in aronia are proanthocyanidins [199]. Procyanidins are the only form of
proanthocyanidins

found

in

aronia

berries.

Procyanidins

are

a

subcategory

of

proanthocyanidins that consist of (epi)catechin subunits and aronia berries have a high
concentration of procyanidins [198]. The degree of polymerization of aronia procyanidins
ranges from 2 to over 30 where large polymers are dominant. The major linkages between the
subunits of aronia procyanidins are C4-C6 and C4-C8 bonds [179]. The content of procyanidins
in dried aronia berries is above 5 g/100 g which is higher than the proanthocyanidins in other
berries, such as bluberries [200]. Anthocyanins are the second most dominant phenolic group in
aronia berries [179]. Aronia is one of the berries that contains the largest concentration of
anthocyanins [79]. Wu et al. reported that the total anthocyanin content in fresh aronia berries
was 1480 mg/100 g, which is higher than that in black raspberry (687 mg/100 g), wild blueberry
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(486.5 mg/100 g), blackcurrant (476 mg/100 g), blackberry (245 mg/100 g), cranberry (140
mg/100g) , and strawberry (21.2 mg/100 g) [201]. There are four major anthocyanins in aronia
berries: cyanidin-3-galactoside, cyanidin-3-glucoside, cyanidin-3-xyloside and cyanidin-3arabinoside where cyanidin-3-galactoside is the dominant anthocyanin followed by cyanidin-3arabinoside [199, 202]. Other anthocyanins were occasionally detected at low concentrations,
such as pelargonidin-3-arabinoside [198]. The major phenolic acids in aronia berries are
chlorogenic acid and neo-chlorogenic acid, the contents of which range from 16.3 to 301.8 and
from 92.3 to 291 mg/100 g in dried aronia berries, respectively [199, 203]. Other phenolic acids,
such as caffeic and ferulic acids were only occasionally identified in aronia berries [204].
1.4.3 Health-promoting Characteristics of Aronia Berries
1.4.3.1 Antioxidant Capacity of Aronia Berries
Antioxidant capacity is an important parameter to evaluate the potential healthbeneficial properties of a food ingredient. Aronia berries exhibit strong antioxidant capacity due
to the large amounts of phenolic compounds [196]. In addition, other compounds, such as
vitamin C and β-carotene, contribute to its antioxidant activity [205]. The consumption of
aronia berries can help to reduce oxidative stress and decrease cellular oxidative damage.
Aronia intake can increase the antioxidant capacity of the plasma and scavenge the excessive
free radicals in the human body. Nowak et al. observed an increase in plasma antioxidant
capacity in healthy people after one-week consumption of aronia juice [206]. In a double-blind
study with rowing athletes, Skarpanska-Stejnborn et al. stated that the antioxidant capacity of
plasma in athletes supplemented with aronia juice consumption (150 mL/day) for eight weeks
was higher than the placebo group [207]. Pilaczynska-Szczesniak et al. observed that daily
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intake of 150 mL aronia juice (containing 34.5 mg anthocyanins) reduced the levels of
thiobarbituric acid-reactive substances (TBARS) in the blood and concluded that an increase in
anthocyanin consumption could decrease exercise-induced oxidative damage to red blood cells
in athletes [208]. Lee et al. reported that aronia extracts reduced ROS production in HT22
mouse hippocampal cells and protected the cells against the glutamate-induced oxidative stress
[209]. The consumption of aronia berries can also improve the antioxidant defense system by
boosting the activity of endogenous antioxidative enzymes. Kardum et al. observed that after
consuming aronia juice for three months, the SOD and GPx activity in healthy women was
increased significantly [210]. Faff et al. observed that the reduction of GSH caused by exercise
was alleviated in aronia-fed rats [211]. A study conducted by Francik et al. showed that aronia
juice administration increased the activity of plasma CAT in rats fed a high-fat diet [212].
Kondeva-Burdina et al. stated that aronia juice prevented GSH depletion caused by tert-butyl
hydroperoxide-induced oxidative stress in rat hepatocytes and increased cell viability [213]. The
positive impacts of aronia on oxidative stress are potentially beneficial to prevent chronic
diseases and slow their progression.
1.4.3.2 Anti-inflammatory Activity of Aronia Berries
Chronic low-grade inflammation is one of the underlying factors of chronic diseases. A
reduction in low-grade inflammation may benefit the diabetic individuals by dealying the
progression of diabetic complications. Additionally, decreased low-grade inflammation may
reduce the risk of T2DM in individuals with metabolic syndroms. The anti-inflammatory effects
of aronia berries have been documented in in-vitro studies using cell models for understanding
the mechanisms. Appeal et al. stated that aronia juice concentrate activated the NF-ƙB pathway
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in RAW264.7 macrophages and inhibited the production of pro-inflammatory cytokines (TNF-α,
IL-6 and IL-8) in human peripheral monocytes which were isolated from a healthy human
volunteer [214]. Martin et al. reported that aronia berries inhibited IL-6 production in
lipopolysaccharide (LPS)-simulated mice splenocytes and that cyanidin-3-arabinoside might be
the major effective anthocyanin [215]. These studies demonstrate that aronia berries exhibit
anti-inflammatory activity by suppressing the production of pro-inflammatory cytokines.
In addition to in-vitro studies, the anti-inflammatory activity of aronia berries has been
tested in animal models. Ohgami et al. reported that aronia extract decreased the levels of NO,
TNF-α and prostaglandin (PG)-E2 in rats with endotoxin-induced uveitis [216]. Goh et al.
observed that aronia concentrate suppressed the formation of 12-o-tetradecanoylphorbol-13acetate (TPA)-induced ear edema in mice and decreased the production of pro-inflammatory
cytokines (TNF-α, IL-1β and IL-6) [217]. Kang et al. concluded that the consumption of aronia
berries ameliorated the symptoms of dextran sulfate sodium-induced ulcerative colitis (a type
of inflammatory bowel disease) in mice, and decreased the production of NO, IL-6 and TNF-α
[218]. Loo et al. carried out an intervention with individuals with slightly high blood pressure
levels and demonstrated that the consumption of dried aronia powder or aronia juice
(equivalent to about 336 g fresh berries per day) decreased low-grade inflammation, while
reductions in TNF-α were observed [219]. Low-grade chronic inflammation increases the risk of
T2DM and CVD. The anti-inflammatory activity of aronia berries can aid in the prevention and
treatment of chronic diseases. More in-vivo, especially clinical research studies, are needed to
establish recommended dosages.
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1.4.3.3 Aronia and Diabetes
The potential benefits of aronia berries for diabetes were suggested by several in-vitro
studies. Rugina et al. demonstrated that aronia extract helped to protect mouse pancreatic βcells (βTC3 cell line) from high glucose-induced cytotoxicity. The authors also observed that the
insulin secretion increased in the aronia extract-treated βTC3 cells [220]. Aronia extracts may
benefit insulin secretion by inhibiting the activity of dipeptidyl peptidase IV (DPP IV). DPP IV is a
serine peptidase which can reduce insulin secretion by inactivating incretin. The inhibition of
DPP IV can increase the secretion of insulin and be beneficial to diabetic individuals. Kozuka et
al. investigated the DPP IV inhibitory activity of aronia juice in-vitro and concluded that the
cyanidin 3,5-diglucoside was more efficient than cyanidin or cyanidin-3-glucoside to inhibit DPP
IV [221]. Aronia consumption may aid in modulating blood glucose levels by inhibiting enzymes
involved in carbohydrate absorption, such as α-glucosidase [222]. Wangensteen et al.
investigated the inhibitory activity of aronia extracts against α-glucosidase and demonstrated
that the inhibitory activity of aronia extracts was stronger than acarbose, which is a therapeutic
agent for diabetes [200]. In-vitro studies suggest that aronia may benefit diabetic individuals by
increasing the secretion of insulin and inhibiting carbohydrate-hydrolyzing enzymes.
The hypoglycemic effects of aronia have been documented by in-vivo studies using
animal models. Valcheva-Kuzmanova et al. reported that the levels of plasma glucose levels in
streptozotocin (STD)-induced diabetic rats were reduced after a six-week administration of
aronia juice. The authors observed 44% and 42% decreases in blood glucose in diabetic rats fed
with 10 and 20 mL/kg aronia juice, respectively [223]. Oprea et al. demonstrated that the
consumption of aronia juice decreased the blood glucose levels of alloxan-induced diabetic rats
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by 42.83% [224]. In a study conducted by Yamane et al., the blood glucose levels of diabetic
mice (KK-Ay mice) supplemented with aronia juice was lower than the control group (without
the supplementation of aronia juice). The trend was consistent over the entire experiment (28
days) [225]. In the same study, aronia juice consumption led to an inhibition of α-glucosidase
activity in the upper small intestine of diabetic mice. Hypoglycemic activity of aronia was also
observed in animal models with metabolic syndrome but not diabetes. Qin and Anderson
performed a study with Wistar rats fed a fructose-rich diet. They demonstrated that the
administration of aronia berry extracts (100 or 200 mg/kg body weight) lowered the risk factors
related to insulin resistance via a variety of possible mechanisms, such as enhancing mRNA
levels of insulin receptor substrate 1 and 2, which may help to increase insulin sensitivity [226].
Takahashi et al. illustrated that four weeks of aronia extract consumption (17.4 g aronia
polyphenols per kg diet) decreased the fasting blood glucose levels in high-fat diet-induced
obese rats [227]. In a human intervention conducted by Simeonov et al., three-month
consumption of aronia juice (200 mL/day) lowered the fasting blood glucose in 21 patients with
non-insulin dependent diabetes [228]. These studies demonstrate that aronia berries can help
to normalize blood glucose levels not only in diabetic individuals, but also in individuals with
metabolic syndrome. Clinical studies in regards to the impacts of aronia on diabetes are limited.
More studies are needed to confirm the beneficial properties of aronia for T2DM and to
establish effective dosages for human.
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1.4.3.4 Aronia and Other Health Problems
In addition to the antioxidant, anti-inflammatory properties and potential benefits for
daibetes, the consumption of aronia berries is also beneficial for other health problems. The
anti-influenza activity of aronia was reported by Park et al. in both in-vivo and in-vitro
experiments [229]. In this study, aronia extracts (0.125 mg/mL) exhibited more than 60%
inhibition against all five tested viruses (H1/K09, H3/PE16, B/BR60, H1/K2785 and HPAI
rH5/IS06) including oseltamivir-resistant strains (H1/K2785 and HPAI rH5/IS06). Oseltamivir is
an antiviral drug used to treat and prevent influenza. The inhibitory activity of aronia extracts
on the influenza virus was dose-dependent. Additionally, the authors observed that the lethal
rate of rPR8-GFP virus-infected mice was reduced by aronia treatment (1 mg/kg, twice daily)
[229]. In a long-term crossover intervention performed by Handeland et al., the incidence of
urinary tract infections (UTI) among nursing home residents was reduced after patients
consumed aronia juice for three months (containing 715 mg/100 mL gallic acid equivalent total
phenolics). The authors observed a 55% and a 38% decrease in UTIs among groups given 156
mL and 89 mL juice consumption, respectively [230]. Aronia consumption may have other
potential beneficials in addition to the properties mentioned above, such as chemoprotective
activity. More studies need to be performed to optimize the health-promoting properties of
aronia and the effective dosages of aronia consumption should be established. Additionally,
more mechanistic research should be carried out to further understand the mechanisms of how
aronia can have positively effects on human health.
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1.4.4 Challenge of Incorporating Aronia Berries in Diet
Regular consumption of aronia berries can increase the consumers’ daily intake of
phenolic compounds and potentially benefit their health. However, aronia berries are not
commonly consumed because they are less palatable than other popular berries, such as
blueberries. A major sensory attribute that negatively affects the flavor of aronia is the
astringency caused by the high phenolic content, especially procyanidins. Duffy et al. conducted
a sensory evaluation of aronia juice and concluded that the juice was not widely accepted due
to the low sweetness and high astringency [77]. The consumer acceptance was increased when
sweeteners were added to the juice [77]. Troszynska et al. observed that the addition of
polysaccharides (guar, xanthan, arabic gums and carboxymethylcellulose) decreased the
sensation of astringency in aronia extracts whereas carboxymethylcellulose was observed to
have the best effects on lowering astringency compared to other gums [231]. Ares et al.
investigated the ability of sucrose, sucralose, polydextrose and milk to mask the astringency of
phenolic-rich extracts from Achyrocline satureioides and Baccharis trimera by conducting a
sensory study [232]. Results of this study showed that milk was the most efficient in lowering
the astringent sensation followed by sucrose. Astringency is caused by the interaction between
polyphenols and salivary proteins. The authors stated that the milk proteins could complex with
polyphenols and yielded less available polyphenols to form insoluble compounds with salivary
proteins. Thus, the astringent mouth-feel was reduced [232]. One concern about using other
food ingredients to reduce astringency is the possibility of lowering the bioavailability of aronia
polyphenols. The liberation pattern of aronia polyphenols during digestion can be altered if
they interact with other food matrices, which affects the absorption of polyphenols. Another
37

concern about incorporating aronia into other food matrices is the stability of aronia
polyphenols may be lowered. For example, the addition of milk is able to decrease the
astringency of the phenolic-rich extract [232]. The pH of milk is neutral to slightly alkaline,
which negatively affects the stability of anthocyanins. Food products incorporated with aronia
in a neutral food matrix may not be able to maintain the full potential of health-promoting
properties during shelf life. In summary, in order to increase the consumption of aronia,
products with reduced astringency need to be developed. Additionally, in regard to optimize
the potential health benefits of aronia berries, the bioavailability of aronia polyphenols in the
new developed food products should not be decreased.
1.5 Elderberries
1.5.1 Botany and Current Commercial Utilization of Elderberries
Black elderberries (Sambucus nigra L. Family Adoxaceae) are deciduous shrubs that can
be located in shady, moist areas in Europe, northern Africa, west and central Asia, and North
America [233]. There are two subspecies of black elderberries: European elderberries
(Sambucus nigra L. ssp Nigra) and American elderberries (Sambucus nigra L. ssp. canadensis)
[234]. European and American elderberries are similar in most botanical characteristics, except
European elderberries are shrubs with a single or a few trunks while American elderberries
usually have many canes and can spread by underground rhizomes [235]. This thesis will focus
on the American elderberry, also known as the “American elder”.
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American elderberry is native to eastern and central North America [236]. American
elderberry plants are multi-stemmed shrubs that can reach up to 9 m in height [236]. The plants
bloom in early summer showing umbrella-shaped clusters of small, white flowers, which
develop into dark purplish-black berries in the late summer or early fall. A cluster of elderberry
fruits can contain up to 2,000 berries (5-9 mm in diameter for an individual berry) [236].
Elderberries are a very attractive food for birds. After consuming the berries, birds will then
disperse the seeds. Elderberry colonies are commonly located in areas where birds nest, such
as along railways, roadways, forest edges and fence lines [235]. Second-year American
elderberry shrubs can yield up to 3 kg per plant. At the fourth year, 8 kg average yields can be
achieved [236]. American elderberries can produce high yields (about 6 kg per plant) in cold
areas, such as Normandin, Quebec, Canada [237]. Traditionally, American elderberries and
elderberry flowers are used as herbal remedies to treat colds, flus and inflammation [238].
Elderberry food products have limited availability in the United States. Elderberry jams, pies,
wines and juices are the major types of food products on the market. However, the demand for
elderberries has increased due to their health-promoting properties [239]. More marketavailable products using elderberries may encourage farmers to grow elderberries, develop
value-added elderberry products and increase their income.
1.5.2. Nutritional Value and Bioactive Compounds of Elderberries
The nutrient level in elderberries is affected by many factors, such as the cultivar of the
plant, the degree of fruit ripeness and environmental conditions [239]. Citric acid is the
dominant acid in most cultivars of American elderberries followed by malic and succinic acid.
Fructose is the dominant sugar in elderberries followed by glucose [240]. American elderberries
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are a good source of vitamin C (36 mg/100 g fresh weight basis), potassium (280 mg/100 g fresh
weight basis), phosphorus (39 mg/100 g fresh weight basis), calcium (38 mg/100 g fresh weight
basis) and magnesium (5 mg/100 g fresh weight basis) [241].
American elderberries are rich in polyphenols. Phenolic compounds are the most
important group of bioactive compounds in elderberries. The total phenolic content of fresh
berries ranges from 277 to 532 mg gallic acid equivalents/100 g [235, 242, 243]. Elderberries
are among the berries that contain the largest amount of anthocyanins [79]. The content of
anthocyanins is up to 446.8 mg cyanidin-3-glucosides/100 g of fresh berries [242, 243]. Most
anthocyanins in American elderberries are cyanidin-based. Cyanidin 3-(E)-p-coumaroylsambubioside-5-glucoside and cyanidin-3-sambubioside-5-glucoside are the most abundant
anthocyanins. Cyanidin-3-glucoside, cyanidin-3,5-diglucoside and cyanidin-3-sambubioside have
been discovered in relatively high amounts in American elderberries [235]. More than 60% of
American elderberry anthocyanins are acylated anthocyanins. In addition to cyanidin-3-(E)-pcoumaroyl-sambubioside-5-glucoside,

cyanidin-3-(Z)-(p-coumarin-sambubioside-5-glucoside,

cyanidin-3-(p-coumarin)-glucoside and cyanidin-3-(p-coumarin)-sambubioside have also been
identified [239]. The presence of these acylated anthocyanins may be used to distinguish
American elderberries from European elderberries since acylated anthocyanins are not found in
European elderberries [235, 244]. Anthocyanins in American elderberries are more stable than
those in European elderberries when exposed to heat and light due to the presence of these
acylated anthocyanins. This stability advantage allows American elderberries to be used as a
source of industrial food colorants [244, 245]. Cinnamic acids, such as neo-chlorogenic acid,
chlorogenic acid and crypto-chlorogenic acid have been identified in elderberries where
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chlorogenic acid is dominant in most cultivars [235, 240]. Rutin (quercetin-3-rutinoside) is the
predominant flavonol glycoside in elderberries; other flavonols, such as isoquercetin,
kaempferol-3-rutinoside, isorhamnetin-3-rutinoside and isorhamnetin-3-glucoside have been
identified, as well [235].
1.5.3 Health Promoting Characteristics of Elderberries
The health-beneficial properties of European elderberries are well documented.
However, most studies involving American elderberries are in regard to cultivation. Research
that investigates the impact of American elderberries on health are limited. In this section,
European elderberry studies are included to introduce the potential bioactivity of American
elderberries on human health since they are closely related.
1.5.3.1 Antioxidant Capacity of Elderberries
American elderberries have been shown to exhibit strong antioxidant capacity in-vitro.
Ozgen et al. evaluated fourteen accessions of American elderberries by the ferric reducing
antioxidant power (FRAP) and the 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging capacity
[242]. All samples exhibited ferric reducing antioxidant power (13.4 – 31.7 µmol Trolox
equivalents/ g on a fresh weight basis) and DPPH scavenging capacity (5.4 – 13.5 µmol Trolox
equivalents/ g fresh weight basis). In the same study, authors observed a strong correlation
between antioxidant capacity and the levels of total phenolic compounds [242]. In a study
conducted by Simonyi et al., anthocyanin-rich extracts of American elderberries inhibited the
production of ROS in LPS or IFN-γ-simulated mouse microglial cells (bv-2), which means
American elderberries may help to decrease the cellular oxidative stress [246].
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Currently,

little to no research studies have documented the ability of American elderberries to decrease
oxidative stress in-vivo. The benefits of European elderberries on oxidative stress have been
observed in several animal studies. Dubey et al. demonstrated that the fish oil-induced
oxidative stress in BioF1B hamsters was attenuated by consuming European elderberry extract
[247]. Ciocoiu et al. reported that the consumption of European elderberry extract (0.05 g/kg
body weight every two days for 16 weeks) decreased lipid peroxides and inhibited LDL
oxidation in STD-induced diabetic rats [248]. In the same study, levels of reduced GSH and SOD
were elevated in both healthy and STD-induced diabetic rats [248]. These results indicate that
the consumption of European elderberries reduced oxidative stress in rats, which may due to
improving their antioxidant defense system. American elderberries may exhibit different
antioxidant activity in-vivo compared to European elderberries due to the presence of acylated
anthocyanins. More studies using rodent models or human subjects need to be conducted
better to understand and utilize the potential health-promoting properties of American
elderberries.
1.5.3.2 Anti-inflammatory Activity of Elderberries
The anti-inflammatory activity of polyphenol-rich fruits has been observed by both invivo and in-vitro studies [100, 249, 250]. However, studies on the anti-inflammatory activity of
American elderberries are rare. Simonyi et al. observed that the NO production in LPS or IFN-γstimulated mouse microglial cells (bv-2) was reduced by American elderberry extracts, which
means that the inflammatory response was decreased [246]. Seeram et al. demonstrated that
anthocyanin-rich extracts from American elderberries inhibited the activity of cyclooxygenase-1
and cyclooxygenase-2 (COX-1 and COX-2) in-vitro. The COX inhibitory activity of American
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elderberry anthocyanins was stronger than cranberries, blueberries and bilberries [251]. COX
can catalyze the production of prostaglandins which are important compounds in the
generation and promotion of the inflammation response [252]. Inhibition of COX activity can
decrease the degree of inflammation. Farrell et al. conducted an in-vivo study where mice were
fed European elderberry extracts for sixteen-weeks (20-40 and 200-400 mg/kg body weight).
Researchers observed lower levels of inflammatory markers (TNF-α and chemoattractant
protein-1) and decreased insulin resistance in obese mice compared to the control group [253].
However, the in-vivo anti-inflammatory activity of American elderberries has not been well
documented. More research investigating the anti-inflammatory bioactivity of American
elderberries needs to be conducted.
In addition to antioxidant and anti-inflammatory activities, American elderberries may
have other health-promoting properties that have been shown in research studies with
European elderberries, such as hypoglycemia [254, 255], anti-influenza virus [256, 257],
cardiovascular protective [258, 259] and chemoprotective activities [260]. However, the
composition of phenolic compounds in American elderberries are different than European
elderberries. Thus, the health-promoting properties of American elderberries may be different,
which provides justification for investigating the potential health benefits of consuming
American elderberries.

43

1.6 Kefir
1.6.1 History and Production of Kefir
Kefir is a fermented dairy beverage that has a creamy texture and sour taste along with
natural carbonation [261]. Kefir originated from the Caucasus Mountains in west Asia. The word
“kefir” is derived from the Turkish word “keyif” which means “good feeling” [262]. Kefir was
first discovered when the people of the Caucasus region stored fresh milk in leather pouches
and the milk naturally fermented into an effervescent beverage [263]. Around the Caucasus
region, kefir is commonly made with sheep milk. Currently, kefir is popular in European
countries where cow milk is the typical base [263].
The major difference between kefir and other fermented dairy products is the presence
of kefir grains and yeast. Kefir grains are white, cauliflower-shaped small granules (3-35 mm in
diameter). These kefir grains are used in the production of kefir and are recovered after the
fermentation process [264]. The composition of kefir grains varies due to many factors, such as
the incubation conditions and the types of milk used [265]. Generally, they are mixtures of
microflora, polysaccharides and proteins [261]. The microflora in kefir grains consists of up to
30 species of lactic acid bacteria, yeasts and sometimes acetic acid bacteria [261, 266]. The kefir
culture used in the research for this dissertation was a commercial products (Yogourmet®,
Canada) containing Lactococcus lactis subsp. lactis, Lactococcus lactis subsp. cremoris,
Lactococcus lactis subsp. bv. diacetylactis, Lactobacillus acidophilus and lactic yeasts. The
polysaccharides in kefir grains are known as kefiran, which comprises glucose and galactose
units [266], while the major proteins in kefir grains are caseins [261].
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Figure 1.4 Brief flowchart of traditional kefir production
Traditionally, kefir fermentation is initiated by adding kefir grains to cooled pasteurized
or unpasteurized milk. The fermentation process takes approximately twenty four hours at
room temperature [267]. After fermentation, kefir grains are recovered and separated by
filtering the kefir with sieves. The collected kefir grains are dried and stored at cold
temperature (4˚C) until the next inoculation [267]. However, lyophilized starters are typically
used in industry instead of kefir grains. One major reason is the difficulty of separating the kefir
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grains at the end of fermentation [266, 267]. In order to obtain consistent kefir products,
cultures with a known composition of microorganisms isolated from kefir grains may be used
[268]. A flowchart of traditional kefir production was illustrated by Guzel-Seydim et al. and is
shown in Figure 1.4 [269].
1.6.2 Nutritional Value of Kefir
The nutritional profile of kefir is affected by the milk composition, kefir grain
composition, fermentation conditions and storage conditions [270-272]. Sarkar reported that
kefir typically contains 89-90% water, 0.2% lipid, 3% protein, 6% sugar and 0.7% ash [270]. Kefir
is a source of complete protein, as the essential amino acid levels in kefir are reported to be:
376 mg/100 g lysine, 262 mg/100 g isoleucine, 231 mg/100 g phenylalanine, 220 mg/100 g
valine, 183 mg/100 g threonine, 137 mg/100 g methionine and 70 mg/100 g tryptophan [273,
274]. Kefiran, a heteropolysaccharide (glucogalactan), is the major sugar in kefir [261]. During
fermentation, the predominant sugar in milk – lactose, is hydrolyzed by β-galactosidase from
bacteria in kefir grains and metabolized to glucose and galactose. Glucose is utilized by lactic
acid bacteria which generates lactic acid. Lactic acid and/or galactose may be used as the
carbon source for the yeasts in kefir grains [275]. Kefir is a suitable dairy beverage for lactoseintolerant individuals due to the activity of β-galactosidase [270, 273, 275, 276]. Kefir contains
various vitamins, such as vitamins B1, B2, B5, B6, B12, folic acid, A, C and K [270, 276]. The vitamin
composition of kefir is influenced by both the type/composition of the milk used and the
microbial profile of the kefir grains [270]. Kefir is a good source of potassium (1.65%),
phosphorus (1.45%), calcium (0.86%) and magnesium (0.30%). Other minerals such as zinc,
copper, iron, molybdenum and cobalt were also reported in kefir [274]. Kefir has also been
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reported to have several bioactive compounds, such as bioactive peptides, exopolysaccharides
(kefiran) and probiotics. These bioactive compounds may work independently or synergistically
to enhance health-promoting activities [277]. The health-promoting properties of kefir will be
introduced in the next section.
1.6.3 Health Promoting Characteristics of Kefir
1.6.3.1 Anti-inflammatory Activity of Kefir
The anti-inflammatory activity of kefir has been documented by several studies using
animal models with metabolic syndrome. In a study performed by Rosa et al., metabolic
syndrome was induced in male SHR (Spontaneously Hypertensive Rats) by monosodium
glutamate injection. After ten weeks of administrating kefir to their diet (kefir group, 1 mL/day)
or using water as placebo (control group), a reduction in pro-inflammatory cytokines (IL-1β) and
an increase in anti-inflammatory cytokine (IL-10) were observed in the kefir group compared to
the control group. Beneficial effects on other biomarkers of metabolic syndrome, such as
reductions in plasma triglycerides and insulin resistance, were also observed [278]. Hadisaputro
et al. observed that the levels of pro-inflammatory cytokines (IL-1, IL-6) in STD-induced
hyperglycemic rats were decreased after thirty days of plain kefir consumption (3.6 mL/day).
Additionally, an increase in the anti-inflammatory cytokines (IL-10) was observed in the kefirfed rats [279]. The anti-inflammatory activity of certain compounds in kefir was investigated.
Kwon et al. reported that the administration of kefiran (50 mg/kg body weight) reduced the
numbers of inflammatory cells in the lavage fluid and the lung tissues of female mice with
ovalbumin-induced asthma. The levels of inflammatory cytokines (IL-4 and IL-5) in
bronchoalveolar lavage fluid was reduced to normal after kefiran consumption [280]. Chen et
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al. performed an experiment using kefir peptide and male mice challenged with high-fructose
corn syrup [281]. The results revealed that the status of mice with fatty liver syndrome was
improved by kefir peptides administration. Decreased levels of inflammatory cytokines (TNF-α,
IL-6 and IL-1β), hepatic triglycerides, cholesterol and serum alanine aminotransferase were
observed in mice fed with kefir peptide compared to mice fed water [281]. In summary, regular
consumption of kefir may help to ameliorate the symptoms of metabolic syndrome and
decrease the risk of chronic diseases due to anti-inflammatory activities. Kefiran and bioactive
peptides appear to contribute to the anti-inflammatory activities.
1.6.3.2 Kefir Benefits for Diabetes
The consumption of kefir may benefit diabetic individuals by aiding in blood glucose
control. In a double-blind intervention conducted by Ostadrahimi et al., sixty T2DM patients
were divided into two groups and consumed 600 mL kefir per day (probiotic group) or 600 mL
placebo per day (conventional fermented milk without probiotics). After an eight-week
intervention, the fasting blood glucose levels and the glycated hemoglobin A1C (HbA1C) levels
of the probiotic groups (6.40 ± 1.91) were significantly reduced compared to baseline (7.61 ±
1.22) [282]. These results indicated that regular consumption of kefir could aid in the blood
glucose control of individuals with diabetes. Compared to the control group, the fasting glucose
levels and HbA1C levels of the probiotic groups were lower. These results also showed that the
probiotic microorganisms (Lactobacillus casei, Lactobacillus acidophilus and Bifidobacteria)
played an important role in the hypoglycemic activity of kefir [282]. In a study using diabetic
KKAy mice, Maeda et al. observed that a thirty-day feeding of kefiran lowered the blood
glucose in these mice [283]. Reductions in insulin resistance resulting from kefir
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supplementation was observed by Rosa et al. in rats with metabolic syndrome [278]. Teruya et
al. investigated the effects of kefir on glucose uptake in an insulin-responsive muscle cell line
(L6 skeletal muscle cells). The authors reported that the glucose uptake ability of L6 cells was
increased by a water-soluble fraction of kefir in the presence or absence of insulin [284].
Punaro et al. demonstrated that eight-weeks kefir consumption (1.8 mL/day) reduced glycogen
accumulation in the renal tubules of STD-induced type 1 diabetic rats. This result indicates that
kefir can slow the progression of renal injury in diabetic individuals [285]. Thus, kefir intake may
be beneficial to diabetic individuals via modulating blood glucose levels, decreasing insulin
resistance, increasing glucose uptake in muscle and reducing the progression of diabetic
complications. The potential benefits of kefir for diabetes may be attributed to both the
probiotic microorganisms and the microbial metabolites, such as kefiran.
In addition to anti-inflammatory properties and potential benefits to diabetes, kefir has
been documented to have anti-allergic activities [286], anti-carcinogenic effects [287],
cardiovascular protective activity [288, 289] and the ability to modulate gut microflora [286,
290]. The probiotic microorganisms in kefir contribute to their health-promoting properties. In
addition, the cell-free fractions of kefir, such as kefiran and bioactive peptides, also exhibit
health-promoting activities [264, 291].
1.7 Conclusions
The onset and progression of T2DM is associated with oxidative stress. The
consumption of dietary antioxidants may help to reduce the risk of T2DM and slow the
progression of secondary complications via decreasing oxidative stress. Dietary polyphenols are
strong antioxidants. Higher consumption of polyphenols has been associated with many health
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benefits. Aronia and American elderberries are polyphenol-rich fruits, and their healthpromoting properties have been suggested by many studies. The health-promoting properties
of phenolic compounds, aronia berries and elderberries are shown in Table 1.1. Aronia berries
and elderberries are suitable to be grown in most areas of the United States, including Maine,
but the consumption of these berries is low due to their unpalatable taste and limited types of
commercial products. The development of new products that are acceptable to consumers may
help to increase the consumption of these berries. One concern about developing food
products using these berries is that processing and the addition of other food ingredients may
lower the amount of bioavailable berry phenolics. Kefir, a fermented dairy beverage, may be a
suitable food matrix for the incorporation of berries due to the following reasons: 1) kefir is
acidic and the low pH environment can be beneficial to the stability of phenolic compounds; 2)
kefir is rich in proteins, which may help to mask the astringency of polyphenols; 3) the
fermentative microorganisms in kefir may increase the bioavailability of phenolic compounds.
In order to ensure consumers will receive the optimal health benefits of theses berries, the
health-promoting properties of the newly developed products must be evaluated. Therefore,
research studies in this dissertation focused on the development of berry-added kefirs and the
evaluation of their bioavailability and heath-beneficial characteristics.
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Table 1.1 Health-promoting characteristics of phenolic compounds, aronia berry, elderberry
and kefir

Phenolic compounds

Aronia berry

Elderberries
(American)

Kefir

Health-promoting characteristics
Reduce oxidative stress in-vivo
Attenuate chronic inflammation
Beneficial to T2DM, including increase insulin sensitivity, aid in blood
glucose control, and decrease AGE production
Reduce oxidative stress in-vivo
Anti-inflammatory activity
Beneficial to T2DM, including increase insulin secretion and help to
control postprandial blood glucose
Others: anti-influenza activity, anti-infection, etc.
Anti-oxidant capacity in-vitro
Anti-inflammatory activity
Anti-inflammatory activity
Beneficial to diabetes, including decrease insulin resistance, aid in
blood glucose control and reduce glycogen accumulation
Others: anti-allergic activity, anti-carcinogenic effect, cardiovascular
protective activity and gut microflora modulatory effect.
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CHAPTER 2
DEVELOPMENT AND EVALUATION OF KEFIR PRODUCTS MADE WITH ARONIA OR ELDERBERRY
JUICE: SENSORY AND PHYTOCHEMICAL CHARACTERISTICS

This chapter is accepted by the International Food Research Journal and will be
published in volume 25, issue 4.

2.1 Chapter Abstract
Aronia and elderberry are edible berries that are rich in anthocyanins and phenolic
compounds. They are rarely consumed raw due to safety concerns and their unpalatable taste.
Aronia and elderberry are not widely grown and they are not commonly used as food
ingredients for commercial products, thus they are considered underutilized. Incorporating
these berries into new products, such as kefir, provides diverse food choices and may increase
the dietary consumption of these bioactive compounds. In this study, kefir containing either
aronia or elderberry juice was developed using different sweeteners and levels of sweetness.
Sensory tests were conducted to evaluate the consumer acceptability of the kefir products
made with fresh aronia juice or commercial elderberry juice from Wyldewood Cellars® (Wichita,
KS, U.S.). In the aronia kefir sensory test, the product sweetened with sucrose received the best
overall acceptability (6.3) while the product sweetened with monk fruit extract was least
favored (4.9). In the elderberry kefir sensory test, 5.7% sucrose-sweetened product was best
accepted (6.6) followed by 4.3% sucrose-sweetened (6.1). Non-nutritive sweeteners (stevia and
monk fruit extracts) were less accepted than sucrose in both tests. Phytochemical analyses
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showed that aronia kefir contained high amounts of total phenolic compounds and
anthocyanins. Kefir made with commercial elderberry juice had a moderate amount of total
phenolics and a low amount of anthocyanins. Antioxidant capacity was observed in all products
indicating that the consumption of berry-added kefir may benefit the decrease of oxidative
stress. Kefir made with aronia or elderberry are acceptable functional foods which may
contribute to the prevention of inflammation and chronic diseases when incorporated into a
healthy diet.
2.2 Introduction
Epidemiological studies suggest that the consumption of anthocyanin-rich fruits may
contribute to decreasing the risk of type 2 diabetes [3]. The protective impacts of phenolic
compounds on oxidative-stress-related diseases are related to their high antioxidant capacity
[292-294]. Rios et al. indicate that blueberry extracts rich in polyphenols could decrease the
levels of oxidized DNA bases in human subjects and attenuate DNA damage induced by H 2O2
[295]. Anthocyanin intake (two levels, 40 and 200mg/kg) is able to reduce high-fat-diet-induced
oxidative stress in mice by boosting the activity of antioxidant enzymes (SOD and GPx).
Systemic inflammation could be decreased with this range of intake by lowering the expression
levels of inflammatory cytokines, such as IL-6 and TNF-α [296]. In-vitro studies revealed that
anthocyanin-rich extracts could inhibit the formation of advanced glycation end products and
consequently decrease the risk of diabetic complications [297].
Aronia melanocarpa (aronia) and Sambucus nigra L. ssp. canadensis (elderberry) are
berries that contain high amount of anthocyanins and polyphenols [179, 239]. They are not
widely commercial cultivated thus they are underutilized. These berries exhibit high antioxidant
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capacity due to the phenolic compounds. Aronia and elderberry are known to reduce oxidative
stress in humans [196, 298]. Aronia and elderberry are popular in Europe where they are
utilized as functional food ingredients and color additives [179, 299]; however, a market for
these berries in the United States has not been well developed.
Kefir is a fermented dairy beverage that originated in the Caucasus Mountains region
over one hundred years ago [268, 300]. Kefir grains consist of complex microbial communities
and contain up to 30 species [301] where lactic acid bacteria is usually predominant, followed
by yeast and acetic acid bacteria [264]. Several studies suggest that kefir has anti-microbial,
anti-inflammatory, and anti-carcinogenic activities [275, 302, 303]. Kefir is naturally lactosefree, this property makes kefir a good source of calcium and protein for lactose intolerant
individuals [270]. The fermentative microorganisms may have the ability to increase the
bioaccessibility and bioavailability of phenolic compounds due to the release of bound phenolic
constituents by some lactic acid bacteria [315, 304]. The low acid environment of kefir is helpful
to decrease the natural degradation of phenolic compounds [305]. Therefore, the combination
of anthocyanin-rich berries and kefir may result in a value-added functional product. The
objective of this study was to develop functional food products by incorporating either aronia
or elderberry juice into a kefir beverage and evaluate their sensory and phytochemical
characteristics. Different natural sweeteners (sucrose, stevia or monk fruit extract) were used
to enhance the sweetness of the products. The consumer acceptability of the products was
evaluated via sensory tests. The aronia sensory test focused on the impact of sweetener variety
on consumer acceptability. The elderberry kefir sensory test assessed the influence of
sweetness levels. Bioactive constituents of the kefir products were analyzed in the laboratory.
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2.3 Material and Methods
2.3.1 Chemicals
Methanol, citric acid anhydrous, potassium chloride, hydrochloric acid, and sodium
bicarbonate were obtained from Fisher’s Scientific (Waltham, MA, U.S.). 2, 2-diphenyl-1picrylhydrazyl (DPPH), Folin - Ciocalteu’s phenol reagent and gallic acid were purchased from
Sigma-Aldrich (St. Louis, MO, U.S.), and sodium acetate from Chem-Impex int’l inc. (Wood Dale,
IL, U.S.). Ultrapure water was obtained from a Millipore water system (EMD Millipore, Billerica,
MA, U.S.).
2.3.2 Dietary Material
Aronia (Aronia melanocarpa, variety ‘Viking’) were obtained from the University of
Connecticut (Storrs, CT, U.S.) from the 2014 growing season. Elderberry juice was a gift of Dr.
John Brewer from Wyldewood Cellars® (Wichita, KS, U.S.). Elderberries (Sambucus nigra, L. ssp.
canadensis) used in making samples for fresh juice phytochemical analyses were collected from
the experimental garden at the University of Maine (Orono, ME, U.S.) during the 2015 harvest
season. Berries were harvested at full ripeness which was determined by a deep purple color
and softness of the berry. They were de-stemmed and washed, then frozen at -20˚C. The
thawed berries were pasteurized (100˚C, 5 minutes) in an aluminum sauce pan then juiced with
a domestic juicer (Hamilton Beach, Southern Pines, NC, U.S.). Juice yield from 1 kg berries
averaged 360 g. Fresh juice was used immediately to make the kefir products. Commercial kefir
culture (Yogourmet®, Lachute, QC, Canada) was used as the starter for the kefir. The viability of
the lactic bacteria in the starter was determined by inoculation on MRS agar (Nedgen, Lansing,
MI, U.S.) at 40˚C for 48 hours. The viability of the yeast in the starter was measured by plating
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on antibiotic plate counting agar (Alpha Biosciences, Baltimore, MD, U.S.) at room temperature
for 96 hours. Sucrose (Great Value®, Bentonville, AR, U.S.), stevia extract (Stevia in the Raw®,
New York City, NY, U.S.), monk fruit extract (Monk Fruit in the Raw®, New York City, NY, U.S.)
and 2% milk (Oakhurst®, Portland, ME, U.S.) were purchased from local supermarkets.
2.3.3 Kefir Manufacture and Formulas
All kefir products were prepared by the following method: 2% milk was heated to 82˚C
in a commercial size aluminum sauce pan, cooled to 26˚C using an ice bath, and then
transferred to a 4 L pyrex glass bowl. The commercial starter was added to the milk (5 g per
quart), and the mixture was stirred for 5 minutes to ensure the starter was dissolved. Either
aronia juice (~13%, w/w) or elderberry juice (~10%, w/w) was added to the mixture. The
amount of non-nutritive sweetener used in each product was adjusted according to the
instruction on the package to create equal sweetness to sucrose. After the addition of all
ingredients, the mixture was covered with a cloth and left at room temperature to ferment for
24 hours. The kefir was homogenized with a Hamilton Beach immersion blender (Southern
Pines, NC, U.S.). Each kefir product was divided into two containers with sealed lids and stored
at 4˚C. The kefir was allowed to chill at 4 ˚C for 2 hours prior the sensory tests. The sensory
tests were completed within 36 hours. Formulas are shown in Table 2.1. Kefir products were
only formulated with juice and sweetening agents (sucrose, stevia extract, or monk fruit
extracts); no additional modifiers were used. Low sucrose levels were selected for reducing
calorie content and to ensure that the predominant flavor was from the berry juice.
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An aliquot of the kefir prepared for the sensory test was collected and stored at -20˚C
until laboratory analyses. The initial study design was to utilize fresh berry juices for the kefir
products but due to crop failures in 2013 and 2014, fresh elderberries were not available.
Commercial elderberry juice (shelf-stable product) was used in this study. To better understand
the difference between commercial and fresh elderberry juice, an additional set of elderberry
kefir products made with fresh juice was prepared and analyzed in the laboratory at a later
date.
Table 2.1 Formulas of kefir products for sensory evaluation
Product

Aronia kefir

Elderberry
kefir
(commercial
juice)

Elderberry
kefir
(Fresh juice)

Sweetener

sucrose
stevia
monk fruit
low sucrose
(4.3%)
high sucrose
(5.7%)
low stevia
(0.4%)
high stevia
(0.6%)
low sucrose
(4.3%)
high sucrose
(5.7%)
low stevia
(0.4%)
high stevia
(0.6%)

Milk with
starter (g)
83
83
83
90

Commercial
elderberry
juice (g)
---------10

Fresh
elderberry
juice (g)
-------------

90

10

----

90

10

90

Sucrose
(g)

Stevia
(g)

4.0
------4.5

---0.40
-------

Monk
fruit
(g)
------0.80
----

----

6.0

----

----

----

----

----

0.45

----

10

----

----

----

0.60

----

90

----

10

----

4.5

----

----

90

----

10

----

6.0

----

----

90

----

10

----

----

0.45

----

90

----

10

----

----

0.60

----

Note: ---- indicates the ingredient was not used in the formula
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Fresh
aronia
juice (g)
13
13
13
----

2.3.4 Sensory Analyses
All sensory tests were performed in the Sensory Testing Center at the University of
Maine, Orono campus. Sensory tests were approved by the Institutional Review Board for the
Protection of Human Subjects at the University of Maine (IRB). Two tests were conducted and
100 healthy participants for each test were recruited from the community. Demographic
information was collected, such as age and gender. Consumer familiarity with the berries and
kefir was assessed. Consumer attitude toward purchasing healthy food was asked. Color, flavor,
sweetness, texture and overall acceptability of all samples were evaluated using a 9-point
hedonic scale (1=dislike extremely, 5=neither like nor dislike, 9=like extremely). Products
received random 3-digit codes and samples were presented to the consumers in a randomized
sequence. Samples were served cold (4 ˚C) in transparent 2 oz plastic cups and water was
offered as a palate cleanser. Information was collected anonymously with computers using
SIMS Sensory Software® (Berkeley Heights, NJ, U.S.). Each participant was compensated with $2
for completion of the sensory test.
2.3.5 pH, Titratable Acidity, Total Soluble Solids and Color Measurements
pH, titratable acidity (TA), and total soluble solids (˚Brix) were evaluated following the
methods reported by Mena et al. with minor modification [306]. Briefly, pH was measured
using a Sartorius pH meter (Bohemia, NY, U.S.). TA was determined by titrating 5 g of kefir with
0.1 M NaOH solution. The results were expressed as % lactic acid [307] in kefir and % citric acid
in juice. Total soluble solids were tested using a PAL-3 refractometer by Atago (Tokyo, Japan)
and values were expressed as ˚Brix. The color was measured using a LabScan XE
spectrophotometer manufactured by HunterLab (Reston, VA, US) and was recorded as L*
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(lightness), a* (redness/greenness), and b* (yellowness/blueness). Hue angle and Chroma
values were calculated by the following formulas [308, 309].
Hue = Arc tan(𝑏 ∗ ⁄𝑎∗ ) for the first quadrant (+a, +b)
Hue = 360 + Arc tan(𝑏 ∗ ⁄𝑎 ∗ ) for the fourth quadrat (+a, -b)

Chroma = √(𝑎∗ 2 + 𝑏 ∗ 2 )

pH and ˚Brix were measured in triplicate, TA was measured in duplicate due to limited
sample availability. Color was measured in five independent tests to confirm the uniformity of
the sample and obtain representative results.
2.3.6 Extraction
Phenolic compounds were extracted following the method reported by Scibisz et al.
with modification [310]. After adding acidified 80% methanol (1% citric acid, w/v, 1:10,
sample:solvent) to the kefir matrix, the mixture was vortexed then sonicated in a Branson 5510
sonicator (Danbury, CT, U.S.) for 1 hour. Samples were centrifuged at 16639×g (Eppendorf
5804R, Hamburg, Germany) for 30 minutes at 4˚C. The supernatant was collected. This process
was repeated three times. The combined supernatant was evaporated under a vacuum
(Eppendorf Vacufuge plus, Hamburg, Germany) at room temperature. Dried samples were resuspended using acidified 100% methanol (1%, citric acid), and kept at ˗20˚C for one hour to
precipitate the protein. The slurry was then centrifuged at 16639×g for 30 minutes at 0˚C and
the supernatant was collected. Supernatant was dried under a vacuum and re-suspended with
80% acidified methanol (1%, w/v). The extract samples were kept at ˗20˚C until analyses.
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2.3.7 Total Phenolic Content
TP content was determined using the Folin-Ciocalteu method as described by Velioglu et
al., with minor modifications [311]. Briefly, after mixing extract (20 µl) and Folin-Ciocalteu
reagent (90 µl), the plate was left at room temperature for 5 minutes and then sodium
bicarbonate (6 g/100 ml, 90 µl) was added. The plate was covered and incubated at room
temperature in the dark for 90 minutes. The absorbance was read at 750 nm with a Biotek plate
reader (ELx 800, Winooski, VT, U.S.). All samples were measured in triplicate, and the results
are expressed as gallic acid equivalents (GAE).
2.3.8 Total Monomeric Anthocyanin Content
TMA content was determined using the pH differential method developed by Lee et al.
with modifications to fit a 96-well plate format [82]. Briefly, the extract (20 µl) was diluted with
180 µl of pH 1.0 buffer (0.025 M, potassium chloride) and 180 µl pH 4.5 buffer (0.4 M, sodium
acetate) separately. The mixture was incubated for 20 minutes at room temperature in the
dark. The absorbance (abs) was read at 520 nm and 690 nm using the plate reader. The TMA
content was calculated by the following formula and expressed as cyanidin-3-glucoside (C3G)
equivalents.

Anthocyanin (cyanidin − 3 − glucoside equivalents , mg⁄L) =

A ×MW×DF×103
ε×L

Where: A = (abs520 nm – abs700 nm) pH 1.0 – (abs520 nm – abs700 nm) pH 4.5;
MW (molecular weight) = 449.2g/mol for cyanidin-3-glucoside;
DF = dilution factor;
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L = pathlength in cm;
ε= 26900L/mol·cm, for cyanidin-3-glucoside;
103 = factor for conversion from g to mg.
2.3.9 Antioxidant Capacity
Antioxidant capacity was determined using the 2,2-diphenyl-1-picrylhydrazyl (DPPH)
free radical scavenging method by Duymus et al. with minor modifications [312]. 150 µl of
DPPH solution (0.3 mM) were added to 150 µl serially diluted extracts, the mixture was
incubated in the dark at room temperature for 30 minutes and read at 515 nm. The inhibition
rate was calculated by the following formula:

%inhibition =

Abs𝐶𝑜𝑛𝑡𝑟𝑜𝑙 −Abs𝑆𝑎𝑚𝑝𝑙𝑒
Abs𝐶𝑜𝑛𝑡𝑟𝑜𝑙

× 100

Inhibition (%) was plotted against extract concentration, and the IC50 (the concentration
to scavenge fifty percent of DPPH free radical) was calculated. Gallic acid was used as a positive
control.
2.3.10 Statistical Analysis
Data are shown as mean ± standard deviation. Sensory data were analyzed with oneway analysis of variance using JMP 12 software by SAS Institute Inc. (Cary, NC, U.S.). Tukey’s
Honest Significant Difference (HSD) test was used for mean comparisons. Pearson test was used
to determine correlations. A significance level was set at α = 0.05.
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2.4 Results and Discussion
2.4.1 Aronia Kefir Evaluations
2.4.1.1 Aronia Kefir Sensory Test
Three aronia kefir products containing different sweeteners were evaluated in this test.
The only difference among aronia kefir products was the type of the sweetener. Participants’
perception about different sweeteners could be assessed. Demographic results demonstrated
that participants in this test were balanced in gender (54 female and 46 male), and the general
age range was 18-34 years old. A question about the importance of purchasing food with
potential health benefits was addressed and 94% of participants responded positively. Thus,
functional food products, like aronia kefir, comply with consumer purchasing trends. Sensory
attributes and overall acceptability results are shown in Figure 2.1. The results show that the
participants accepted the color of all the products equally; however, significant differences in
acceptability were detected for other attributes. Based on the ratings for sweetness, the
participants liked the sucrose-sweetened sample best followed by stevia and monk fruit extract
was the least favored. Similar results were obtained by another study where chocolate milk
sweetened with sucrose received better acceptability compared to stevia or monk fruit extracts
[313]. A study by Cardello et al. demonstrate that many non-nutritive sweeteners, such as
stevia and aspartame have a residual bitter taste which is not well accepted by the consumers
[314]. In our test, consumers noted that kefir products sweetened with non-nutritive
sweeteners (stevia and monk fruit extract) had a “bad”, “longer”, or “unpleasant aftertaste”
which lowered consumer liking of the products. Flavor was best received in the sucrosesweetened aronia product. Kefir has a unique flavor due to the lactic acid and carbon dioxide
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[273]. In this study, aronia juice and sweeteners were added to the kefir, and contributed to the
overall flavor profile. Aftertaste of non-nutritive sweeteners may be a reason for the low
hedonic scores of the products in the flavor attribute. The best texture was received in the
sucrose-sweetened product where a thicker consistency was noticed. Cardoso and Bolini
indicated that sucrose contributed a more viscous texture to a beverage product compared to
non-nutritive sweeteners [315]. The unique foamy texture of kefir generated by carbonation
during fermentation [267] may be novel to the American palate and may have an impact on the
acceptability. Consumer preference of the texture may be influenced by the viscosity and the
carbonation of the product. The best overall acceptability (6.3) was received in aronia kefir
made with sucrose. Aronia kefir made with monk fruit extract, by contrast, received the lowest
hedonic score (4.9). In addition to the influence by sweeteners, consumers’ unfamiliarity with
the kefir and/or aronia berry may be another reason which had an impact on the overall
acceptability of the products. Over half of the participants (57%) were naive to kefir (never
consumed kefir previously) and 78% were not familiar with aronia. Orjuela-Palacio et al. proved
that repeated exposure to a high-polyphenol beverage increased the consumer acceptance
[316]. This indicates that the acceptability of the kefir products in this study could be higher if
our participants were more familiar with either kefir or aronia. Generally, overall acceptability
of each aronia kefir product was better received by participants who were previously familiar
with kefir compared to the kefir-naive participants (data not shown).
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Aronia kefir with sucrose
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Overall
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Figure 2.1. Consumer acceptability of aronia kefir made with different sweeteners
Note: Data are shown as means ± standard deviation. n=100.
Different letters indicate significant differences among means within each attribute,
p<0.05.
2.4.1.2 Aronia Kefir Quality Parameters
The results of pH, TA, ˚Brix and color of aronia kefir are shown in Table 2.2. The pH
values of aronia kefir were in the acidic range as expected and this acidic environment is
necessary to maintain the integrity of the phenolic compounds [305]. TA is representative of
the sour taste in the product. Lactic acid produced by the kefir culture and organic acids in
aronia juice contributed to TA values. No correlation was observed between TA and pH (r = 0.13, p = 0.73). The highest ˚Brix value was observed in the sucrose-sweetened product as
expected. Several factors contribute to the ˚Brix of the product. They include the added
sucrose, fructose in aronia berries and the breakdown products of the milk disaccharides by the
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living culture. Concentrations of viable lactic acid bacteria and yeasts in the commercial kefir
starter were 9.83 × 108 CFU/g and 5.3 × 104 CFU/g, respectively.
Table 2.2 Quality evaluation of juices, aronia kefir, elderberry kefir made with commercial juice,
and elderberry kefir made with fresh juice
Product
Sucrose
Aronia kefir

Stevia
Monk fruit
4.3% sucrose

Elderberry
kefir
(commercial
juice)

5.7% sucrose
0.4% stevia
0.6% stevia
4.3% sucrose

Elderberry
kefir
(fresh juice)

5.7% sucrose
0.4% stevia
0.6% stevia
Aronia

Juice

Commercial
elderberry
Fresh
elderberry

pH
(n=3
)
4.4±
0.01
4.4±
0.01
4.4±
0.01
4.5±
0.01
4.6±
0.01
4.5±
0.01
4.5±
0.01
4.5±
0.01
4.5±
0.01
4.6±
0.01
4.6±
0.01
3.4±
0.00
4.0±
0.01
4.3±
0.01

TSS
(˚Brix
n=3)
13.2 ±
0.10
8.9 ±
0.06
9.5 ±
0.12
13.1 ±
0.06
14.6 ±
0.06
9.2 ±
0.00
9.2 ±
0.06
13.5 ±
0.01
14.9 ±
0.06
9.1 ±
0.06
9.5 ±
0.01
17.1 ±
0.06
20.7 ±
0.06
12.5 ±
0.00

Color (n=5)

%TA
(w/w
n=2)
0.64
0.67
0.66
0.73
0.70
0.77
0.75
0.74
0.74
0.76
0.74
1.15
1.90
0.55

L*

a*

b*

53.1 ±
0.26
53.2 ±
0.04
54.0 ±
0.12
60.5 ±
0.11
60.4 ±
0.11
60.8 ±
0.48
61.6 ±
0.27
60.7 ±
0.07
60.6 ±
0.02
59.9 ±
0.04
59.6 ±
0.09
0.4 ±
0.01
0.3 ±
0.00
2.40 ±
0.12

16.9 ±
0.29
16.7 ±
0.11
16.9 ±
0.17
10.9 ±
0.02
10.9 ±
0.03
10.8 ±
0.07
10.6 ±
0.16
12.0 ±
0.09
12.1 ±
0.03
12.2 ±
0.03
12.7 ±
0.05
0.1 ±
0.02
-0.1 ±
0.01
2.7 ±
0.22

-4.9 ±
0.14
-5.1 ±
0.04
-4.6 ±
0.09
1.5 ±
0.04
1.6 ±
0.05
1.7 ±
0.08
1.6 ±
0.05
0.1 ±
0.06
-0.3 ±
0.04
0.6 ±
0.03
0.3 ±
0.07
-0.3 ±
0.03
-0.8 ±
0.01
3.5 ±
0.22

Hue
angle
359.7
± 0.01
359.7
± 0.00
359.7
± 0.01
360.1
± 0.00
360.1
± 0.00
360.2
± 0.01
360.2
± 0.00
360.0
± 0.01
360.0
± 0.00
360.1
± 0.00
360.0
± 0.01
358.7
± 0.07
361.4
± 0.01
360.9
± 0.05

Note: Data are shown as means ± standard deviation except for %TA.
Since hue values were close to 0°/360° on hue angle scale, hue angle values were
transformed by adding 360° for comparison [308].
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Chroma
17.6 ±
0.24
17.5 ±
0.09
17.5 ±
0.14
11.0 ±
0.03
11.1 ±
0.04
10.9 ±
0.08
10.7 ±
0.17
12.0 ±
0.09
12.1 ±
0.03
12.2 ±
0.03
12.7 ±
0.05
0.3 ±
0.02
0.8 ±
0.01
4.4 ±
0.24

Chroma values indicate the saturation or the intensity of the color. High Chroma values
of the aronia kefir products indicated the color was saturated. Based on the similar Chroma
values among the aronia kefir products, there was no difference in the color intensity. Hue
angle values close to 0° (360°) indicated reddish color. The hue angle values of aronia kefir
indicate that the products displayed a reddish color. High L* values of the aronia kefir show the
products had a bright color. Positive a* values and negative b* values of the products indicate
the products presented a bluish-red color. Anthocyanins present a red to a blue color when the
environment changes from acidic to alkaline. The bluish-red color was expected in the products
due to the acidic environment of kefir.
2.4.1.3 Aronia Kefir Phytochemical Analyses
The results of the phytochemical analyses of aronia kefir samples are shown in Table
2.3. Aronia kefir products had high TMA contents (16.57-17.22 mg C3G/100 g kefir). A typical
serving size of kefir is 8 oz. One serving of the aronia kefir product would provide more than 39
mg TMA. Average TMA intake in the United States is 12.5 mg/day/person [201]. Our products
provided three times more than the average intake for TMA. An epidemiologic study shows
that in a population with an intake of 22.3-24.3 mg/day of TMA there was a lower incidence of
type 2 diabetes compared to a population with only 2.0-2.3 mg/day [3]. In addition, Jennings et
al. indicated that a TMA intake of 39.9 mg/day was associated with lower inflammation levels
and improved insulin resistance compared to a TMA consumption of only 3.54 mg/day [317].
According to Seymour et al., consumption of cherries containing 25.83 mg TMA increased the
plasma antioxidant capacity for 12 hours in healthy humans [149]. This evidence confirms that
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the consumption of aronia kefir could increase anthocyanin intake in a normal diet and
contribute to decreasing in inflammation and preventing type 2 diabetes.
Table 2.3 Phytochemical evaluation results of juices, aronia kefir, elderberry kefir made with
commercial juice and elderberry kefir made with fresh juice
Product

Anthocyanin
Content
(mg C3G/100 g
sample)
17.22 ± 0.17

Total Phenolic
Compounds
(mg GAE/100 g
sample)
43.04 ± 1.05

28.84 ± 0.26

Stevia

16.57 ± 0.44

40.32 ± 1.02

27.59 ± 0.26

Monk fruit

16.94 ±0.38

40.37 ± 0.51

27.84 ± 0.26

4.3% sucrose

1.02 ± 0.22

19.61 ± 0.25

59.19 ± 0.37

5.7% sucrose

0.95 ± 0.01

18.76 ± 0.19

65.52 ± 0.13

0.4% stevia

1.13 ± 0.02

19.86 ± 0.32

60.36 ± 0.56

0.6% stevia

1.06 ± 0.02

20.13 ± 0.58

61.65 ± 0.76

4.3% sucrose

18.67 ± 0.08

42.31 ± 0.96

20.86 ± 0.43

5.7% sucrose

20.10 ± 0.14

43.66 ± 1.90

20.36 ± 0.86

0.4% stevia

17.05 ± 0.06

39.00 ± 0.46

24.11 ± 0.67

0.6% stevia

18.90 ± 0.07

43.50 ± 0.82

20.68 ± 0.55

Aronia

275.64 ± 3.18

604.49 ± 14.90

1.54 ± 0.04

25.59 ± 1.58

337.28 ± 4.75

4.39 ± 0.03

416.92 ± 3.18

369.47.59 ± 1.38

2.14 ± 0.01

Sucrose
Aronia kefir

Elderberry kefir
(commercial
juice)

Elderberry kefir
(fresh juice)

Juice

Commercial
elderberry
Fresh
elderberry

DPPH IC50
(mg
sample/mL)

Note: Data are shown as means ± standard deviation, n=3.
TP content in aronia products were 40.32 – 43.04 mg GAE/100 g kefir. An 8 oz serving
provides more than 95 mg GAE of phenolics to the consumers. This equals about one-fifth of
the average daily consumption of TP (450 mg GAE/person) in the American diet [318]. Dall’Asta
et al. proved that dietary polyphenols could stimulate insulin secretion and protect β-cells from
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the damage induced by oxidative stress [106]. Aronia kefir products could add to the overall
consumption of total phenolics in the diet and contribute to the prevention of diabetes. DPPH
IC50 values of aronia kefir products were between 27.59 to 28.84 mg kefir/mL. These results
showed that the products had the ability to sequester free radicals. The antioxidant capacity of
aronia kefir products is associated with the amount of TMA and TP. Kefir is a live culture and
the environment is dynamic. TMA and TP are being actively metabolized which helps explain
the low recovery rates. Recovery rates of TMA and TP were about 45% and 55% respectively.
TMA ingested from fruit and vegetables are usually conjugated and have low bioavailability
[319]. Using a food matrix like kefir that contains live cultures may enhance the bioaccessibility
of the aronia bioactive compounds by increasing TMA due to the de-conjugation of the
anthocyanins.
2.4.2 Elderberry Kefir Evaluations (Commercial Juice)
2.4.2.1 Elderberry Kefir Sensory Test
Four elderberry kefir products sweetened with either sucrose or stevia were evaluated
in this test. In the previous sensory test of aronia kefir, monk fruit extract was not well accepted
and it was eliminated from the test of elderberry kefir. The elderberry kefir products were
sweetened to two levels to test the impact of sweetness. Commercial products, such as
blueberry flavored Lifeway® kefir, usually have about 20% sugars including 8 g added sugars.
The ˚Brix values of the products in this study without added sweetener were approximately 9%
(data not shown). Thus 4.3% or 5.7% sucrose was used to sweeten elderberry kefir to keep the
total ˚Brix at least 5% lower than commercial products. 0.4% and 0.6% stevia extracts were
used to create equal sweetness to the sucrose products respectively. Demographic results
68

showed that participants in this test were balanced for gender (55 female and 45 male) and the
major age range was 18-34 years old. All participants in this test responded positively that
purchasing health-beneficial food was important.
The consumer acceptability test (Figure 2.2) demonstrated that the products were
accepted equally for color. The best acceptability in sweetness was observed in elderberry kefir
sweetened with higher sucrose content (5.7%). Significantly lower ratings were observed in the
two products sweetened with stevia extract. This is potentially driven by the unpleasant
aftertaste of stevia extract based on the consumer comments. Sweeter products (5.7% sucrose
and 0.6% stevia) were accepted better compared to less sweet products (4.3% sucrose and
0.4% stevia), but there was no significant difference between two stevia-sweetened products in
this study. A similar trend was observed by Johansen et al. [320]. Their study indicated that
yogurt sweetened with 13% sucrose significantly increased consumer preference compared to a
product sweetened with 9% sucrose. Flavor was rated best in elderberry kefir sweetened with
higher sucrose content (5.7%) which was not significantly different from elderberry kefir
sweetened with 4.3% sucrose. The acid in kefir matrix, added sweetener and elderberry juice
contributed to the complex flavor of the elderberry products. Fermented dairy products have a
distinctive sour taste which may be a negative influencing factor on the consumers’
acceptability [321]. The addition of sucrose to the products resulted in an increased sweet to
sour ratio (˚Brix:TA) and may present a better-balanced flavor. The two products sweetened
with stevia extract were less-accepted for flavor. The reason may be the unpleasant aftertaste
of stevia extract. The best texture was received in the elderberry product with 5.7% sucrose.
Sucrose contributes to a more viscous texture which was observed in this product.
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Effervescence in dairy products induced by fermentation may be unfamiliar to consumers and
might be an influencing factor. Best overall acceptability (6.6) was rated in elderberry kefir
sweetened with high sucrose content (5.7%), and the product made with low stevia content
(0.4%) received the lowest rating (5.8). Similar to what was observed in the previous aronia
kefir consumer testing, participants’ unfamiliarity with either kefir or elderberry may
undermine the overall acceptability of the products. In this test, 40% of the consumers had
never consumed kefir and 58% of the participants were unfamiliar or had never heard of
elderberry. Elderberry kefir products were better accepted by previous kefir consumers
compared to the kefir-naive group (data not shown).
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Figure 2.2 Consumer acceptability of elderberry kefir made with different sweeteners
Note: Data are shown as means ± standard deviation. n=100. Different letters indicate
significant differences among means within each attribute, p<0.05.
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2.4.2.2 Elderberry Kefir Quality Parameters (Commercial Juice)
pH, TA, ˚Brix and color results of elderberry kefir made with commercial juice are shown
in Table 2.2. The pH values demonstrated that the elderberry kefir products were acidic, which
is necessary for the stability of bioactive compounds [305]. TA of products sweetened with 5.7%
sucrose was the lowest while stevia-sweetened (0.4%) elderberry kefir was the highest. TA
represents the sour taste. The sour taste in elderberry kefir was associated with the lactic acid
generated by fermentation and the organic acids from the elderberry juice. There was no
significant correlation between TA and pH (r = 0.49, p = 0.25). The highest ˚Brix value was
observed in 5.7% sucrose-sweetened products as expected. Product sweetened with 4.3%
sucrose was second highest. Stevia products both had low ˚Brix values. Color was analyzed for
elderberry kefir products. All elderberry kefir products had similar color intensity based on the
Chroma values. Hue angle values of all elderberry products were close to 0 (360) indicating that
the products presented as a reddish color. High L* values indicated that the products had a light
color. a* and b* values of all products were positive. This indicated that elderberry kefir
products present light red color. Since anthocyanins present a red color in an acidic
environment, this color was reasonable.
2.4.2.3 Elderberry Kefir Phytochemical Analyses (Commercial Juice)
Phytochemical results of elderberry kefir made with commercial juice are shown in
Table 2.3. Kefir products made with commercial elderberry juice contained a low amount of
TMA (0.95 – 1.13 mg C3G/100 g kefir) and a moderate amount of TP (18.76 – 20.13 mg
GAE/100 g kefir). The TMA and TP contents of commercial elderberry juice were 25.59 mg
C3G/100 g and 337.28 mg GAE/100 g respectively. These amounts were much lower than the
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reported values in the literature [322]. The recovery rates of TMA and TP were about 40% and
60% respectively (data not shown). Literature suggests several factors may impact TMA content
in elderberry or elderberry products. For instance, plant variety and growing conditions can
alter anthocyanin content [322, 323]. Processing, such as thermal treatments or filtration, could
result in anthocyanin loss [324-326]. The processing parameters and elderberry varieties of
commercial juice (a shelf stable product) are unknown, an additional set of kefir made with
fresh juice was made to better understand the difference between the commercial and fresh
elderberry juice. The same product formulas were used. Phytochemical evaluation of the
additional elderberry kefir products is discussed in the next section.
2.4.3 Elderberry Kefir Evaluation (Fresh Juice)
The results for the biochemical measurements of the fresh elderberry juice are shown in
Table 2.2. ˚Brix and TA values of the fresh elderberry juice were lower than the commercial
juice. Color parameter values of commercial and fresh elderberry juice are different. Based on
the Chroma values, fresh elderberry juice had a more saturated color than commercial juice.
Phytochemical properties of the fresh and the commercial elderberry juices were measured to
better understand the difference (Table 2.3). The results demonstrated that the TMA content in
fresh elderberry juice was 16 times higher than the commercial juice. Higher TP content was
observed in fresh elderberry juice. Gonzalez-Molina et al. revealed that anthocyanin content in
elderberry juice decreased more than 50% during 56 days storage at room temperature [327].
Elderberry juice should be utilized fresh to ensure the highest levels of anthocyanins in
products like elderberry kefir.
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A sensory test was not conducted on the products made with fresh juice due to
insufficient fresh elderberries. pH, TA, ˚Brix and color results of elderberry kefir made with fresh
juice are shown in Table 2.2. The elderberry kefir products made with fresh juice exhibited
similar pH, TA and ˚Brix values. No correlation was found between pH and TA (r = 0.22, p =
0.61). Based on the Chroma values, fresh-elderberry-juice-added kefir product with 0.6% stevia
had a more saturated color.
Phytochemical analyses results of elderberry kefir made with fresh juice are shown in
Table 2.3. TMA content of kefir made with fresh elderberry juice was 14 times higher than that
in the product made with commercial juice. TP content in fresh-juice elderberry kefir was two
times higher compared to the products made with commercial juice. Smaller IC50 values in the
products made with fresh elderberry juice were observed. This indicates that kefir made with
fresh elderberry juice exhibits stronger antioxidant capacity than the commercial-elderberryjuice kefir. The higher TMA and TP contents in fresh-elderberry-juice kefir due to the larger
amount of TMA and TP in the fresh juice. One serving (8 oz) of the elderberry kefir products
made with fresh juice contains more than 40 mg TMA and 93 mg TP. Elderberry kefir products
made with fresh juice could contribute to the enhancement of consumers’ dietary intake for
both TMA and TP. Increased consumption of TMA and TP may contribute to a decrease in the
chronic inflammation and in the risk of type 2 diabetes [3, 106]. Therefore, the freshness of
juice and a shorter shelf life are important to maximize the delivery of bioactive compounds.
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The recovery rate of TMA in products made with fresh elderberry juice was around 45%.
For TP, the recovery rate exceeded 100%. Similarly, increased total phenolics were observed in
myrtle berry homogenate after fermentation with Lactobacillus plantarum C2 and the main
increase was in phenolic acids [176]. This study suggested that the increase was due to the
esterase activity in the lactic bacteria. Esterase cleaves the ester bond which liberates the
phenolic acids from their glycosylated form. During fermentation, the constituents of
elderberry juice are metabolized by the living kefir culture. This enhancement may lead to a
functional food with an increased amount of bioavailable phenolic compounds.
2.5 Conclusion
Kefir products made with aronia or elderberry were evaluated for their sensory
attributes, quality parameters and phytochemical properties. Both sensory tests indicated that
consumers preferred sucrose over non-nutritive sweeteners. Results of phytochemical analyses
revealed that the freshness of juice was critical for maximum bioactive compounds in the
products. The fermentation process may contribute to the liberation of phenolic compounds in
part by esterase activity and may be important to enhance the bioavailability of bioactive
compounds. Further research is needed to better understand the impact of fermentation on
bioavailability and liberating the phenolic compounds to potentially increase their absorption.
Developing value-added functional food products could be a good way to utilize aronia or
elderberries. Kefir products with berries may increase dietary intake of anthocyanins and total
phenolics, which may contribute to the prevention of type 2 diabetes and other inflammatory
chronic diseases.
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CHAPTER 3
FERMENTATION ALTERS THE BIOACCESSIBLE PHENOLIC COMPOUNDS AND INCREASES THE
ALPHA-GLUCOSIDASE INHIBITORY EFFECTS OF ARONIA JUICE IN A DAIRY MATRIX
FOLLOWING IN-VITRO DIGESTION

This chapter is published in the Food & Function 2018, volume 9, page 2998-3007.

3.1 Chapter Abstract
The prevalence of diabetes reached 415 million worldwide in 2015. Polyphenol-rich food
intake can benefit the glycemic control for individuals with diabetes. Fermentation may
increase the bioavailability of polyphenols, w°°hich is generally low.

Aronia (Aronia

melanocarpa) is a polyphenol-rich berry that is native to North America. Proanthocyanins and
anthocyanins are the major phenolic compounds in aronia. In this study, aronia kefir was made
by fermenting cow’s milk with added aronia juice. The changes in bioaccessible polyphenols of
aronia kefir during digestion were assessed using an in-vitro model. The impact of fermentation
on the potential bioactivity of aronia polyphenols was evaluated. Results showed that the
bioaccessible polyphenols in aronia kefir were elevated during digestion and the antioxidant
capacity increased (IC50 of DPPH scavenging decreased from 24.07 mg kefir/mL to 8.97 mg
kefir/mL). Digested aronia kefir had stronger inhibitory activity on α-glucosidase (IC50: 152.53
mg kefir/mL) compared to the non-fermented control (IC50: 484.93 mg kefir/mL). Both aronia
kefir and the non-fermented control had weak inhibition on pancreatic α-amylase. Specific
inhibitors of α-glucosidase, such as aronia polyphenols, have the potential to delay
carbohydrate digestion and reduce the absorption of glucose without side effects. Utilizing
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aronia kefir in the diet is a good strategy to help control blood glucose levels. Fermentation may
be an effective method to increase the bioavailability of dietary polyphenols in other food.
More studies about the effects of fermentation on polyphenol-rich food are needed to optimize
the potential health-promoting properties.
3.2 Introduction
Diabetes has been a global issue for the past few decades. In 2015, 30.3 million people
(9.4%) in the United States and 415 million people in the world had diabetes [328]. Diabetes is
associated with a decline in life expectancy and a reduction in life quality [32]. Tight blood
glucose control is crucial for diabetic patients to delay the progression of complications, such as
diabetic retinopathy, neuropathy and nephropathy [329]. The modulation of postprandial
glucose absorption is one important method for management of hyperglycemia. Synthetic
pharmaceutical agents are used to inhibit carbohydrate-hydrolyzing enzymes for delaying and
reducing the absorption of glucose. Despite the effectiveness of the drugs, most of them have
side effects that impact the gastrointestinal tract and hepatic system [329, 330]. Studies
suggest that dietary polyphenols derived from plant-based food exhibit similar activity in
inhibiting carbohydrate-hydrolyzing enzymes in-vitro and have the potential to aid in blood
glucose control without side effects [329].
Dietary polyphenols are commonly ingested as a part of daily diet. They are found in
high levels in plant-based foods, especially in berries. Generally, polyphenols have low
bioavailability due to their instability in the small intestine and their large molecular size [331].
The food matrix may limit or improve the absorption of polyphenols and influence the
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bioavailability [92]. Several methods have been suggested to increase the bioavailability of
polyphenols, such as using encapsulation to increase the stability in the gastrointestinal tract
[332, 333]. Additionally, some microorganisms are capable of breaking down the complex
phenolic compounds and the metabolites may be more bioactive [177].
Aronia (Aronia melanocarpa) fruit is a berry native to eastern North America [334].
Aronia contains more total polyphenols (10-20 mg gallic acid equivalent/g fresh weight) than
many other plant-based food, such as blueberry (1 to 4 mg gallic acid equivalent/g fresh weight)
[202, 335, 336]. The astringent mouth-feel of aronia is caused by the high procyanidin content.
Aronia is rarely consumed raw due to the astringency and the lack of sweetness. Aronia was
traditionally used by Native Americans as medicine to treat the common cold [179]. The
phenolic compounds are the major bioactives that are responsible for the therapeutic effects of
aronia. In Russia, aronia has been used as a natural remedy to treat hypertension and
atherosclerosis [179]. A recent study conducted by Loo et al. showed that consumption of
aronia juice decreased low-grade inflammation in hypertensive patients [219]. Broncel et al.
observed that consuming aronia extract reduced the oxidative stress in patients with metabolic
syndrome [337].
Kefir is a fermented dairy product consisting of up to 30 species of microorganisms
including lactic bacteria, yeast and sometimes acetic acid bacteria [338]. Functional properties
of kefir are well documented, including anti-bacterial, anti-carcinogenic and anti-inflammatory
effects [261]. Kefir is naturally lactose-free, making it a good calcium and protein source for
lactose-intolerance individuals. In this study, kefir was selected as the matrix to incorporate
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aronia polyphenols for the following reasons: 1) kefir is rich in protein, which can minimize the
astringent mouth-feel of aronia [339] and may protect the polyphenols from degradation in the
small intestine [340]; 2) the diverse microorganism community in kefir starter has the potential
to metabolize phenolic compounds and increase the bioavailability [341]. Incorporating aronia
into kefir may be a good way to optimize the potential health-promoting properties of aronia;
3) the acidic pH of kefir helps to protect the anthocyanins from degradation.
Digestion is a key process influencing the bioavailability of a dietary component [134]
because factors such as pH and enzymes in the digestive tract can modify the components and
alter their liberation behavior [333]. Understanding the changes of the aronia polyphenols
during digestion is important to assess their potential bioactivity. The functional properties of
aronia before ingestion is well studied, but knowledge about the changes in a fermented matrix
and the potential anti-diabetic properties after digestion remain unknown. To our knowledge,
this is the first study to examine the bioaccessibility of aronia polyphenols in a fermented dairy
matrix. The objectives of this study were: 1) to investigate the effects of kefir-fermentation on
the potential bioactivity of aronia polyphenols in a dairy matrix; 2) to evaluate the changes in
the bioaccessibility and antioxidant capacity of aronia kefir in the digestive tract using an in
vitro model.
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3.3 Materials and Methods
3.3.1 Chemicals
Acetonitrile (HPLC grade), ammonium chloride, sodium phosphate dibasic, hydrochloric
acid, methanol, potassium chloride, potassium thiocyanate, sodium hydroxide, sodium
bicarbonate, soluble starch and urea were purchased from Fisher Scientific (Waltham, MA,
U.S.). 2,2-diphenyl-1-picrylhydrazyl (DPPH), dinitrosalicylic acid, formic acid, ox-bile, pnitrophenyl β-D-glucopyranoside (pnp-G), potassium sodium tartrate tetrahydrate, porcine αamylase, rat intestinal powder and HPLC standards (quercetin, chlorogenic acid, neochlorogenic acid and cyanidin-3-galactoside) were obtained from Sigma-Aldrich (St. Louis, MO,
U.S.). Bovine serum albumin, glucose, glucosamine hydrochloride, glucuronic acid, lipase,
magnesium chloride, mucin, pepsin, sodium phosphate monobasic and uric acid were
purchased from MP Biomedicals (Santa Ana, CA, U.S.). Calcium chloride was purchased from
Ward’s Science (Rochester, NY, U.S.), potassium dihydrogen phosphate was purchased from
Alfa Aesar (Haverhill, MA, U.S.). All water used was obtained from a Millipore water system
(EMD Millipore, Billerica, MA, U.S.).
3.3.2 Food Material
Aronia (Aronia melanocarpa, variety ‘Viking’) were harvest based on the apparent
ripeness of uniform deep purple color from the University of Connecticut (Storrs, CT, U.S.) from
the 2014 growing season. Berries were de-stemmed, washed and stored at -20 ˚C. Frozen
berries were thermal-treated (100 ˚C, 5 minutes) and juiced with a domestic juicer (Hamilton
Beach, Southern Pines, NC, U.S.). Juice was used immediately. Commercial kefir starter
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(Yogourmet®, Lachute, QC, Canada) and 2% milk (Oakhurst®, Portland, ME, U.S.) were
purchased from a local supermarket.
3.3.3 Sample Preparation
Aronia kefir was prepared by the following method: 2% milk was heated to 82 ˚C in an
aluminum saucepan, and cooled to 26 ˚C in an ice bath. The cooled milk and the commercial
starter (5 g per quart of milk) were combined in a glass bowl. The mixture was stirred for 5
minutes to ensure that the starter was fully dissolved. Freshly made aronia juice was added to
the milk-starter matrix (15%, w/w) and mixed well. The mixture was covered with a breathable
cloth and kept at room temperature (23 ˚C) to ferment overnight. After 24 hours of
fermentation, the aronia kefir was homogenized with an immersion blender (Hamilton Beach®,
Southern Pines, NC, U.S.). The homogenized aronia kefir was transferred into a sealed glass jar
and stored at 4 ˚C for 24 hours before carrying out the in-vitro digestion. Three batches of
aronia kefir were made and in-vitro digestion was performed individually.
Milk and aronia juice without the addition of kefir starter was used as a non-fermented
control. Non-fermented control was made by mixing 2% milk with 15% (w/w) freshly made
aronia juice in a glass jar and sealed with a lid. The mixture was kept at 4 ˚C for 24 hours (the
fermentation time of making kefir) and then acidified to pH 4.5 (the pH of kefir). The acidified
non-fermented control was stored in the refrigerator (4 ˚C) for another 24 hours before the invitro digestion process was carried out. Batches were made in triplicate.
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3.3.4 in-vitro Digestion Procedure
The digestion process was simulated using a modified method from Oomen et al. to
assess the changes of polyphenols in the digestive tract after ingestion [342]. For each
digestion, three compartments in the digestive tract were simulated: mouth, stomach and small
intestine. Artificial digestive juices (saliva, gastric juice, intestinal juice and bile) were prepared
fresh before the in-vitro digestion was performed. The composition of digestive juices are listed
in Table 3.1. pH values of the digestive juices were adjusted with concentrated HCl or 2M NaOH
to the appropriate range. The digestion process was carried out as follows: the process was
initiated by adding saliva to 27 mL aronia kefir (2:3, v/v). The mixture was stirred gently for 5
minutes at 37˚C in an Isotemp™ water bath (Fisher’s Scientific, Waltham, MA, U.S.). One-third
of the oral-digested sample was removed and collected as the oral-digested fraction. Gastric
digestion was initiated by adding in gastric juice to the remaining oral-digested sample (4:5, v/v)
and incubating the mixture at 37 ˚C in a shaking water bath (Edvotek®, Washington D.C., U.S.)
for 2 hours. This process consisted of two steps because the pH environment in the stomach is
not stable at the beginning of gastric digestion due to food influx: for the first hour, one portion
of gastric juice was added to the remaining oral digesta and the pH of the mixture was not
adjusted; for the second hour, three portions of gastric juice were added to the mixture, the pH
was adjusted to 2.0 with concentrated hydrochloric acid. At the end of gastric digestion, half of
the gastric digesta was removed and collected as the gastric-digested fraction. Digestion in the
small intestine was initiated by adding NaHCO3 (1 M) to the remaining gastric-digested sample,
resulting in a pH of 5.7. Intestinal juice and bile were added to the mixture (4:2:9, v/v). pH of
the mixture was adjusted to 7.5 with 2 M sodium hydroxide and the mixture was incubated at
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37 ˚C in the shaking water bath for two hours. All of the intestinal digesta were collected as the
small intestine-digested fraction. Though the collected volume of the individual fractions was
different, each fraction contained an equal amount of aronia kefir (9 mL). All incubations were
conducted in the dark and the mixtures were sealed with parafilm to reduce oxygen exposure.
The aronia kefir controls for each stage of digestion were processed by the same procedure in
the absence of enzymes and bile. Non-fermented control was treated with the same in-vitro
digestion procedure.
All collected samples were centrifuged at 16639×g (Eppendorf 5804R, Hamburg,
Germany) for 10 minutes at 0 ˚C. The collected supernatant was acidified to pH 2.0 with
concentrated hydrochloric acid to inactivate the digestive enzymes and to stabilize the phenolic
compounds [331]. Methanol was added to the supernatant (2:1, v/v) and it was chilled at -20 ˚C
to precipitate proteins. After 30 minutes, proteins in the mixture were removed by
centrifugation at 0 ˚C for 30 minutes (16639×g, Eppendorf 5804R). Samples were filtered
through a 0.20 µm syringe filter (Corning Inc., Corning, NY, U.S.) where an aliquot of the filtered
supernatant was stored at -80 ˚C for phenolic compound quantification and antioxidant
capacity evaluation. The remaining filtered supernatant was evaporated under a vacuum
(Eppendorf Vacufuge plus, Hamburg, Germany) to remove methanol. The aqueous supernatant
was purified with a C18 cartridge (Sigma-Aldrich, St. Louis, MO, U.S.) and washed with water to
remove reducing sugars. The phenolic compounds in the supernatant were eluted with
methanol. The purified sample was dried under a vacuum and resuspended in ultrapure water.
The re-suspended samples were stored at -80 ˚C for enzyme inhibition activity analyses.
Digestion was carried out in triplicate.
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Table 3.1 The composition of digestive juices
Artificial saliva

Gastric juice

Intestinal juice

Bile

Inorganic compounds
10 mL KCl 89.6 g/L

15.7 ml NaCl 175.3g/L

40 ml NaCl 175.3 g/L

30 mL NaCl
175.3 g/L

10 mL KSCN 20 g/L

18 mL CaCl2·2H2O
22.2 g/L

40 mL NaHCO3
84.7 g/L

68.3 mL NaHCO3
84.7 g/L

10 mL NaH2PO4
88.8 g/L

9.2 mL KCl 89.6 g/L

10 mL KH2PO4
8.0 g/L

4.2 mL KCl 89.6 g/L

10 mL Na2PO4
57.0 g/L

3 mL NaH2PO4
88.8 g/L

6.3 mL KCl 89.6 g/L

200 µl HCL 37% g/g

1.7 mL NaCl
175.3 g/L

10 mL NH4Cl 30.6 g/L

10 mL MgCl2 5 g/L

1.8 mL NaOH
40.0 g/L

8.3 mL HCl 37% g/g

180 µl HCl 37% g/g

10 mL glucose 65.0 g/L

4 mL urea 25.0 g/L

10 mL urea 25.0 g/L

Organic compounds
8 mL urea 25.0 g/L

10 mL glucuronic acid
2.0 g/L
3.4 mL urea 25.0 g/L
10 mL glucosamine
hydrochloride
33.0 g/L
Others
145 mg α-amylase

1.0 g BSA

9 mL CaCl2·2H2O
22.2 g/L

10 mL CaCl2·2H2O
22.2 g/L

15 mg uric acid

1.0 g pepsin

1.0 g BSA

1.8 g BSA

50 mg mucin

3.0 g musin

3.0 g pancreatin

6.0 g bile

0.5 g lipase
pH
6.5 ± 0.2

1.07 ± 0.07

7.8 ± 0.2

8.0 ± 0.2

Note: The organic and inorganic solutions were adjusted into 500mL with distilled water
separately. Other constituents were added to the mixture of organic and inorganic
solutions and the pH was adjusted to the appropriate intervals with 2 M NaOH or
concentrated HCl
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3.3.5 UPLC Analysis of Phenolic Compounds
The profile of polyphenols would be altered during digestion, monitoring these changes
is important to understand the possible metabolism of polyphenols in the digestive tract and
the impacts of digestion on the potential bioactivity of polyphenols. In this study, the
quantification of the anthocyanins and phenolic acids (chlorogenic acid and neo-chlorogenic
acid) in the collected digesta was performed on an Ultra Performance Liquid Chromatography
(UPLC) (Agilent Technologies1290 Infinity, Santa Clara, CA, U.S.) with a Photodiode Array (PDA)
detector. The method used was modified from Teleszko et al. [343]. Separation was carried out
using a C18 column (3 µm, 150 × 4.6 mm, Thermo Scientific, Waltham, MA, U.S.) at 25 ˚C.
Samples were injected at a flow rate of 1.3 mL/min. Phenolic compounds were eluted with a
gradient mobile phase consisting 4.5% formic acid in water (phase A) and 4.5% formic acid in
acetonitrile (phase B). The gradient was as follows: 0 min: 1% phase B; 4.5 min: 10% phase B; 7
min: 20% phase B; 10 min: 24% phase B; 14 min: 36% phase B; 15min: 60% phase B; 16 min: 1%
phase B. The post run time was 5 min. Samples were spiked with quercetin (25 µg/mL) as an
internal standard. An external calibration curve was drawn using cyanidin-3-galactoside (3.9,
7.8, 15.6, 31.2, 62.5, 125 and 250 µg/mL, r2 = 0.9987), chlorogenic acid (3.9, 7.8, 15.6, 31.2,
62.5, 125 and 250 µg/mL, r2 = 0.9999) and neo-chlorogenic acid (3.9, 7.8, 15.6, 31.2, 62.5, 125
and 250 µg/mL, r2 = 0.9998) standards. Anthocyanins were detected at 520 nm and expressed
as cyanidin-3-galactoside equivalents. The individual anthocyanins were identified by the
elution order reported by Jakobek et al. [202]. Chlorogenic acid and neo-chlorogenic acid were
detected at 320 nm. Peak areas were used for quantification and the results were expressed as
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mg polyphenols per part (one part contains 9 mL aronia kefir). Measurements were conducted
in triplicate.
3.3.6 DPPH Free Radical Scavenging Assay
Antioxidant capacity of polyphenols is a crucial parameter to evaluate their potential
health benefits. In the presented study, the antioxidant capacity of each digested fraction was
evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging activity. The method
was slightly modified from Duymus et al. [312]. Briefly, equal amounts of 0.3 mM DPPH solution
(150 µL) and the diluted samples (150 µL) were loaded to a 96-well plate. The mixture was
incubated in the dark at room temperature for 30 minutes and the absorbance was read at 515
nm with a Biotek plate reader (ELx800, Winooski, VT, U.S.). A mixture of DPPH solution and
water was used as the negative control for this assay. Scavenging percentage was calculated
with the following formula:

%Scavenging =

Abs𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − Abs𝑆𝑎𝑚𝑝𝑙𝑒
× 100
Abs𝐶𝑜𝑛𝑡𝑟𝑜𝑙

Scavenging activity of each fraction was measured at five different concentrations to
calculate IC50 values, which is the concentration of the sample to scavenge 50% of the DPPH
free radicals. Measurements were conducted in triplicate.
3.3.7 Rat Intestinal α-glucosidase Inhibitory Activities
Alpha-glucosidase is a vital carbohydrate-hydrolyzing enzyme catalyzes the breakdown
of disaccharides and oligosaccharides to release glucose in the small intestine [344]. In this
study, α-glucosidase inhibitory activity was evaluated using a method reported by Oki et al.
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with modification [345]. Alpha-glucosidase was extracted from rat intestine powder by using
0.1 M sodium phosphate buffer at pH 6.9 (1:30, w/v) in an ice bath with sonication. Sonication
was performed 12 times (30 seconds for each round) and the mixture was vortexed after each
sonication. The mixture was centrifuged at 0 ˚C for 10 minutes at 16639×g. The supernatant
was filtered through a 0.45 µm syringe filter (Phenomenex, Torrance, CA, U.S.) and kept on ice
until use in the assay. Samples (50 µL) and α-glucosidase extract (100 µL) were mixed and
incubated at 37 ˚C for 10 minutes in the dark. Water was used to prepare controls. The reaction
was initiated by the addition of 50 µL 4-nitrophenyl α-glucopyranoside (pnp-G, 5 mM). The
mixture was incubated at 37 ˚C for 30 minutes in the dark and read at 405 nm. Phosphate
buffer (0.1 M) was used to prepare sample blank to correct for the background color. The
inhibitory activity of the sample on intestinal α-glucosidase was calculated as follows:

%inhibition =

𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − (𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒 𝑏𝑙𝑎𝑛𝑘 )
× 100
𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙

Five dilutions of each sample were measured to calculate IC50 values. Measurements
were carried out in triplicate.
3.3.8 Porcine Pancreatic α-amylase Inhibitory Activities
Pancreatic α-amylase is a key enzyme that starts the digestion of complex
carbohydrates by hydrolyzing the glycosidic linkages in the small intestine. Inhibitory effects of
samples on porcine pancreatic α-amylase were conducted with the method reported by
Nampoothiri et al. with modification [346]. Briefly, sodium phosphate buffer (0.02 M, pH 6.9)
with 0.006 M sodium chloride was used to dissolve α-amylase and the starch. 100 µL sample
and 100 µL α-amylase solution (100 unit/mL) were mixed and incubated at 25 ˚C for 10 min.
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The reaction was initiated by adding 100 µL starch solution (1 g/mL). The mixture was
incubated at 25 ˚C for an additional 10 min. The reaction was stopped by adding 200 µL
dinitrosalicylic acid reagent and incubating the mixture in a water bath for 5 minutes at 100 ˚C.
The dinitrosalicylic acid reagent was made of 1 g/mL dinitrosalicylic acid in water containing 2%
NaOH (2 M, v/v) and 30% (w/v) potassium sodium tartrate tetrahydrate. When the mixture
temperature reached the room temperature (23 ˚C), 50 µL of the mixture was loaded to a 96well microplate, diluted with 200 µL water and read at 540 nm. Sample blank was prepared
using sodium phosphate buffer to correct for the background color. The control was prepared
with sodium phosphate buffer instead of samples. The α-amylase inhibitory activity of the
samples was calculated as follows:
%inhibition =

𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − (𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒 − 𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒 𝑏𝑙𝑎𝑛𝑘 )
× 100
𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙

The inhibitory activities of individual samples were tested at five different dilutions. IC20
values, the concentration of the sample required to inhibit 20% porcine pancreatic α-amylase,
were calculated. The measurements were conducted in triplicate.
3.3.9 Statistical Analysis
Data are shown as means ± standard deviations. Statistical analyses were conducted
using SAS Studio (Cary, NC, USA). Analysis of Variance and Tukey’s HSD post hoc were carried
out to evaluate the differences. A significance level was set at α = 0.05.
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3.4 Results
3.4.1 Quantification of Bioaccessible Phenolic Compounds
The contents of the bioaccessible phenolic compounds in aronia kefir and nonfermented control during in-vitro gastrointestinal digestion are presented in Table 3.2. Four
major monomeric anthocyanins (cyanidin-3-galactoside, cyanidin-3-glucoside, cyanidin-3arabinoside and cyanidin-3-xyloside) and two dominant phenolic acids (chlorogenic acid and
neo-chlorogenic acid) were identified and quantified via UPLC analyses. Caffeic acid, a
metabolite of chlorogenic acid, was not detected. Most phenolic compounds in aronia kefir
increased after gastric digestion, with the exception of cyanidin-3-glucoside which showed no
change compared to the oral-digested sample. During intestinal digestion, the chlorogenic acid
content was increased (from 1.04 ± 0.02 mg/part to 1.29 ± 0.09 mg/part) and the other
identified anthocyanins and phenolic acids remained the same.
The total anthocyanin content is shown in Figure 3.1. After the entire gastrointestinal
digestion, total bioaccessible anthocyanins were increased by 96.9% compared to the
undigested aronia kefir. Total anthocyanins in intestinal-digested kefir was 5.09 ± 0.40 mg/part
(1 part = 9 mL aronia kefir). One serving of commercial kefir is 240 mL thus one serving aronia
kefir would provide 135.73 mg bioaccessible anthocyanins.
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Table 3.2 Quantification of individual phenolic compounds (mg/part)
Fractions
Undigested
C
*

Oral

D
*

Aronia
Kefir

C
*

Gastric

D
*

C
*

Intestinal

D
*

Undigested
C
Oral

*

D
*

Nonfermented
control

C
*

Gastric

D
*

C
*

Intestinal

D
*

Cyanidin3galactoside
1.87 ±0.11
d
1.87 ±0.15
d
1.96 ±0.13
d
2.60 ±0.34
cd
3.14 ±0.42
c
3.10 ±0.33
c
3.50 ±0.29
bc
2.60 ±0.13
cd
3.10 ±0.45
c
3.29 ±0.16
bc
4.13 ±0.32
ab
4.59 ±0.41
a
4.67 ±0.29
a
4.69 ±0.36
a

Cyanidin3glucoside
0.09 ±0.01
cd
0.07 ±0.02
d
0.07 ±0.02
d
0.10 ±0.03
bcd
0.12 ±0.04
abcd
0.11 ±0.02
abcd
0.13 ±0.01
abcd
0.13 ±0.01
abcd
0.12 ±0.03
abcd
0.13 ±0.02
abcd
0.16 ±0.04
abc
0.18 ±0.04
a
0.17 ±0.02
ab
0.17 ±0.03
ab

Cyanidin3arabinoside
0.57 ±0.03
e
0.55 ±0.07
e
0.58 ±0.06
e
0.85 ±0.14
de
1.13 ±0.19
cd
1.08 ±0.12
cd
1.33 ±0.10
bc
0.87 ±0.06
de
1.06 ±0.21
cd
1.15 ±0.07
cd
1.56 ±0.17
ab
1.79 ±0.21
a
1.85 ±0.11
a
1.88 ±0.19
a

Cyanidin-3xyloside

Chlorogenic
acid

0.05 ±0.01
e
0.05 ±0.01
e
0.06 ±0.01
e
0.08 ±0.01
de
0.11 ±0.02
cd
0.10 ±0.01
cd
0.13 ±0.01
bc
0.08 ±0.01
de
0.11 ±0.02
cd
0.11 ± 0.01
cd
0.16 ±0.02
ab
0.18 ±0.02
a
0.19 ±0.01
a
0.19 ±0.02
a

0.61 ±0.03
g
0.76 ±0.02
efg
0.78 ±0.02
efg
0.92 ±0.04
cde
1.04 ±0.02
bc
1.17 ±0.11
ab
1.29 ±0.09
a
0.70 ±0.04
fg
0.84 ±0.06
def
0.85 ±0.05
def
0.97 ±0.02
cd
1.08 ±0.05
bc
1.19 ±0.07
ab
1.31 ±0.06
a

Neochlorogenic
acid
0.49 ±0.02
e
0.59 ±0.02
cde
0.60 ±0.02
cde
0.69 ±0.02
abc
0.75 ±0.02
ab
0.74 ±0.03
ab
0.70 ±0.09
abc
0.54 ±0.03
de
0.65 ±0.04
bcd
0.64 ±0.04
bcd
0.72 ±0.02
ab
0.77 ±0.03
a
0.78 ±0.01
a
0.72 ±0.07
ab

Note: data are shown as means ± standard deviations (n=3), values in the same column with the
same letter are not significantly different at p < 0.05; *: C stands for control and D stands
for digesta; one part was equivalent to 9 mL sample; anthocyanins were expressed as mg
cyanidin-3-galactoside/part; chlorogenic acid was expressed as mg chlorogenic/part; neochlorogenic acid was expressed as mg neo-chlorogenic/part.
No differences were observed among phenolic compounds in the individual stages of
digestion between aronia kefir digesta and aronia kefir controls (Table 3.2 and Figure 3.1). After
intestinal digestion, the non-fermented control contained larger amount of cyanidin-3-
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galactoside, cyanidin-3-arabinoside and cyanidin-3-xyloside (4.69 ± 0.36 mg/part, 1.88 ± 0.19
mg/part and 0.19 ± 0.02 mg/part) compared to aronia kefir (3.50 ± 0.29 mg/part, 1.33 ± 0.10
mg/part and 0.13 ± 0.01 mg/part respectively). Differences in the other identified phenolic
compounds between non-fermented control and aronia kefir were not observed. The total
bioaccessible anthocyanins in intestinal-digested non-fermented control was 88.5% higher than
in the undigested non-fermented control. After digestion, the increase of anthocyanins was
lower in non-fermented control compared to the increase in aronia kefir.

Control

Total anthocyanins
(mg cyanidin-3-galactoside/part)

8.00

Digesta

a a

ab

7.00
6.00

cd

5.00

cd

bc

de
e e

cd bcd
de de

4.00
3.00

a

e e

2.00
1.00
0.00
Undigested

Oral

Gastric

Intestinal

Aronia kefir

Undigested

Oral

Gastric

Intestinal

Non-fermented control

Figure 3.1 Quantification of total anthocyanins during in-vitro digestion
Note: Data are shown as means ± standard deviations (n=3), one part was equivalent to 9 mL
sample, bars with the same letter are not significantly different at p < 0.05.
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3.4.2 Antioxidant Capacity
Antioxidant activity of aronia kefir and the non-fermented control was measured using
the capacity to scavenge DPPH free radicals. IC50 values were calculated and the results are
shown in Figure 3.2.

Aronia kefir exhibited antioxidant capacity during the entire

gastrointestinal digestion. Antioxidant capacity of aronia kefir digesta was improved during
gastric digestion (DPPH IC50 values from 24.07 ± 0.78 mg/part to 12.01 ± 0.57 mg/part) and
held consistent after intestinal digestion (DPPH IC50: 8.97 ± 0.93 mg/part). Aronia kefir digesta
exhibited similar antioxidant capacity compared to the corresponding aronia kefir controls at
each digestive stage. Aronia kefir digesta and non-fermented control digesta exhibited similar
antioxidant capacity after gastric- and intestinal-digestion. A strong correlation between IC50
values of DPPH and total anthocyanins was observed (r = - 0.89) as well as between IC50 values
and the sum of chlorogenic and neo-chlorogenic acid contents (r = - 0.90).

Control
30.00

a

a

ab

25.00

DPPH IC50 (mg sample/mL)

Digesta

bc

20.00

cd
def

15.00

de

ef

def

f

10.00

ef

f

5.00
0.00
Oral

Gastric

Intestinal

Aronia kefir

Oral

Gastric

Intestinal

Non-fermented control

Figure 3.2 Antioxidant capacity of kefir during in-vitro digestion
Note: Data shown as means ± standard deviations (n=3), bars with the same letter are not
significantly different at p < 0.05.
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3.4.3 Inhibitory Activity of Carbohydrate-hydrolyzing Enzymes
The inhibitory effects of intestinal digested aronia kefir and non-fermented control on αglucosidase and pancreatic α-amylase were tested. The results are shown in Figure 3.3 and
Figure 3.4. Digested aronia kefir exhibited strong inhibitory activity toward α-glucosidase and
weak inhibitory activity on α-amylase. Compared to the digested non-fermented control,
digested aronia kefir had a stronger inhibitory effect on α-glucosidase. The IC50 values for αglucosidase inhibition of aronia kefir and non-fermented controls were 152.53 ± 15.24 mg
kefir/mL and 365.16 ± 48.84 mg non-fermented control/mL respectively. Digested aronia kefir
as well as the digested non-fermented control exhibited similar inhibitory activity against
pancreatic α-amylase. IC20 values of α-amylase for the aronia kefir and the non-fermented
control were 146.52 ± 5.37 mg kefir/mL and 196.21 ± 5.50 mg non-fermented control/mL. Plain
kefir was processed using the in-vitro digestion system with the same method as the samples.
Inhibitory activity of plain kefir on enzymes was not observed.

600.00

a

a

IC50 (mg sample/mL)

500.00

a

400.00
300.00
200.00

b

100.00
0.00
Aronia kefir
Control

Non-fermented control
Digesta

Figure 3.3 α-glucosidase inhibitory activity
Note: Data shown as means ± standard deviations (n=3), bars with the same letter are not
significantly different at p < 0.05.
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600.00

IC20 (mg kefir/mL)

500.00

a
a

400.00
300.00

b

b

200.00
100.00
0.00

Aronia kefir
Control

Non-fermented control
Digesta

Figure 3.4 Pancreatic α-amylase inhibitory activity
Note: Data shown as means ± standard deviations (n=3), bars with the same letter are not
significantly different at p < 0.05.
3.5 Discussion
This study examined the bioaccessibility and the antioxidant capacity of phenolic
compounds in aronia kefir during a simulated gastrointestinal digestion. The impacts of
fermentation on aronia polyphenols and on their carbohydrate-hydrolyzing enzyme inhibitory
activities were evaluated.
The in-vitro digestion model used in this study simulated three compartments of the
digestive tract: mouth, stomach and small intestine. Digestive juices (saliva, gastric juice,
duodenal juice and bile) used in this model contained not only corresponding enzymes but also
other compounds that exist in human digestive juices, such as calcium chloride which may
chelate phenolic compounds in the digestive tract and alter their bioaccessibility [347].
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In this study, salivary α-amylase, which is the main digestive enzyme in the mouth, had
negligible effects on the release of bioaccessible phenolic compounds in aronia kefir as
expected, because the aronia kefir is a protein-rich beverage and the duration for the simulated
oral digestion is short.
During gastric digestion, the acidic environment helps to stabilize the free anthocyanins
and phenolic acids in aronia kefir. The low pH environment in the stomach contributes to the
liberation of the phenolic compounds from the phenolic-protein complex and lead to the
increase in bioaccessible anthocyanins and phenolic acids [143, 305, 333].

In addition,

proanthocyanins, the oligomeric and/or polymeric flavan-3-ols, are the most abundant
bioactive constituents in aronia. The depolymerization of proanthocyanins due to the acidic
environment may contribute to the enhancement of the monomeric anthocyanin levels and
potentially increase the bioavailability of aronia polyphenols [22, 135]. Bermudezsoto et al.
reported that digestive enzymes did not affect the aronia polyphenol content in the absence of
food matrix [331]. In this study, a similar trend was observed. Though the amount of
bioaccessible polyphenols in the gastric-digested aronia kefir (4.50 ± 0.66 mg/part for total
anthocyanins, 1.04 ± 0.02 mg/part for chlorogenic acid and 0.75 ± 0.02 mg/part for neochlorogenic acid) was slightly higher than that in the gastric control (3.63 ± 0.52 mg/part for
total anthocyanins, 0.92 ± 0.04 mg/part for chlorogenic acid and 0.69 ± 0.02 mg/part for neochlorogenic acid), the difference was not significant.
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The small intestine is the major absorption site for most phenolic compounds so the
quantity of bioaccessible polyphenols is important [141]. Many studies demonstrated that
phenolic compounds are labile in the small intestine due to the mild alkaline environment.
Bermudezsoto et al. conducted a study demonstrating that more than 35% of anthocyanins and
20% phenolic acids were lost after in-vitro intestinal digestion of aronia juice [331]. Similar
results were reported by Correa-Betanzo et al. where anthocyanins in blueberry decreased to
10% – 15% during in-vitro intestinal digestion [348]. Bouayed et al. reported a complete loss of
anthocyanins but an increase in phenolic acids after in-vitro intestinal digestion of apples [349].
However, depending on the type of polyphenols and the food matrix, the changes of
bioaccessible polyphenols in the small intestine may be different. In the present study, the
bioaccessible chlorogenic acid in aronia kefir increased and the anthocyanins content remained
the same during intestinal digestion. The increases in chlorogenic acid may be attributed to the
degradation of anthocyanins in addition to the liberation from the kefir matrix. Similar results
were observed in other studies that utilized a protein-rich food matrix to protect the
polyphenols from degradation in the small intestine. A study conducted by Lamothe et al.
showed that the stability of tea polyphenol in the small intestine was improved by dairy
matrices (milk, yogurt and cheese) [340]. The protective effects of food matrices (dairy and
egg) on the stability of grape anthocyanins during the intestinal digestion were observed by
Pineda-Vadillo et al. [350]. Stanisavljevic et al. reported that after in-vitro digestion of aronia
juice in a food matrix, bioaccessible anthocyanins and total phenolic compounds increased
[351]. It is important to note that the referenced study only tested the anthocyanin and the
total phenolic contents before and after the entire gastrointestinal digestion process (not at the
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individual digestive stage). The changes of the soluble anthocyanins in the small intestine
remains unknown. Digestive enzymes and bile did not contribute to the liberation of phenolic
compounds in aronia kefir since the differences in anthocyanins, chlorogenic acid and neochlorogenic acid between the digested aronia kefir and aronia kefir controls were not
significant.
The antioxidant capacity of polyphenols is associated with their health-promoting
properties. The consumption of polyphenols may help to decrease oxidative stress, attenuate
the production of pro-inflammatory biomarkers and lower the risk of chronic diseases, such as
type 2 diabetes [352]. Foods that have strong antioxidant capacity before consumption may
lose their antioxidant activity during the digestion process. This is caused by the structural
alterations that occur due to the harsh conditions in the digestive tract and/or the interaction
with other food ingredients. A loss of antioxidant capacity of polyphenol-rich food after in-vitro
gastrointestinal digestion was documented in many studies and this loss was associated with
the degradation of phenolic compounds [348, 353]. In this study, the antioxidant capacity of the
intestinal-digested aronia kefir was higher than the oral-digested aronia kefir. The progressive
release of phenolic compounds during digestion may contribute to the increase [350]. It is
important for food to exhibit antioxidant capacity in the gut lumen, where dietary polyphenols
could inhibit the proliferation of abnormal cells and slow the progression of cancer [331]. In
addition, dietary polyphenols in the lumen may have protective effects on other food
components during digestion, such as protecting unsaturated fatty acids from oxidation [350,
354]. The protective activity of polyphenols on unsaturated fatty acids may contribute to a
healthier cardiovascular status.
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Alpha-glucosidase and pancreatic α-amylase are carbohydrate-hydrolyzing enzymes that
play a vital role in catalyzing the breakdown of complex carbohydrates. Inhibition of these
enzymes can delay the absorption of carbohydrates and aid in the management of
hyperglycemia. In the present study, only intestinal-digested samples were tested for enzyme
inhibitory activity because pancreatic α-amylase and α-glucosidase exist in the small intestine.
It is important to note that yeast α-glucosidase was frequently used in other research, but this
study used α-glucosidase extracted from rat small intestinal powder because mammalian αglucosidase is more relevant to human α-glucosidase [355]. This study demonstrated that
polyphenols in aronia were the major compounds affecting the enzyme inhibitory activity
because plain kefir treated in the same method did not show any inhibitory activity (data not
shown). The inhibitory effects of dietary polyphenols on pancreatic α-amylase and αglucosidase are well documented [356]. In this study, intestinal-digested aronia kefir exhibited
strong inhibitory activity on α-glucosidase and minor inhibitory effect on pancreatic α-amylase.
Strong inhibition of pancreatic α-amylase may lead to undigested complex carbohydrates in the
large intestine and cause abdominal pain, flatulence, and/or diarrhea [357]. Therapeutic agents,
such as acarbose, can cause gastrointestinal side effects because of their non-specific inhibitory
effects on both pancreatic α-amylase and α-glucosidase. Due to this effect, the specific
inhibitory activity of aronia kefir on α-glucosidase over pancreatic α-amylase might be desirable
for hyperglycemia management [358, 359]. Incorporating aronia kefir into a normal diet may be
a good strategy to control postprandial plasma glucose level without causing side effects.
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Fermentation altered the composition of bioaccessible aronia polyphenols in kefir and
changed their potential bioactivity. The impacts of the fermentative microorganisms on
polyphenols from various studies suggest that the phenolic metabolites produced by
microorganisms might be more bioavailable. This is due to the smaller size of the metabolites
and thus they are better absorbed compared to the parent compounds [173, 177]. A study
conducted by Curiel et al. observed that fermentation by lactic acid bacteria increased the
antioxidant capacity of Myrtle berry homogenate [176]. In addition, Hunaefi et al. stated that
24 hours lactic acid fermentation decreased the total phenolic compounds in red cabbage
sprouts but increased the antioxidant activity [360]. Zhao et al. also reported that fermentation
by lactic acid bacteria decreased the flavan-3-ols content and increased phenolic acid
derivatives in tea extract [341]. There was also evidence that the antioxidant activity was
elevated [341]. These results demonstrate that fermentation may be a feasible method to
enhance the antioxidant capacity of dietary polyphenols in different food matrices. However, in
this study, there was no difference in the antioxidant capacity between aronia kefir and the
non-fermented control after gastric- and intestinal-digestion.
In this study, digested aronia kefir had stronger inhibitory activity on α-glucosidase than
the digested non-fermented control (IC50 values are 152.53 mg kefir/mL and 365.16 mg nonfermented control/mL, respectively) though digested non-fermented control had higher
cyanidin-3-galactoside, cyanidin-3-arabinoside and cyanidin-3-xyloside. The stronger enzyme
inhibitory effects of digested aronia kefir may due to the metabolites of polyphenols generated
by the fermentation. Frediansyah et al. observed similar results where fermentation by lactic
acid bacteria increased the inhibitory activity of black grape juice for α-amylase and α98

glucosidase [174]. Fermentation may be a good strategy to increase the bioavailability of
polyphenols in other foods. In addition, a fermented dairy matrix may be a suitable carrier for
dietary polyphenols due to their protective effects on the stability of phenolics in the small
intestine. More research is needed to better utilize the potential activity of fermentation on
improving the bioavailability of dietary polyphenols.
3.6 Conclusion
In this study, the stability and bioaccessibility of the polyphenols in aronia kefir were
evaluated using an in-vitro gastrointestinal digestion model, where the impacts of fermentation
on aronia polyphenols were evaluated. After digestion, the bioaccessible polyphenols in aronia
kefir and its antioxidant capacity increased. The digested aronia kefir exhibited strong inhibitory
activity toward α-glucosidase but weak inhibition of pancreatic α-amylase. Intestinal-digested
aronia kefir contained less cyanidin-3-galactoside, cyanidin-3-arabinoside and cyanidin-3xyloside compared to the intestinal-digested non-fermented control but exhibited similar
antioxidant capacity. Fermentation enhanced the inhibitory activity of aronia polyphenols on αglucosidase. In conclusion, consuming aronia kefir may aid in controlling blood glucose level
without side effects. Fermentation may be a good strategy to enhance the bioavailability of
dietary polyphenols. In order to better understand the positive impacts of fermentation on the
bioavailability of dietary polyphenols, the identification of the metabolites in aronia kefir is
necessary.
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CHAPTER 4
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS
4.1 Study Conclusions
Aronia and elderberry are underutilized fruits with great health-promoting properties.
They are rarely consumed raw due to the astringent sensation caused by a large amount of
phenolic compounds. In this research, berries were incorporated into a fermented dairy matrix,
kefir, and sweetened with different natural sweeteners (sucrose, stevia extract and monk fruit
extract) to mask the astringency. Studies were conducted to evaluate the consumer
acceptability and health-promoting properties of these products. The key findings are
summarized in table 4.1.
The first objective of this study was to develop new palatable kefir products using aronia
or elderberries. The levels of sucrose used in the aronia and elderberry kefir were lower than
most flavored commercial kefir products in the market, such as blueberry, mango and
raspberry flavored Lifeway® kefirs. The reason for minimizing the amounts of added sucrose is
to ensure that these products are attractive to health-conscious consumers. The final level of
sucrose in aronia and elderberry kefirs was at least 5% lower than flavored commercial kefirs. In
order to test how berry kefirs were received by the potential consumers, two separate sensory
tests on either aronia or elderberry kefir products were conducted to evaluate the consumer
acceptability. In the first sensory test, aronia kefir products were sweetened with sucrose,
stevia extract or monk fruit extract to the same level of sweetness. Both the sucrose- and
stevia-sweetened aronia kefirs were slightly liked by the consumers where the overall
acceptability of the sucrose-sweetened products were higher (6.3). Monk fruit-sweetened
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aronia kefir was not well accepted by the consumers. In the second sensory test, elderberry
kefirs were sweetened with either sucrose or stevia extract to two levels of sweetness. The
highest overall acceptability was observed in elderberry kefir sweetened with a higher amount
of sucrose (5.7%). All elderberry kefirs were accepted by the consumers where all ratings were
higher than 5. In summary, berry kefirs, which were less sweetened than most commercial
products, were accepted by consumers. Sucrose appeared to be the best accepted sweetener
than monk fruit or stevia extract based on the consumers’ rating. Aronia and elderberry kefirs
have the potential to be successful commercial products. Additionally, the berry kefirs made
with stevia and monk fruit extracts are suitable for pre-diabetic and diabetic individuals.
The second objective of this study was to evaluate the health-related characteristics of
the aronia and elderberry kefirs, including the total phenolic levels, monomeric anthocyanins
content and antioxidant capacity. The results showed that all the berry kefirs contained high
levels of phenolic compounds and exhibited moderate antioxidant capacity. Compared to
elderberry kefirs made with commercial juice, a pasteurized shelf-stable product, elderberry
kefir made with fresh juice had approximately twenty times more anthocyanins, and two times
more total phenolics. One serving of aronia kefir or elderberry kefir made with fresh juice can
provide three times more than the average intake for anthocyanins and contribute to
approximately one-fifth of the average intake of phenolic compounds in the United States. The
consumption of phenolic compounds may help to decrease the risk of T2DM and slow the
progression of its complications. Currently, the available food products of aronia and
elderberries are limited in the United States. More commercial available products using aronia
or elderberry may help to increase the consumption of phenolic compounds among consumers.
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In addition, the development of aronia and elderberry products may enhance consumers
demand for these berries, which may encourage farmers to grow them and gain profits.
The third objective of this research was to evaluate the bioaccessibility of phenolic
compounds in aronia kefir and their potential to assist blood glucose control. The levels of free
phenolic compounds and their antioxidant capacity during digestion were assessed using an invitro model of simulated digestion. The inhibitory activity of digested aronia kefir on the
carbohydrate-hydrolyzing enzymes was measured. After digestion, the bioaccessible phenolic
compounds and antioxidant capacity of the aronia kefir increased. The digested aronia kefir
exhibited a strong inhibitory activity toward α-glucosidase and weak inhibitory activity for
pancreatic α-amylase. The inhibition of α-glucosidase and pancreatic α-amylase can slow the
digestion of carbohydrates and thus reduce their absorption. However, strong inhibition of
pancreatic α-amylase can lead to un-digested complex carbohydrates in the large intestine,
affect the bacterial fermentation and then cause side effects, such as abdominal pain and
flatulence. Thus, the consumption of aronia kefir may aid in blood glucose control without side
effects due to its specific inhibition of α-glucosidase over pancreatic α-amylase. In addition, the
impacts of fermentation on the potential bioactivity of aronia kefir were evaluated in this part.
Compared to the non-fermented control, aronia kefir exhibited stronger inhibitory activity of αglucosidase after digestion. Both the digested aronia kefir and the non-fermented control had
weak inhibition on pancreatic α-amylase. This is the first study to investigate the impact of kefir
fermentation on berry polyphenols and their health-promoting properties. Kefir fermentation
may be a good strategy to improve the bioavailability of dietary polyphenols.
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In summary, this research provides evidence that both aronia and elderberries have the
potential to be used as food ingredients in commercial food products. Also, the results of
sensory tests show a possibility for the industry to lower the sucrose content of their products
without sabotaging the consumers’ acceptability. A reduction in sucrose content may lead to
healthier products which may be favored by health-conscious consumers. The berry-containing
kefirs developed in these studies may be beneficial to pre-diabetic and diabetic individuals for
their potential to help control blood glucose. Additionally, the berry-containing kefirs are a
good source of protein and calcium for individuals with lactose intolerance due to the lactosefree properties of kefir.
Table 4.1 Key findings of these studies
Chapter No.

2

Samples
Elderberry
and aronia
kefirs
sweetened
with
sucrose,
stevia or
monk fruit
extract

Evaluations

Consumer
acceptability test

Phytochemical
analyses

Bioaccessibility
3

Aronia
kefir

Benefits to
diabetes
Impact of
fermentation

Key findings
1. Kefirs that were less sweetened than
commercial products were accepted by
consumers;
2. Sucrose-sweetened kefirs were best
accepted compared to the products
sweetened with stevia or monk fruit extract.
1. Berry kefirs contained high levels of
phenolic compounds and exhibited moderate
antioxidant capacity;
2. Freshness of juice used in making kefirs
affected their phenolic content
Levels of bioaccessible phenolic compounds,
including anthocyanins and phenolic acids,
increased during digestion
Consumption of aronia kefir may aid in blood
glucose control
Fermentation increased the inhibitory activity
of polyphenols toward α-glucosidase
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4.2 Study Limitations
In the sensory test (chapter 2), we investigated the impacts of sweetener type and
sweetness levels on consumers’ acceptability toward aronia or elderberry kefirs. The first
limitation of this study is that we did not include a control sample in sensory tests. If we
included an aronia or elderberry kefir without additional sweetener in each individual test, we
could know if the addition of sweetener can increase the consumer acceptability. Alternatively,
we could add a plain kefir sample with the same sweetness levels to each sensory tests, which
would allow us to draw a conclusion if the addition of berry juice is favored by consumers.
However, more than four samples are not recommended to be evaluated in one sensory
session because increased sample numbers will lead to participant fatigue, which may
negatively affected the accuracy of the evaluation. Thus, in order to obtain accurate results, we
did not add a control sample. The second limitation was that the phenolic metabolites in
digested aronia kefir could not be identified (chapter 3). We observed new peaks in the
digested aronia kefir compared to the digested non-fermented control. However, due to lack of
mass spectrometry, the identification could not be conducted.
4.3 Future Directions
4.3.1 Impacts of Kefir Culture on Proanthocyanins
In a previous study (presented in Appendix A), we made an assumption that the
increases of monomeric anthocyanins in elderberry kefir during storage may be related to the
microbial depolymerization of proanthocyanins. Proanthocyanins exist in many berry fruits and
cereals. One major restriction of the bioavailability of proanthocyanins is the large molecular
size. Kefir culture may contain microorganisms that can depolymerize proanthocyanins and
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produce smaller, more bioavailable molecules, such as monomeric anthocyanins. To date, there
is no study that investigates the impact of kefir culture on the bioavailability of
proanthocyanins. It is worth investigating the impact of kefir fermentation on the bioavailability
of proanthocyanins from various foods. Studies aiming at separation and identification of the
microorganisms in kefir culture may be needed. The microorganisms which could depolymerize
proanthocyanins may be good candidates for the bioprocessing of proanthocyanin-rich foods to
increase their bioavailability.
4.3.2 Identification of the Metabolites in Aronia Kefir after Digestion
In chapter four of this dissertation, the in-vitro digested aronia kefir exhibited stronger
α-glucosidase inhibitory activity than the non-fermented control. This result may be due to the
phenolic metabolites generated by microorganisms in the kefir. However, due to limitations of
our experiments, the metabolites in aronia kefir were not identified. The identification of these
metabolites needs to be conducted in order to better understand how kefir microorganisms
interact with phenolic compounds. In addition, the metabolites may be isolated and used as
nutraceutical agents to aid in blood glucose control of diabetic individuals. Currently, there is no
available literature investigating the phenolic metabolites from kefir fermentation.
4.3.3 Evaluation of Berry-incorporated Kefir with in-vivo Studies
For this research study, the strong inhibitory activity of aronia kefir on α-glucosidase
was observed in-vitro. However, the question if aronia kefir can alter the activity of αglucosidase in-vivo and decrease the postprandial blood glucose level has not been answered.
Though in-vitro studies showed positive results, the results of in-vivo studies may be different.
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In order to confirm the potential benefits of berry kefirs in an integrated metabolic system, invivo studies need to be conducted. Currently, no research in regards to the in-vivo bioactivity of
polyphenol-enriched kefirs has been done. In addition, no publication is available on the
bioavailability of kefir-fermented phenolic metabolites using animal models. Studies utilizing
animal models are needed to investigate if kefir fermentation improves the bioavailability of
dietary polyphenols in-vivo.
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APPENDIX A: EFFECTS OF SWEETENERS ON THE LEVELS OF PHENOLIC COMPOUNDS AND
ANTIOXIDANT CAPACITY OF ARONIA AND ELDERBERRY KEFIRS DURING STORAGE
1. Chapter Abstract
Aronia berries and elderberries are rich in phenolic compounds including anthocyanins.
Some phenolic compounds, specifically anthocyanins, are very labile. The instability of phenolic
compounds can restrict their applications in the food industry. The addition of sweeteners may
help the stability of phenolic compounds. In this study, aronia and elderberry juice were
individually incorporated into kefir, a fermented dairy beverage. Products were sweetened with
natural sweeteners, sucrose, stevia extract or monk fruit extract, at varying concentrations. The
total phenolic (TP) content, total monomeric anthocyanin (TMA) content and DPPH (2,2diphenyl-1-picrylhydrazyl) free radical scavenging capacity of each product was tested every
seven days during twenty-eight days of storage at 4˚C. The results demonstrated that,
compared to aronia kefir without added sucrose, the addition of sucrose at 4.8% and 6.3%
negatively affected the levels of TP and TMA. Compared to sucrose, monk fruit extract
appeared to be a better sweetener for aronia kefir and elderberry kefir with a low level of
sweetness to produce kefirs with a higher amount of TP and TMA. Stevia-sweetened berry
kefirs contained more TMA but exhibited lower antioxidant capacity than sucrose-sweetened
products. After twenty-eight days of cold storage (4˚C), TP content decreased in most berry
kefirs. The levels of TMA decreased in aronia kefirs but increased in elderberry kefirs during
storage. DPPH scavenging capacity of all kefir products declined after twenty-eight days of
storage. The changes in the levels of TP, TMA and antioxidant capacity over time may be
associated with both natural degradation and microbial metabolism of polyphenols.
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2. Introduction
Aronia (Aronia melanocarpa) and elderberry (Sambucus nigra L. spp. canadensis) fruits
are underutilized berries that are rich in polyphenols, especially anthocyanins. Development of
new products using these berries could increase the diversity of food products on the market
and potentially help to increase the consumer’s daily intake of anthocyanins. The utilization of
anthocyanins in food products is restricted because anthocyanins are labile, which means the
levels of anthocyanins in food products will decrease during processing and storage. Reque et
al. reported that after 10 days of storage at 4˚C, the anthocyanins in blueberry juice degraded
by 83% [83]. Queiros et al. demonstrated that the level of anthocyanins in sweet cherry juice
was reduced by 42% after 28 days of refrigeration [361]. Anthocyanins are stable at pH levels
ranging from 1 to 4. The degradation of anthocyanins is accelerated in an alkaline environment
[83]. An acidic food matrix such as a fermented dairy beverage, may help to decrease the
degradation of anthocyanins compared to a neutral food matrix. The presence of sweeteners
may alter the stability of anthocyanins during storage. Kopjar et al. reported that blackberry
juice with sucrose added contained a higher amount of anthocyanins than juice without addedsucrose after ten days of storage stored at 4˚C [362]. In order to ensure the quality of an
anthocyanin-rich product during its shelf life, methods to increase the stability of anthocyanins
are important.
Kefir is a fermented dairy product that originated in the Caucasus Mountain region. Kefir
is an effervescent beverage with a sour taste and creamy texture [261]. Kefir was chosen to be
the food matrix for incorporating aronia and elderberries for the following reasons: 1) kefir is
acidic, which may help to stabilize the phenolic compounds during storage; 2) studies have
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showed that fermentation with lactic acid bacteria or yeast increased the antioxidant capacity
of polyphenol-rich foods [176, 177, 360]. Kefir is a symbiotic community of various lactic acid
bacteria and yeast. Some lactic acid bacteria and yeast in kefir may have the ability to increase
the antioxidant capacity of phenolic compounds in berries. 3) kefir is a suitable dairy beverage
for lactose-intolerant individuals due to the consumption of lactose by the microorganisms. In
this study, aronia or elderberry juice was incorporated into kefir, and different sweeteners were
added. The objective of this study was to investigate the influence of sweeteners on the
phenolic compounds and the antioxidant capacity of berry kefirs during storage. In the first part
of this study, the impacts of sucrose on phenolic compounds in berry-added kefirs were tested
at five concentrations. The effects of sucrose and two non-nutritive sweeteners (stevia and
monk fruit extracts) were evaluated in the second part.
3. Material and Methods
3.1 Chemicals and Dietary Ingredients
Citric acid anhydrous, hydrochloric acid, methanol, potassium chloride, and sodium
bicarbonate were purchased from Fisher’s Scientific (Waltham, MA, U.S.). 2, 2-diphenyl-1picrylhydrazyl (DPPH), Folin - Ciocalteu’s phenol reagent and gallic acid monohydrate were
obtained from Sigma-Aldrich (St. Louis, MO, U.S.). Sodium acetate was purchased from ChemImpex international, Inc. (Wood Dale, IL, U.S.). Ultra pure water used in this study was obtained
from a Millipore water system (EMD Millipore, Billerica, MA, U.S.).
Aronia berries (Aronia melanocarpa, variety ‘Viking’) used in the first part of this
experiment were obtained from the University of Connecticut (Storrs, CT, U.S.) in 2013. Aronia
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berries used in the second part of this study to test the effects of different sweeteners were
harvested from the University of Connecticut (Storrs, CT, U.S.) in 2014. Elderberries (Sambucus
nigra L. spp. canadensis) were harvested from the Littlefield experimental garden at the
University of Maine from the 2014 growing season (Dr. Myracle’s Hatch Projet, Hatch #
ME021924). The berries were harvested at their full ripeness based on their deep purple color.
The berries were de-stemmed, washed and stored at -20˚C until use. A commercial kefir culture
(Yogourmet®, Lachute, QC, Canada) containing lactic bacteria (Lactococcus lactis subsp. lactis,
Lactococcus lactis subsp. cremoris, Lactococcus lactis subsp. bv. diacetylactis, Lactobacillus
acidophilus) and lactic yeasts was used to make kefir products. Dietary sweeteners and low-fat
milk (2%, Oakhurst®, Portland, ME, U.S.) were purchased from a local supermarket. The dietary
sweeteners used in this study include sucrose (Great Value®, Bentonville, AR, U.S.), stevia
extract (Stevia in the Raw®, New York City, NY, U.S.) and monk fruit extract (Monk Fruit in the
Raw®, New York City, NY, U.S.).
3.2 Kefir Preparation and Formulas
The kefir formulas products are shown in Table A.1, Table A.2 and Table A.3. All kefir
products were prepared using the following method: low-fat milk was heated to 82˚C on the
gas stove and then cooled to 26˚C using an ice bath within 30 min. The temperature was
measured using a digital thermometer. During the cooling process, frozen aronia berries or
elderberries were heated (100˚C, 5 min) and then juiced using a domestic juicer (Hamilton
Beach®, Southern Pines, NC, U.S.). The cooled milk was transferred to a glass bowl and the
commercial starter was added (5 g/quart). The mixture was stirred for 5 minutes to fully
dissolve the starter. Aronia or elderberry juice was added to the mixture, and then the
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sweeteners were added. The amounts of non-nutritive sweeteners (stevia and monk fruit
extracts) used in the individual samples were adjusted according to the instructions on the
package to standardize the sweetness to equal sucrose. The sweetness levels of the aronia
kefirs presented in Table A.2 was the same. Elderberry kefirs (Table A.3) were grouped
according to the sweetness levels. The products with 3 g sucrose, 0.3 g stevia or 0.6 g monk
fruit extract were grouped as products with a low level of sweetness (Group L). The other
elderberry kefirs were grouped as products with a high level of sweetness (Group H). Once
prepared, kefir mixture samples were covered with a cloth and incubated at room temperature
(23˚C) for fermentation. After 24 hours, pH values of the kefir products were 4.5. Then the kefir
products were homogenized with a blender (Hamilton Beach®, Southern Pines, NC, U.S.) and
transferred to sealable glass containers, and each sample batch was divided into five aliquots,
sealed and stored at 4˚C. The phenolic analyses were performed after 2 hours of storage (day
0), and subsequent analyses were conducted on days 7, 14, 21 and 28 of storage. Samples are
duplicated.
Table A.1 Aronia kefir formulas sweetened with sucrose
Product Code
Aronia-S0.0
Aronia-S1.6
Aronia-S3.2
Aronia-S4.8
Aronia-S6.3

Milk (g)
100
100
100
100
100

Aronia Juice (g)
20
20
20
20
20

Sucrose (g)
0
2
4
6
8

Note: Aronia-S0.0: aronia kefir without added sucrose; Aronia-S1.6: aronia kefir with 1.6%
added sucrose; Aronia-S3.2: aronia kefir with 3.2% added sucrose; Aronia-S4.8: aronia
kefir with 4.8% added sucrose; Aronia-S6.3: aronia kefir with 6.3% added sucrose.
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Table A.2 Aronia kefir formulas sweetened with different sweeteners
Sweetener (g)
Aronia kefir
AroniaSucrose
AroniaStevia
AroniaMonk

Milk (g)

Aronia Juice (g)

100
100
100

20
20
20

Sucrose

Stevia

4
---------

----0.4
-----

Monk
fruit
--------0.8

Note: ----- indicates the ingredient was not used in the product.
AroniaSucrose: aronia kefir sweetened with sucrose; AroniaStevia: aronia kefir
sweetened with stevia extract; AroniaMonk: aronia kefir sweetened with monk fruit
extract.
Table A.3 Elderberry kefir formulas sweetened with different sweeteners

Group*
L
H

Sweetener (g)

Elderberry kefir

Milk
(g)

Elderberry juice
(g)

Sucrose

Stevia

EberrySucrose-L
EberryStevia-L
EberryMonk-L
EberrySucrose-H
EberryStevia-H
EberryMonk-H

80
80
80
80
80
80

20
20
20
20
20
20

3
--------4.5
---------

----0.3
--------0.5
-----

Monk
fruit
--------0.6
--------0.9

Note: ----- indicates the ingredient was not used in the product
*: Products in each group had a similar level of sweetness. Products in group L were less
sweet than products in group H.
EberrySucrose-L: elderberry kefir sweetened with 3% sucrose; EberryStevia-L: elderberry
kefir with 0.3% stevia extract; EberryMonk-L: elderberry kefir with 0.6% monk fruit
extract; EberrySucrose-H: elderberry kefir sweetened with 4.5% sucrose; EberryStevia-H:
elderberry kefir with 0.5% stevia extract; EberryMonk-H: elderberry kefir with 0.9% monk
fruit extract.
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3.3 Extraction
Phenolic compounds were extracted from the berry kefirs following a modified method
from Scibisz et al. [310]. Briefly, kefir products were extracted with 80% acidified methanol (1%
citric acid, w/v). The kefir to solvent ratio was 1:10. The samples were sonicated for one hour
in a Branson 5510 sonicator (Danbury, CT, USA) and centrifuged at 16639×g (Eppendorf 5804R,
Hamburg, Germany) for 30 min at 4˚C. The supernatant was collected and the residue was
extracted two additional times. The supernatant was pooled and dried under a vacuum
(Eppendorf Vacufuge plus, Hamburg, Germany). The dried extracts were re-suspended using
100% acidified methanol (citric acid, 1%, w/v) and kept at -20˚C to precipitate proteins. The
slurry was centrifuged at 0˚C for 30 minutes at 16639×g. The supernatant was vacuum-dried at
room temperature and re-suspended with 80% acidified methanol (citric acid, 1%, w/v). The
samples were stored at -20˚ C until analysis.
3.4 Total Phenolic Content
The total phenolic (TP) content in kefir extracts was measured using a modified FolinCiocalteu method reported by Velioglu et al. [311]. The extract (20 µL) and Folin-Ciocalteu
reagent (90 µL, 1:9 diluted with water) were loaded into a 96-well plate. After 5 min incubation
at room temperature in the dark, sodium bicarbonate (6 g/100 mL, 90 µL) was added to
samples. The mixture was incubated for 90 minutes at room temperature in the dark. Gallic
acid was used to create the standard curve. Absorbance was read at 750 nm using a Biotek
plate reader (Elx 800, Winooski, VT, USA). The data are presented in gallic acid equivalents
(GAE), as the average of triplicate measurements of duplicated samples.
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3.5 Total Monomeric Anthocyanin Content
The total monomeric anthocyanin (TMA) levels in the kefir products was measured using
the pH differential method established by a modified method from Lee et al. [82]. Generally,
the extract (20 µL) was mixed with either pH 1.0 buffer (0.025 M potassium chloride, 180 µL) or
pH 4.5 buffer (0.4 M sodium acetate, 180 µL) in 96-well plates. The mixture was incubated at
room temperature for 20 minutes in the dark. The absorbance (Abs) was read at 515 nm and
690 nm using a Biotek plate reader (Elx 800, Winooski, VT, USA). The total monomeric
anthocyanin content was calculated using the following formula and expressed in cyanidin-3glucoside (C3G) equivalents. Samples were measured in triplicate.

𝐴𝑛𝑡ℎ𝑜𝑐𝑦𝑎𝑛𝑖𝑛 (𝑚𝑔 𝐶3𝐺 ⁄𝐿) =

𝐴 × 𝑀𝑊 × 𝐷𝐹 × 103
Ɛ×𝐿

Where: A = (Abs515-Abs690) pH 1.0 – (Abs515-Abs690) pH 4.5;
MW (molecular weight) = 449.2/mol for cyanidin-3-glucoside;
DF = dilution factor;
L = pathlength in cm;
Ɛ = 26900 L/mol·cm, for cyanidin-3-glucoside;
103 = factor for conversion from g to mg.
3.6 Antioxidant capacity
The antioxidant capacity of kefir products was evaluated using the 2,2-diphenyl-1picrylhydrazyl (DPPH) free radical scavenging capacity method. The method was modified from
Duymus et al. [312]. Equal amounts (150 µL) of the sample and DPPH methanol solution (0.3
mM) were loaded into a 96-well plate. The plate was incubated at room temperature in the
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dark for 30 min. A mixture of 80% acidified methanol (solvent of the extract) and DPPH solution
was used as the control. The absorbance was read at 515nm. The inhibition rate of the sample
was calculated using the following formula:

%𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =

𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐴𝑏𝑠𝑠𝑎𝑚𝑝𝑙𝑒
× 100
𝐴𝑏𝑠𝑐𝑜𝑛𝑡𝑜𝑙

Five dilutions of each sample were measured for DPPH scavenging capacity. The IC50
values, which is the concentration of the sample required to scavenge 50% of DPPH radicals,
were calculated and expressed as mg/mL. Measurements were conducted in triplicate.
3.7 Statistical Analysis
Data are shown as mean ± standard deviations. Significant differences among sample
means were evaluated using one way Analysis of Variance and Tukey’s HSD post hoc tests (p ≤
0.05). Pearson correlation coefficient test was conducted to determine the correlation between
the levels of phenolic compounds and DPPH scavenging capacity. Data were analyzed using SAS
University Edition (Cary, NC, U.S.).
4. Results
4.1 The Impacts of Sucrose on the Levels of Phenolic Compounds, Monomeric Anthocyanins
and Antioxidant Activity of Aronia Kefir
The impacts of sucrose concentration on the phenolic compounds including
anthocyanins were evaluated by comparing the five samples (Aronia-S0.0, Aronia-S1.6, AroniaS3.2, Aronia-S4.8 and Aronia-S6.3) that had been stored for the same duration. TP of aronia
kefir sweetened with different concentrations of sucrose are shown in Figure A.1. Compared to
Aronia-S0.0 (no added sucrose), the TP levels were higher in the sample with 1.6% added
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sucrose on day 0 (95.23 ± 2.02 mg GAE/100 g) and 3.2% sucrose on day 14 (110.57 ± 0.52 mg
GAE/100 g). On every individual testing day, TP content of Aronia-S4.8 and Aronia-S6.3 were
lower than Aronia-S0.0.
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Figure A.1 Total phenolic compound levels of aronia kefir sweetened with different
concentrations of sucrose
Note: Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements). Among
the samples that were tested on the same day, different letters indicate significant
differences at p≤0.05.
TMA in different concentrations of sucrose-sweetened aronia kefir are shown in Figure
A.2. All samples contained the highest TMA on day 0. After fermentation (on day 0), only
aronia kefir sweetened with 6.3% sucrose (Aronia-S6.3) contained less monomeric
anthocyanins (41.14 ± 0.85 mg C3G/100 g) than Aronia-S0.0 (44.50 ± 1.95 mg C3G/100 g). No
significant differences of TMA among all samples were detected on day 7. After day 14, 21 or 28
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of storage, Aronia-S4.8 and Aronia-S6.3 contained less monomeric anthocyanins compared to
Aronia-S0.0 that had been stored for the same period.
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Figure A.2 Total monomeric anthocyanin levels in aronia kefir sweetened with different
concentrations of sucrose
Note: Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements). Among
the samples that were tested on the same day, different letters indicate significant
differences at p≤0.05.
The antioxidant capacity of the aronia kefir samples were evaluated and the results are
shown in Figure A.3. Aronia-S0.0 exhibited either higher or similar antioxidant capacity
compared to the other samples on every testing day during storage, with the exception of Day
21. On day 21, Aronia-S1.6 exhibited the strongest scavenging capacity (IC50 was 13.25 ± 0.27
mg kefir/mL). Overall, the antioxidant capacity of aronia kefir samples sweetened with different
concentrations of sucrose were slightly decreased during 28 days of storage.
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Figure A.3 DPPH IC50 values of aronia kefir sweetened with different concentrations of sucrose
Note: Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements). Among
the samples that were tested on the same day, different letters indicate significant
differences at p≤0.05.
4.2 The Impacts of Different Sweeteners on the Levels of Total Phenolic Compounds,
Monomeric Anthocyanins and Antioxidant Capacity in Aronia Kefir
TP content of aronia kefirs are shown in Figure A.4. The impact of sweetener type
(sucrose, stevia and monk fruit) on TP levels were evaluated by comparing the three aronia
kefirs stored for the same time period (day). Compared to AroniaSucrose, AroniaMonk
contained more TP on each testing day except for day 0. On day 0, the TP content of
AroniaSucrose and AroniaMonk was the same. Compared to AroniaSucrose, AroniaStevia had
an equal amount of TP on day 0, higher levels on day 7, 14 and 21, and then a lower level on
day 28.
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The effects of storage time on the TP content of samples assessed. TP levels of
AroniaSucrose decreased on day 14, and then increased on day 28. TP levels of AroniaMonk
decreased on day 14 and gradually increased on days 21 and 28. A decreases of the TP in the
AroniaStevia sample was observed after 14 days of storage, and the TP content of AroniaStevia
increased on day 21. After twenty-eight days of storage, the TP levels of AroniaSucrose and
AroniaMonk were almost the same as their corresponding values on day 0. The AroniaStevia
sample had a lower amount of TP on day 28 compared to day 0.
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Figure A.4 Total phenolic compound levels of aronia kefir sweetened with sucrose, stevia
extract and monk fruit extracts
Note: 1. Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements).
2. Lowercase letters indicate significant differences (p ≤ 0.05) among the three samples
that were tested on the same day;
3. Capital letters indicate significant differences (p ≤ 0.05) of the same sample over
storage time.
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The TMA content of aronia kefir is shown in Figure A.5. The impacts of sweetener types
were evaluated by comparing the three products tested on the same day. On each testing day,
AroniaMonk contained higher levels of TMA than AroniaSucrose. AroniaStevia also had slightly
higher levels TMA than AroniaSucrose on day 0 (31.53 ± 0.18 and 29.94 ± 0.76 mg C3G/100 g,
respectively) and day 28 (13.67 ± 0.36 and 11.50 ± 0.11 mg C3G/100 g, respectively). The TMA
levels of AroniaStevia and AroniaSucrose were similar on all other testing days.
The TMA content of all aronia kefirs dramatically decreased after seven days of storage.
TMA levels of AroniaMonk declined until day 21 and slightly increased during the last week of
storage. The amount of TMA in AroniaStevia decreased until Day 14, remained the same on day
21 and slightly increased on day 28. The level of TMA in AroniaSucrose maintained the same
from day 14 to the end of the storage study.
The antioxidant capacity levels of the aronia kefirs are shown in Figure A.6. Comparisons
among products stored for the same time period were conducted to evaluate the impacts of
the sweeteners. On days 0, 7 and 14, the antioxidant activity of AroniaMonk (IC50s were 16.31 ±
0.47, 15.59 ± 0.16, 16.54 ± 0.34 mg kefir/mL) was higher than AroniaSucrose (IC50s were 17.86 ±
0.47, 16.97 ± 0.10, 16.95 ± 0.57 mg kefir/mL). However, the antioxidant capacity of AroniaMonk
(IC50s were 19.87 ± 0.33 and 20.07 ± 0.32 mg kefir/mL) was lower than AroniaSucrose (IC50s
were 18.09 ± 0.36 and 19.42 ± 0.21 mg kefir/mL) on Day 21 and 28. AroniaStevia exhibited
similar antioxidant capacity as AroniaSucrose on most testing days except for day 21 where the
antioxidant capacity of AroniaStevia (IC50 was 19.02 ± 0.28 mg kefir/mL) was lower than
AroniaSucrose (IC50 was 18.09 ± 0.36 mg kefir/mL). The antioxidant capacity of all aronia kefir
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samples were maintained over 14 days of storage but slightly decreased on either day 21 or day
28. Decreases in antioxidant capacity of AroniaMonk and AroniaStevia were observed on day
21. The antioxidant activity of AroniaSucrose decreased on day 28.
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Figure A.5 Total monomeric anthocyanin levels of aronia kefir sweetened with sucrose, stevia
extract and monk fruit extracts
Note: 1. Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements).
2. Lowercase letters indicate significant differences (p ≤ 0.05) among the three samples
that were tested on the same day;
3. Capital letters indicate significant differences (p ≤ 0.05) of the same sample over
storage time.
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Figure A.6 DPPH IC50 means of aronia kefir sweetened with sucrose, stevia extract and monk
fruit extracts
Note: 1. Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements).
2. Lowercase letters indicate significant differences (p ≤ 0.05) among the three samples
that were tested on the same day;
3. Capital letters indicate significant differences (p ≤ 0.05) of the same sample over
storage time.
4.3 The Impacts of Different Sweeteners on the Levels of Total Phenolic Compounds,
Anthocyanins and Antioxidant Capacity of Elderberry Kefir
The TP contents of elderberry kefir samples are shown in Figure A.7. Comparisons were
conducted among the products with a comparable level of sweetness.

The impacts of

sweetener type were evaluated by comparing the different products over storage time. In
group L (products with a low level of sweetness), EberryMonk-L higher TP levels than
EberrySucrose-L on days 0, 14 and 28. Compared to EberrySucrose-L, EberryStevia-L had a
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higher TP content on day 14 but a less amount on day 21. No significant differences of TP levels
were noted between EberryStevia-L and EberrySucrose-L on other testing days. In group H
(products with a high level of sweetness), the EberryMonk-H and EberryStevia-H samples
contained higher TP content than EberrySucrose-H on day 0.

There was no significant

difference in TP content among EberrySucrose-H, EberryStevia-H and EberryMonk-H on day 7,
14 and 21.
The TP levels of elderberry kefirs appeared to decrease over storage time for samples
with both high and low sweetness levels. In group L, TP content of EberrySucrose-L decreased
after one week of storage and maintained the same level until day 21 and then decreased
again. The TP levels of EberryStevia-L and EberryMonk-L fluctuated during the first 21 days of
storage. The lowest amount of TP for all elderberry kefir samples was observed on day 28. In
group H, TP levels of EberryStevia-H decreased over storage time. The TP content of
EberrySucrose-H and EberryMonk-H slightly fluctuated during storage time. After 28 days, all
elderberry kefirs in group H contained less TP levels than day 0.
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Figure A.7 Total phenolic compound levels of elderberry kefir sweetened with sucrose, stevia
extract and monk fruit extracts
Note: 1. Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements).
2. Graph I: Results of elderberry kefir with a low level of sweetness;
Graph II: Results of elderberry kefir with a high level of sweetness.
3. Lowercase letters indicate significant differences (p ≤ 0.05) among the three samples
that were tested on the same day;
Capital letters indicate significant differences (p ≤ 0.05) of the same sample over
storage time.
157

The TMA content of elderberry kefir samples is shown in Figure A.8. In group L,
EberryMonk-L sample contained higher TMA content than EberrySucrose-L samples on days 7,
14, 21 and 28. EberryStevia-L levels were also higher than EberrySucrose-L on day 7, 14 and 28.
In Group H, EberryMonk-H sample contained higher TMA content than EberrySucrose-H on
days 0, 21 and 28. No significant differences among all samples were observed on day 7.
EberryStevia-H and EberrySucrose-H contained similar amounts of TAM content on days 0, 7, 14
and 21. On Day 28, EberryStevia-H had higher TAM content than EberrySucrose-H.
The TMA content of elderberry kefir samples for both sweetness level groups increased
over time. Over storage time, the highest TMA amount for each elderberry kefir treatment was
observed on day 28. After twenty-eight days of storage, the amount of TMA in EberrySucrose-L,
EberryStevia-L, EberryMonk-L, EberrySucrose-H, EberryStevia-H, EberryMonk-H increased by
32.6%, 36.2%, 46.4%, 32.3%, 43.8% and 35.6% compared to their corresponding values on day
0, respectively.
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Figure A.8 Total monomeric anthocyanin content of elderberry kefir sweetened with sucrose,
stevia extract and monk fruit extracts
Note: 1. Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements).
2. Graph I: Results of elderberry kefir with a low level of sweetness;
Graph II: Results of elderberry kefir with a high level of sweetness.
3. Lowercase letters indicate significant differences (p ≤ 0.05) among the three samples
that were tested on the same day;
Capital letters indicate significant differences (p ≤ 0.05) of the same sample over
storage time.
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Figure A.9 DPPH IC50 means of elderberry kefir sweetened with sucrose, stevia extract and
monk fruit extracts
Note: 1. Data are shown as mean ± standard deviation, n=2 (batches) x 3 (measurements).
2. Graph I: Results of elderberry kefir with a low level of sweetness;
Graph II: Results of elderberry kefir with a high level of sweetness.
3. Lowercase letters indicate significant differences (p ≤ 0.05) among the three samples
that were tested on the same day;
Capital letters indicate significant differences (p ≤ 0.05) of the same sample over
storage time.
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The antioxidant activity levels of elderberry kefir samples are shown in Figure A.9. In
group L, no significant differences in antioxidant capacity were detected among kefir samples
on day 0. EberryMonk-L exhibited a higher antioxidant capacity than EberrySucrose-L on days
14 and 21 but a lower antioxidant capacity on days 7 and 28. The antioxidant capacity of
EberryStevia-L was similar with EberrySucrose-L samples on day 0, 7 and 14 but lower than
EberrySucrose-L on day 21 and 28. In group H, the antioxidant capacity of EberryMonk-H
sample was higher than EberrySucrose-H on days 0 and 21 but lower on all other testing days.
Compared to EberrySucrose-H, EberryStevia-H exhibited a lower antioxidant capacity on days
14 and 28 but no significant difference on days 0, 7 and 21.
After twenty-eight days of storage, the antioxidant capacity of elderberry kefir samples
decreased over storage time. The decreases in antioxidant capacity of EberrySucrose-L,
EberryStevia-L, EberryMonk-L occured on day 14, day 7 and day 21, respectively. The
antioxidant capacity of EberrySucrose-H, EberryStevia-H and EberryMonk-H reduced on day 14,
day 14 and day 7, respectively.
5. Discussion
5.1 Impacts of Sucrose
In our study, aronia kefir samples with 4.8% and 6.3% added-sucrose contained less TP
and TMA levels than aronia kefir without added-sucrose on each testing day. The addition of
sucrose did not appear to protect the TP or TMA levels during storage. To our knowledge, this is
the first study to investigate the impacts of sucrose concentration on polyphenols in a
fermented dairy matrix. The aronia phenolic compounds in our study were exposed to various
161

fermentative microorganisms, such as lactic bacteria and yeasts in kefir. Some fermentative
microorganisms may have the ability to alter the amount of phenolic compounds by releasing
the bound phenolic compounds and/or metabolizing them [173, 363]. The ability of yeast
(Kluyveromyces marxianus) isolated from kefir to increase the antioxidant capacity of grape
polyphenols synergistically has been observed in other research studies [364]. In addition,
researchers noted that the presence of added-sucrose (1%) altered the growth pattern of both
lactic acid bacteria and yeast in soymilk kefir compared to samples without sucrose [365]. Thus,
the concentration of sucrose may influence TP and TMA levels by altering the capacity of
microorganisms to metabolize phenolic compounds. The protective impacts of sucrose on
phenolic compounds in fruit juice have been documented by several studies [366-368]. These
protective impacts may be related to a decrease in water activity [367, 369]. In our study, the
addition of 6.3% sucrose may not be sufficient to substantially affect water activity levels of the
kefir sample to a critical point that would be beneficial to the stabilize polyphenols over storage
time.
The antioxidant capacity of aronia kefir is contributed by the phenolic compounds.
However, in this study, the correlation analyses did not show a significant relationship between
TP and the DPPH radical scavenging activity. These results indicate that in addition to changes
of TP levels, there were other alterations that may have affected the antioxidant capacity of
aronia kefir samples, such as changes in polyphenol composition. The changes in phenolic
composition may lead to altered antioxidant capacity levels because the antioxidant capacity of
individual phenolic compound differs [370]. Fermentation may have affected the composition
of polyphenols in our study. Aronia kefir was stored at 4˚C, at which temperature the
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fermentation process might be slowed but not stopped because the ˚brix values of sucroseadded aronia kefir decreased over storage (data not shown). The addition of sucrose at
different concentrations may lead to varied activities of microorganisms during storage and
influence the profile of the fermentative metabolites. Wang et al. reported that fermentation
with yeasts (Saccharomyces cerevisiae bayanus EC 118) decreased the amount of total
polyphenols but increased the level of gallic acid and the antioxidant capacity of maqui berry
juice [177]. Jimenez-Lopez et al. demonstrated that fermentation decreased the concentration
of epicatechin, increased the amount of total phenolic compounds and resulted in slightly
enhanced antioxidant capacity in caper berries [371]. In summary, the impacts of sucrose on
the antioxidant capacity of aronia kefir during storage may be achieved by altering the
metabolism activity of microorganisms in addition to the changes of phenolic levels. More
research is needed to verify this assumption.
5.2 Effects of Non-nutritive Sweeteners
In our study, monk fruit-sweetened aronia kefir contained more TP and TMA compared
to sucrose-sweetened kefir samples at the lower sweetness levels. However, among the
elderberry kefirs in group H, the levels of TP and TMA between monk fruit- and sucrosesweetened samples fluctuated at different testing points. Based on our results, no clear
apparent trend occurred between antioxidant capacities of monk fruit and sucrose-sweetened
berry kefirs. These results indicate that monk fruit extract may be a preferred sweetener to use
than sucrose for aronia kefirs and elderberry kefirs with a low level of sweetness to produce
products with higher levels of TP and TMA. Our results are similar to a study conducted by
Nowicka and Wojdylo [372]. They demonstrated that after six months storage at 4˚C, sour
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cherry puree with the addition of 1% monk fruit (referred as “Luo Han Kuo”), had higher TP and
TMA levels compared to the sample with 7% added sucrose [372]. To our knowledge, this
research is the only study involving monk fruit extract on the stability of phenolic compounds to
date. However, the food matrix and the amount of sweeteners used in our study was different
from the referenced study. In addition to the direct interactions between sweeteners and
polyphenols, the impacts of sweeteners on the microorganisms may also contribute to our
results. There has been no published study about the impacts of monk fruit on fermentation.
Compared to sucrose, the addition of stevia appeared to be beneficial to maintain TMA
levels but decreased the antioxidant capacity of berry kefirs over time. However, the results did
not show a clear trend of the TP content among stevia- and sucrose-sweetened aronia kefir and
elderberry kefir in group L. Some of our findings are in agreement with a former study
conducted by Skapska et al., where the replacement of sucrose with stevia extract reduced the
antioxidant capacity of an aronia-herbal beverage [373]. However, Wozniak et al. demonstrated
that in the absence of microorganisms, sucrose exhibited protective effects on anthocyanins
but steviol glycosides (the sweet compounds in stevia extract) did not, which was different than
our findings [374]. One factor that may influence the impact of sweeteners on TMA levels in our
study is the presence of fermentative microorganisms. Both sucrose and stevia are carbon
sources for lactic acid bacteria [375]. The addition of sucrose or stevia may alter the
fermentation activity of microorganisms in kefir and then influence their pattern to interact
with polyphenols. One other factor that may result in this difference is the type of
anthocyanins. In the referenced study, purified cyanidin-3-glucoside and pelargonidin-3-
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glucoside were used. In our study, both aronia and elderberries contain various types of
anthocyanins.
Twenty-eight days of storage at 4˚C decreased the TP levels in most berry kefirs and
reduced the antioxidant capacity of all berry kefirs. The decreases may be caused by the natural
and microbial degradation of phenolic compounds. In a study conducted by Muniandy et al.,
decreases of TP levels in tea extract-enriched yogurt was observed during 21 days of storage.
However, the DPPH scavenging capacity of tea extract-added yogurt was not altered [376]. The
different results may be due to the different fermentation culture and polyphenol sources used
in our study versus the referenced study.
During storage, the TMA content of the aronia kefirs decreased but the TMA levels in
the elderberry kefirs increased over time. The decreases in aronia kefir are associated with the
degradation of monomeric anthocyanins over time. Reque et al. also observed that 10 days of
storage at 4˚C decreased the anthocyanin content in blueberry juice by 83% [74]. The increases
of TMA content in elderberry kefir may be related to the microbial activity in the kefir. Some
microorganisms can produce enzymes that can catalyze the hydrolysis of proanthocyanins, such
as tannase [377, 378]. The hydrolysis of proanthocyanins can yield monomeric anthocyanins.
The proanthocyanin compositions of aronia and elderberries are different [198], and this may
be a reason for the different trends of TMA changes in aronia versus elderberry kefirs. The
majority of the proanthocyanins in aronia are polymers with more than ten degrees of
polymerization.

In

elderberries,

the

polymerization

degrees

of

the

predominant

proanthocyanins are lower than seven. More studies are needed to test this assumption.
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6. Conclusion
The impacts of sweeteners (sucrose, stevia and monk fruit) on the levels of TP, TMA and
antioxidant capacity of berry-added kefir were tested during 28 days of storage at 4˚C. Results
showed that compared to Aronia kefir without sucrose, the addition of sucrose at 4.8% and
6.3% decreased the contents of TP and TMA. Compared to sucrose, monk fruit extract may be a
preferred sweetener for aronia kefirs and elderberry kefirs with a low level of sweetness for
protecting the levels of TP and TMA. Berry kefirs sweetened with stevia contained more TMA
than the samples sweetened with sucrose, but the free radical scavenging capacity showed an
opposite trend.
Twenty-eight days of storage at 4˚C decreased the antioxidant capacity of all berry
kefirs. Decreases of TP were observed during storage, but with fluctuations. The TMA content in
aronia kefir decreased over time, but the content in elderberry kefir increased. The different
trends may be related to the distinct polyphenol compositions of aronia and elderberries. In
addition, it may be associated with the activity of microorganisms in kefir. More studies are
needed to understand the influences of microorganisms on polyphenols during storage.

166

APPENDIX B: APPLICATION FOR APPROVAL OF RESEARCH WITH HUMAN SUBJECTS
1. Summary of the proposal
Chronic diseases have become a global issue causing many health issues with increased
morbidity and mortality. A healthy diet is critical to the prevention of many chronic diseases
such as type 2 diabetes and cancer. The functional properties of food and the bioactive
compounds they contain are current research interests to increase health benefit.
Fermented products such as kefir and berries that contain phytonutrients are two attractive
topics in this area.
Fermented milk products have a good reputation in maintaining gut health due to their
microorganisms that influence the fermentation process and make them a rich source of
probiotics. Probiotics are also linked to healthy metabolic effects such as reducing blood
cholesterol, boosting the immune system, preventing cancer, and attenuating lactose
intolerance symptoms [1]. Kefir, a fermented dairy product, has been proven to have similar
impacts on human health similar to other fermented dairy products such as yogurt. In
addition, due to the composition of several different microorganisms in kefir, it is naturally
free of lactose, which is very important. As reported, lactose intolerance is a popular
disorder that influences approximately 75% of the world’s adults [2]. Considering there is no
lactose in kefir, it would be a good source of protein and calcium for the lactose intolerance
population.
Berries are rich in phenolic compounds, especially anthocyanins which make them an
attractive resource for health related research. Anthocyanins are secondary plant
metabolites that are proven to have high antioxidant capacity [3]. The health benefits of
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anthocyanins, especially their antioxidant effects which are related to their role in lowering
the risk of several chronic diseases, have been reported by many articles [4].
Aronia and elderberries are under-utilized berries, reported to have high anthocyanin
content [5, 6]. Due to the astringent mouth feel caused by the high phenolic content, they
are considered unpleasant to consumers. The use of these berries in a dairy matrix may
minimize this flavor, and the acidic environment of fermented dairy could stabilize the
phenolic compounds in berries. The aim of this study is to develop new desirable products
that incorporate elderberry and aronia into kefir. The consumption of this berry product
might help to decrease the prevalence of chronic diseases by boosting the public’s intake of
antioxidant compounds, especially anthocyanins.
New products will be made with low fat milk (2%) and a commercial-available kefir
starter mix (Yogourmet™), either aronia or elderberry will be added to the product. Each
product will be sweetened by natural sweeteners (monk fruit or stevia extract) or table
sugar. One concentration of each sweetener will be applied to aronia products, while two
different concentrations will be used in elderberry products. Overall, three products will be
developed using aronia berry and six p tests will be carried out in the Consumer Testing
Center in University of Maine in four days, two days for aronia products and another two
days for elderberry products. During each test, three or six samples (about one ounce each)
marked with three randomized digit numbers will be served to every participant. Flyers,
Consent form, and Questionnaires are presented in Appendices A to F.
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2. Personnel
Principal Investigator: Xue Du, MS.
Xue Du is a PhD student in the School of Food and Agriculture in University of Maine,
majoring in Food Science and Nutrition. She will be in charge of participant
recruitment, sample preparation, conduction of sensory evaluation, and data
analysis. CITI training is current.
Mentor (Faculty Sponsor): Angela Myracle, MPH, PhD.
Dr. Myracle is an Assistant Professor in the School of Food and Agriculture in
University of Maine. She obtained her PhD in Human Nutrition, Purdue University.
She has 25 years of experience in biochemical analysis, epidemiological studies, and
sensory evaluation. She is the major supervisor of this project and will oversee the
entire project. CITI training is current.
Research Associates:
Mary Ellen Camire, PhD.
Dr. Camire is a Professor of the School of Food and Agriculture, University of Maine.
She has more than 20 years’ sensory evaluation experience, and presently teaches
the graduate course: Sensory Evaluation. CITI training is current.
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Katherine Davis-Dentici.
Ms Davis-Dentici is an employee in University of Maine since 1993, and she has rich
experience with sensory evaluation and product development. She will help through
the entire project. CITI training is current.
Students: Some students in the School of Food and Agriculture might help with this project,
and all of them will complete CITI training before assisting the project.
3. Participant recruitment
100 participants who aged 18 or older will be recruited for each sensory evaluation test
(elderberry or aronia products tasting) via flyers, Facebook, and FirstClass notices (attached
as Appendix C and D); both male and female will be recruited. Consumers who are allergic to
any ingredient of the products, such as milk and elderberry / aronia, will be excluded. The
number of subjects for the study is chosen according to Gacula and Rutenbeck [7], to allow
enough power to obtain statistically significant results.
4. Informed consent
Subjects will be asked to read the printed informed consent form (as presented in
Appendices E and F), which will be written at an 8th reading level, before participation.
Participation in the study will be assumed to indicate consent.
5. Confidentiality
Subjects will login on the SIMS program in the Consumer Testing Center of University of
Maine; data will be collected anonymously and only available to the study investigators.
Password protected data file will be saved in the computers that are kept in a locked room.
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Data will be deleted once the analysis is completed and the resulting article has been
accepted; data will not be kept for more than one year after the completion of the study,
which is December 20th, 2016.
6. Risks to participants
Potential food allergens will be announced to the subjects in the recruitment notices
and informed consent forms.
Subjects will risk losing personal time. Even though each test should take no more than
30 minutes, unfamiliarity of the SIMS computer program may lead to longer testing time.
Assistance will be provided during the test to minimize the time.
In general, the risks involved are minimal, and should be no greater than daily eating.
7. Benefits
Participants will have the opportunity to taste new products and may like them.
Developing new products in this project may help the elderberry and aronia farmers to
utilize the berries. In addition, new products will contribute to the varieties of diary food
products, and may also boost the consumption of polyphenols, which is a health-beneficial
phytochemical that has been related to lower the risk of chronic disease.
Risk of this project will be no more than associated with normal eating, so the benefits
are expected to outweigh the risk.
8. Compensation
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Participants who complete the whole evaluation process will receive $2 as
compensation.
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APPENDIX C: ELDERBERRY KEFIR TASTING RECRUITMENT NOTICE
Would you like to taste kefir, a fermented milk beverage? New kefir products are
developed and volunteers are needed to provide their opinions; if you are aged 18 or older, and
have about 20 minutes spare time, please come and help the researchers!
Testing session will be held in the Consumer Testing Center, Hitchner Hall 158. The date
will be announced. Scheduling a time by calling (207)889-7117 or e-mailing xue.du@maine.edu
will be preferred; however, volunteers are welcome to show up at any time.
Volunteers will receive $2 for participating in the study; however, if you are allergic to
milk, elderberry, sugar, monk fruit or stevia, please do not participate.

Contacts: Xue Du (Magic): (207)889-7117 or e-mail xue.du@maine.edu;
Dr. Angela Myracle at (207)581-1617 or angela.myracle@maine.edu.
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APPENDIX D: ARONIA KEFIR TASTING RECRUITMENT NOTICE
Would you like to eat kefir, a fermented milk beverage? New kefir products are
developed and volunteers are needed to provide their opinions; if you are aged 18 or older, and
have about 20 minutes spare time, please come and help the researchers!
Testing session will be held in the Consumer Testing Center, Hitchner Hall 158. The date
will be announced. Scheduling a time by calling (207)889-7117 or e-mailing xue.du@maine.edu
will be preferred; however, volunteers are welcome to show up at any time.
Volunteers will receive $2 for participating in the study; however, if you are allergic to
milk, aronia berry (chockberry), sugar, monk fruit or stevia, please do not participate.

Contacts: Xue Du (Magic): (207)889-7117 or e-mail xue.du@maine.edu;
Dr. Angela Myracle at (207)581-1617 or angela.myracle@maine.edu.
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APPENDIX E: ELDERBERRY KEFIR INFORMED CONSENT FORM
Dear Consumer,
You are invited to participate in a research study being carried out by Xue Du, a PhD
student under the supervision of Dr. Angela Myracle, Assistant Professor of Human Nutrition
from the School of Food and Agriculture at the University of Maine. The purpose of this study is
to determine whether new kefir products with underutilized berries (elderberries) and different
sweeteners are well accepted by consumers.
If you know that you are allergic or sensitive to milk, elderberry, sugar or stevia, please
do not participate; and you must be at least 18 years of age to participate.

What Will You Be Asked to Do?
If you decide to participate in this study, you will be asked to answer a list of questions
about yourself. The questions will include your age, gender, and your familiarity of elderberry
and kefir. You will be given 6 different samples to taste and evaluate. The test might take 20
minutes.
Risks
The risks of participating in this study should be minimal and no greater than normal
daily eating.
Benefits
You will taste new products and may like them. Also, this research may help the
elderberry farmers and industries to develop new products and increase food varieties. In
addition, this research may increase the fruit intake of consumers.
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Compensation
After completing all the questions listed, you will receive $2. No compensation will be
offered if the questions are not completed.
Confidentiality
The data will be collected anonymously, and your name will not be shown in any
document. Data will be kept on pass-word protected computers in a locked room. All data will
be destroyed no later than 12 months after this study is completed (December 20 th, 2016).
Voluntary
Participation is voluntary. You may choose to not participate at the beginning or stop at
any time during the study. Compensation will be provided only if you complete the tasting and
the questions.
Contact Information
If you have any questions about this study, please contact Xue Du at (207)889-7117 or
xue.du@maine.edu; or Dr. Angela Myracle at (207)581-1617 or angela.myracle@maine.edu. If
you have any questions about your rights as a research participant, please contact Gayle Jones,
Assistant to the University of Maine’s Protection of Human Subjects Review Board, at 581-1498
(or e-mail gayle.jones@umit.maine.edu).

Your participation in the study indicates that you have read and understand the above
information and agree to participate in the study.
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APPENDIX F: ARONIA KEFIR INFORMED CONSENT FORM
Dear Consumer,
You are invited to participate in a research study being carried out by Xue Du, a PhD
student under the supervision of Dr. Angela Myracle, Assistant Professor of Human Nutrition
from the School of Food and Agriculture at the University of Maine. The purpose of this study is
to determine whether new kefir products with underutilized berries (aronia berries) and
different sweeteners are well accepted by consumers.
If you know that you are allergic or sensitive to milk, aronia berry, sugar, monk fruit or
stevia, please do not participate; and you must be at least 18 years of age to participate.

What Will You Be Asked to Do?
If you decide to participate in this study, you will be asked to answer a list of questions
about yourself. The questions will include your age, gender, and your familiarity of aronia
(chockberry) and kefir. You will be given 3 different samples to taste and evaluate. The test
might take 20 minutes.
Risks
The risks of participating in this study should be minimal and no greater than normal
daily eating.
Benefits
You will taste new products and may like them. Also, this research may help the aronia
farmers and industries to develop new products and increase food varieties. In addition, this
research may increase the fruit intake of consumers.
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Compensation
After completing all the questions listed, you will receive $2. No compensation will be
offered if the questions are not completed.
Confidentiality
The data will be collected anonymously, and your name will not be shown in any
document. Data will be kept on a pass-word protected computer in a locked room. All data will
be destroyed no later than 12 months after this study is completed (December 20 th, 2016).
Voluntary
Participation is voluntary. You may choose to not participate at the beginning or stop at
any time during the study. Compensation will be provided only if you complete the tasting and
the questions.
Contact Information
If you have any questions about this study, please contact Xue Du at (207)889-7117 or
xue.du@maine.edu; or Dr. Angela Myracle at (207)581-1617 or angela.myracle@maine.edu. If
you have any questions about your rights as a research participant, please contact Gayle Jones,
Assistant to the University of Maine’s Protection of Human Subjects Review Board, at 581-1498
(or e-mail gayle.jones@umit.maine.edu).

Your participation in the study indicates that you have read and understand the above
information and agree to participate in the study.
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APPENDIX G: SENSORY EVALUATION QUESTIONNAIRE OF ELDERBERRY KEFIR
Attribute 1: Instruction
Thank you for agreeing to participate in our research. Please click the bottom button on
the screen to start the evaluation, and evaluate the samples following the order shown on the
screen and verify that each 3-digit code matches the sample that you taste. Please choose the
answers that best describe your attitude towards the product. Please take a sip of water
between tasting samples.
Attribute 2: check all that apply
Please indicate your gender:


Male



Female



Would prefer not to say

Attribute 3: check one
Please indicate your age range:


18-24



25-34



35-44



45-54



55-65



Over 65
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Attribute 4: yes or no
Have you ever consumed kefir?


Yes



No



I don’t know what kefir is

Attribute 5: check one
How familiar are you with elderberries?


Never heard of



Somewhat unfamiliar



Somewhat familiar



Very familiar

Attribute 6: check one
How important is it to you to consider the health benefits of food before purchasing?


Not important



Slightly important



Neutral



Moderately important



Extremely important
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Attribute 7: hedonic scale
How much do you like the color of this sample?
1

2

3

4

5

6

7

8

9

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

Like
moderately

Like very
much

Like
extremely

Attribute 8: hedonic scale
How much do you like the flavor of this sample?
1

2

3

4

5

6

7

8

9

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

Like
moderately

Like very
much

Like
extremely

9

Attribute 9: hedonic scale
How much do you like the sweetness of this sample?
1

2

3

4

5

6

7

8

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

Like
moderately

Like very
much

Like
extremely

Attribute 10: hedonic scale
How much do you like the texture of this sample?
1

2

3

4

5

6

7

8

9

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

Like
moderately

Like very
much

Like
extremely
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Attribute 11: hedonic scale
How do you rate the overall acceptability of this product?
1

2

3

4

5

6

7

8

9

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

Like
moderately

Like very
much

Like
extremely

Attribute 12: comment
If you want to refer to any product you have tasted, please use the three-digit code of
the product.

Thank you for your time.
Please lift the window up to let the staff know that you are finished.
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APPENDIX H: SENSORY EVALUATION QUESTIONNAIRE OF ARONIA KEFIR
Attribute 1: Instruction
Thank you for agreeing to participate in our research. Please click the bottom button on
the screen to start the evaluation, and evaluate the samples following the order shown on the
screen and verify that each 3-digit code matches the sample you taste. Please choose the
answers that best describe your attitude towards the product. Please take a sip of water
between tasting samples.
Attribute 2: check all that apply
Please indicate your gender:


Male



Female



Would prefer not to say

Attribute 3: check one
Please indicate your age range:


18-24



25-34



35-44



45-54



55-65



Over 65
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Attribute 4: yes or no
Have you ever consumed kefir?


Yes



No



I don’t know what kefir is

Attribute 5: check one
How familiar are you with aronia berries (Chokeberries)?


Never heard of



Somewhat unfamiliar



Somewhat familiar



Very familiar

Attribute 6: check one
How important is it to you to consider the health benefits of food before purchasing?


Not important



Slightly important



Neutral



Moderately important



Extremely important
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Attribute 7: hedonic scale
How much do you like the color of this sample?
1

2

3

4

5

6

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

7
Like
moderately

8

9

Like very
much

Like
extremely

8

9

Like very
much

Like
extremely

8

9

Like very
much

Like
extremely

Attribute 8: hedonic scale
How much do you like the flavor of this sample?
1

2

3

4

5

6

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

7
Like
moderately

Attribute 9: hedonic scale
How much do you like the sweetness of this sample?
1

2

3

4

5

6

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

7
Like
moderately

Attribute 10: hedonic scale
How much do you like the astringency (dry, shrinking mouth-feel of dry wine, tea, or coffee) of
this sample?
1

2

3

4

5

6

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly
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7
Like
moderately

8

9

Like very
much

Like
extremely

Attribute 11: hedonic scale
How much do you like the texture of this sample?
1

2

3

4

5

6

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

7
Like
moderately

8

9

Like very
much

Like
extremely

8

9

Like very
much

Like
extremely

Attribute 12: hedonic scale
How do you rate the overall acceptability of this product?
1

2

3

4

5

6

Dislike
extremely

Dislike
very much

Dislike
moderately

Dislike
slightly

Neither like
nor dislike

Like
slightly

7
Like
moderately

Attribute 13: comment
If you want to refer to any product you have tasted, please use the three-digit code of the
product.

Thank you for your time.
Please lift the window up to let the staff know that you are finished.
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